INDUCING CELLULAR IMMUNE RESPONSES TO p53 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS

Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare p53 epitopes, and to develop epitope-based vaccines directed towards p53-bearing tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of cancer.

Description: INDUCING CELLULAR IMMUNE RESPONSES TO p53 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS I. BACKGROUND OF THE INVENTION A growmg body of evidence suggests that cyto toxic T lymphocytes (CTL) are important m the immune response to tumor cells CTL recognize peptide epitopes m the context of HLA class I molecules that are expressed on the surface of almost all nucleated cells Following intracellular processmg of endogenously synthesized tumor antigens, antigen-denved peptide epitopes bmd to class I HLA molecules in the endoplasmic reticulum, and the resulting complex is then transported to the cell surface CTL recognize the peptide-HLA class I complex, which then results in the destruction ofthe cell beaπng the HLA-peptide complex directly by the CTL and/or via the activation of non-destructive mechanisms, e g , activation of lymphokines such as tumor necrosis factor-α (TNF- α) or mterferon-γ (IFNγ) which enhance the immune response and facilitate the destruction of the tumor cell Tumor-specific helper T lymphocytes (HTLs) are also known to be important for maintaining effective antitumor immunity Their role in antitumor immunity has been demonstrated in ammal models in which these cells not only serve to provide help for induction of CTL and antibody responses, but also provide effector functions, which are mediated by direct cell contact and also by secretion of lymphokmes (e g , IFNγ and TNF- α) A fundamental challenge in the development of an efficacious tumor vaccme is immune suppression or tolerance that can occur There is therefore a need to establish vaccme embodiments that elicit immune responses of sufficient breadth and vigor to prevent progression and/or clear the tumor The epitope approach employed m the present invention represents a solution to this challenge, in that it allows the incorporation of various antibody, CTL and HTL epitopes, from discrete regions of a target tumor-associated antigen (TAA), and/or regions of other TAAs, in a single vaccine composition Such a composition can simultaneously target multiple dominant and subdominant epitopes and thereby be used to achieve effective immunization in a diverse population The p53 protem is normally a tumor suppressor gene that, in normal cells, mduces cell cycle arrest which allows DNA to be monitored for irregularities and maintains DNA integrity (see, e g , Kuerbitz et al , Proc Natl Acad Set USA 89 7491-7495, 1992) Mutations in the gene abolish its suppressor function and result in escape from controlled growth The most common mutations are at positions 175, 248, 273, and 282 and have been observed m colon (Rodπgues et al , Proc Natl Acad Sci USA 87 7555-7559, 1990), lung (Fujmo et al , Cancer 76 2457-2463, 1995), prostate (Eastham et al , Clin Cancer Res 1 1111-1118, 1995), bladder (Vet et al , Lab Invest 73 837-843, 1995) and osteosarcomas (Abudu et ai , Br J Cancer 79 1185-1189, 19999, Hung et al , Acta Orthop Scand Supp 273 68-73, 1997) The mutations in p53 also lead to overexpression of both the wildtype and mutated p53 (see, e g , Levme et al , Nature 351 453-456, 1991) thereby makmg it more likely that epitopes withm the protein may be recognized by the immune system Thus, ρ53 is an important target for cellular immunotherapy The mformation provided in this section is mtended to disclose the presently understood state of the art as of the filing date of the present application Information is mcluded in this section which was generated subsequent to the pπoπty date of this application Accordmgly, information in this section is not intended, in any way, to delineate the priority date for the invention II. SUMMARY OF THE INVENTION This invention applies our knowledge of the mechanisms by which antigen is recognized by T cells, for example, to develop epitope-based vaccines directed towards TAAs More specifically, this application communicates our discovery of specific epitope pharmaceutical compositions and methods of use in the prevention and treatment of cancer Upon development of appropriate technology, the use of epitope-based vaccines has several advantages over current vaccines, particularly when compared to the use of whole antigens in vaccine compositions For example, immunosuppressive epitopes that may be present in whole antigens can be avoided with the use of epitope-based vaccines Such immunosuppressive epitopes may, e g , correspond to lmmunodommant epitopes m whole antigens, which may be avoided by selectmg peptide epitopes from non-dominant regions (see, e g , Disis et al , J Immuno! 156 3151-3158, 1996) An additional advantage of an epitope-based vaccme approach is the ability to combme selected epitopes (CTL and HTL), and further, to modify the composition of the epitopes, achieving, for example, enhanced lmmunogenicity Accordmgly, the immune response can be modulated, as appropnate, for the target disease Similar engineering of the response is not possible with traditional approaches Another major benefit of epitope-based immune-stimulating vaccines is their safety The possible pathological side effects caused by infectious agents or whole protem antigens, which might have their own intrinsic biological activity, is eliminated An epitope-based vaccme also provides the ability to direct and focus an immune response to multiple selected antigens from the same pathogen (a "pathogen" may be an infectious agent or a tumor- associated molecule) Thus, patient-by-patient variability m the immune response to a particular pathogen may be alleviated by inclusion of epitopes from multiple antigens from the pathogen in a vaccme composition Furthermore, an epitope-based anti-tumor vaccme also provides the opportunity to combme epitopes derived from multiple tumor-associated molecules This capability can therefore address the problem of tumor-to tumor variability that aπses when developing a broadly targeted anti-tumor vaccme for a given tumor type and can also reduce the likelihood of tumor escape due to antigen loss For example, a breast cancer tumor m one patient may express a target TAA that differs from a breast cancer tumor m another patient Epitopes deπved from multiple TAAs can be mcluded m a polyepitopic vaccme that will target both breast cancer tumors One ofthe most formidable obstacles to the development of broadly efficacious epitope-based lmmunotherapeutics, however, has been the extreme polymorphism of HLA molecules To date, effective non-genetically biased coverage of a population has been a task of considerable complexity, such coverage has required that epitopes be used that are specific for HLA molecules corresponding to each individual HLA allele unpractically large numbers of epitopes would therefore have to be used m order to cover ethnically diverse populations Thus, there has existed a need for peptide epitopes that are bound by multiple HLA antigen molecules for use m epitope-based vaccmes The greater the number of HLA antigen molecules bound, the greater the breadth of population coverage by the vaccme Furthermore, as described herem m greater detail, a need has existed to modulate peptide binding properties, e g , so that peptides that are able to bind to multiple HLA molecules do so with an affinity that will stimulate an immune response Identification of epitopes restπcted by more than one HLA allele at an affinity that correlates with immunogenicity is important to provide thorough population coverage, and to allow the ehcitation of responses of sufficient vigor to prevent or clear an infection in a diverse segment of the population Such a response can also target a broad array of epitopes The technology disclosed herein provides for such favored immune responses In a preferred embodiment, epitopes for inclusion in vaccine compositions of the invention are selected by a process whereby protein sequences of known antigens are evaluated for the presence of motif or supermotif-beanng epitopes Peptides corresponding to a motif- or supermotif-beaπng epitope are then synthesized and tested for the ability to bmd to the HLA molecule that recognizes the selected motif Those peptides that bmd at an mtermediate or high affinity i e , an IC 3θ (or a K D value) of 500 nM or less for HLA class I molecules or an IC 50 of 1000 nM or less for HLA class II molecules, are further evaluated for their ability to mduce a CTL or HTL response Immunogenic peptide epitopes are selected for inclusion in vaccme compositions Supermotif-beanng peptides may additionally be tested for the ability to bmd to multiple alleles withm the HLA supertype family Moreover, peptide epitopes may be analogued to modify bmdmg affinity and/or the ability to bmd to multiple alleles withm an HLA supertype The invention also includes embodiments compnsmg methods for monitoring or evaluating an immune response to a TAA in a patient havmg a known HLA-type Such methods compnse incubating a T lymphocyte sample from the patient with a peptide composition compnsmg a TAA epitope that has an ammo acid sequence described m, for example, Tables XXIII, XXIV, XXV, XXVI, XXVII, and XXXI which binds the product of at least one HLA allele present m the patient, and detecting for the presence of a T lymphocyte that binds to the peptide A CTL peptide epitope may, for example, be used as a component of a tetrameπc complex for this type of analysis An alternative modality for defining the peptide epitopes m accordance with the invention is to recite the physical properties, such as length, primary structure, or charge, which are correlated with bmdmg to a particular allele-specific HLA molecule or group of allele-specific HLA molecules A further modality for defining peptide epitopes is to recite the physical properties of an HLA bmdmg pocket, or properties shared by several allele-specific HLA bmdmg pockets (e g pocket configuration and charge distribution) and recitmg that the peptide epitope fits and binds to the pocket or pockets As will be apparent from the discussion below, other methods and embodiments are also contemplated Further, novel synthetic peptides produced by any of the methods descnbed herem are also part of the mvention III. BRIEF DESCRIPTION OF THE FIGURES not applicable IV. DETAILED DESCRIPTION OF THE INVENTION The peptide epitopes and corresponding nucleic acid compositions of the present invention are useful for stimulating an immune response to a TAA by stimulating the production of CTL or HTL responses The peptide epitopes, which are derived directly or indirectly from native TAA protem ammo acid sequences, are able to bind to HLA molecules and stimulate an immune response to the TAA The complete sequence ofthe TAA proteins to be analyzed can be obtained from GenBank Peptide epitopes and analogs thereof can also be readily determined from sequence mformation that may subsequently be discovered for heretofore unknown variants of particular TAAs, as will be clear from the disclosure provided below A list of target TAA mcludes, but is not limited to, the following antigens MAGE 1, MAGE 2, MAGE 3, MAGE- 11, MAGE-A10, BAGE, GAGE, RAGE, MAGE-C1, LAGE-1, CAG-3, DAM, MUC1, MUC2, MUC18, NY-ESO-1, MUM-1, CDK4, BRCA2, NY-LU-1, NY-LU-7, NY-LU-12, CASP8, RAS, KIAA-2-5, SCCs, p53, p73, CEA, Her 2/neu, Melan-A, gplOO, tyrosinase, TRP2, gp75/TRPl, kalhkrein, PSM, PAP, PSA, PT1-1, B-catemn, PRAME, Telomerase, FAK, cyclm DI protem, NOEY2, EGF-R, SART-1, CAPB, HPVE7, pi 5, Folate receptor CDC27, PAGE-1, and PAGE-4 The peptide epitopes ofthe invention have been identified m a number of ways, as will be discussed below Also discussed m greater detail is that analog peptides have been derived and the bmdmg activity for HLA molecules modulated by modifying specific ammo acid residues to create peptide analogs exhibitmg altered lmmunogenicity Further, the present mvention provides compositions and combinations of compositions that enable epitope-based vaccmes that are capable of interacting with HLA molecules encoded by various genetic alleles to provide broader population coverage than prior vaccmes IV.A. Definitions The invention can be better understood with reference to the following definitions, which are listed alphabetically A "construct" as used herein generally denotes a composition that does not occur m nature A construct can be produced by synthetic technologies, e g , recombinant DNA preparation and expression or chemical synthetic techniques for nucleic or ammo acids A construct can also be produced by the addition or affiliation of one material with another such that the result is not found m nature in that form A "computer" or "computer system" generally includes a processor, at least one mformation storage/retπeval apparatus such as, for example, a hard dπve, a disk dnve or a tape drive, at least one mput apparatus such as, for example, a keyboard, a mouse, a touch screen, or a microphone, and display structure Additionally, the computer may include a communication channel in communication with a network Such a computer may include more or less than what is listed above "Cross-reactive binding" mdicates that a peptide is bound by more than one HLA molecule, a synonym is degenerate bmdmg A "cryptic epitope" elicits a response by immunization with an isolated peptide, but the response is not cross-reactive in vitro when intact whole protein which compπses the epitope is used as an antigen A "dominant epitope" is an epitope that induces an immune response upon immunization with a whole native antigen (see, e g , Sercarz, et al , Annu Rev Immunol 11 729-766, 1993) Such a response is cross-reactive in vitro with an isolated peptide epitope With regard to a particular ammo acid sequence, an "epitope" is a set of ammo acid residues which is involved m recognition by a particular immunoglobulin, or in the context of T cells, those residues necessary for recognition by T cell receptor protems and/or Major Histocompatibility Complex (MHC) receptors In an immune system setting, in vivo or in vitro, an epitope is the collective features of a molecule, such as primary, secondary and tertiary peptide structure, and charge, that together form a site recognized by an immunoglobulin, T cell receptor or HLA molecule Throughout this disclosure epitope and peptide are often used mterchangeably It is to be appreciated that protein or peptide molecules that comprise an epitope of the mvention as well as additional amino acιd(s) are within the bounds of the mvention In certain embodiments, there is a limitation on the length of a peptide ofthe invention which is not otherwise a construct as defined herein An embodiment that is length-limited occurs when the protein/pephde comprising an epitope ofthe invention comprises a region (l e , a contiguous series of ammo acids) having 100% identity with a native sequence In order to avoid a recited definition of epitope from readmg, e g , on whole natural molecules, the length of any region that has 100% identity with a native peptide sequence is limited Thus, for a peptide compnsmg an epitope ofthe invention and a region with 100% identity with a native peptide sequence (and which is not otherwise a construct), the region with 100% identity to a native sequence generally has a length of less than or equal to 600 amino acids, often less than or equal to 500 ammo acids, often less than or equal to 400 ammo acids, often less than or equal to 250 ammo acids, often less than or equal to 100 ammo acids, often less than or equal to 85 ammo acids, often less than or equal to 75 ammo acids, often less than or equal to 65 amino acids, and often less than or equal to 50 ammo acids In certain embodiments, an "epitope" of the mvention which is not a construct is compnsed by a peptide havmg a region with less than 51 ammo acids that has 100% identity to a native peptide sequence, in any increment of (50, 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5) down to 5 amino acids Certain peptide or protein sequences longer than 600 amino acids are within the scope of the mvention Such longer sequences are withm the scope of the mvention so long as they do not comprise any contiguous sequence of more than 600 amino acids that have 100% identity with a native peptide sequence, or if longer than 600 amino acids, they are a construct For any peptide that has five contiguous residues or less that correspond to a native sequence, there is no limitation on the maximal length of that peptide m order to fall withm the scope of the invention It is presently prefened that a CTL epitope ofthe invention be less than 600 residues long m any increment down to eight ammo acid residues "Human Leukocyte Antigen" or "HLA" is a human class I or class II Major Histocompatibility Complex (MHC) protem (see, e g , Stites, et al , IMMUNOLOGY, 8™ ED , Lange Publishing, Los Altos, CA, 1994) An "HLA supertype or family", as used herein, describes sets of HLA molecules grouped on the basis of shared peptide-binding specificities. HLA class I molecules that share somewhat similar binding affinity for peptides bearing certain amino acid motifs are grouped into HLA supertypes. The terms HLA superfamily, HLA supertype family, HLA family, and HLA xx-like molecules (where xx denotes a 5 particular HLA type), are synonyms. Throughout this disclosure, results are expressed in terms of "ICso's." IC 50 is the concentration of peptide in a binding assay at which 50% inhibition of binding of a reference peptide is observed. Given the conditions in which the assays are run (i.e., limiting HLA proteins and labeled peptide concentrations), these values approximate K D values. Assays for determining binding are described in detail, e.g., in PCT ft) publications WO 94/20127 and WO 94/03205. It should be noted that IC 50 values can change, often dramatically, if the assay conditions are varied, and depending on the particular reagents used (e.g., HLA preparation, etc.). For example, excessive concentrations of HLA molecules will increase the apparent measured IC 50 of a given ligand. Alternatively, binding is expressed relative to a reference peptide. Although as a particular assay 15 becomes more, or less, sensitive, the ICso's of the peptides tested may change somewhat, the binding relative to the reference peptide will not significantly change. For example, in an assay run under conditions such that the IC 50 ofthe reference peptide increases 10-fold, the IC 50 values ofthe test peptides will also shift approximately 10-fold. Therefore, to avoid ambiguities, the assessment of whether a peptide is a good, intermediate, weak, or negative binder is generally based on its IC 50 , relative to the IC 50 of a 0 standard peptide. Binding may also be determined using other assay systems including those using: live cells (e.g., Ceppellini et al, Nature 339:392, 1989; Christnick et al, Nature 352:67, 1991; Busch et al, Int. Immunol. 2:443, 19990; Hill et al, J. Immunol. 147: 189, 1991; del Guercio et al, J. Immunol. 154:685, 1995), cell free systems using detergent lysates (e.g., Cerundolo et al., J. Immunol. 21 :2069, 1991), immobilized 5 purified MHC (e.g., Hill et al, J. Immunol. 152, 2890, 1994; MarshaU et al, J. Immunol. 152:4946, 1994), ELISA systems (e.g., Reay et al, EMBO J. 11 :2829, 1992), surface plasmon resonance (e.g., Khilko et al, J. Biol. Chem. 268: 15425, 1993); high flux soluble phase assays (Hammer et al, J. Exp. Med. 180:2353, 1994), and measurement of class I MHC stabilization or assembly (e.g., Ljunggren et al, Nature 346:476, 1990; Schumacher et al, Cell 62:563, 1990; Townsend et al, Cell 62:285, 1990; Parker et al, J. Immunol. 0 149: 1896, 1992). As used herein, "high affinity" with respect to HLA class I molecules is defined as binding with an IC 50 , or K D value, of 50 nM or less; "intermediate affinity" is binding with an IC 50 or K D value of between about 50 and about 500 nM. "High affinity" with respect to binding to HLA class II molecules is defined as binding with an IC 50 or K D value of 100 nM or less; "intermediate affinity" is binding with an IC 50 or K D 5 value of between about 100 and about 1000 nM. The terms "identical" or percent "identity," in the context of two or more peptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues that are the same, when compared and aligned for maximum correspondence over a comparison window, as measured using a sequence comparison algorithm or by manual alignment and visual 0 inspection. An "immunogemc peptide" or "peptide epitope" is a peptide that comprises an allele-specific motif or supermotif such that the peptide will bind an HLA molecule and mduce a CTL and/or HTL response Thus, immunogemc peptides of the invention are capable of bmdmg to an appropnate HLA molecule and thereafter inducing a cytotoxic T cell response, or a helper T cell response, to the antigen from which the immunogemc peptide is derived The phrases "isolated" or "biologically pure" refer to material which is substantially or essentially free from components which normally accompany the material as it is found m its native state Thus, isolated peptides in accordance with the invention preferably do not contain matenals normally associated with the peptides m their in situ environment "Link" or "join" refers to any method known in the art for functionally connecting peptides, including, without limitation, recombmant fusion, covalent bondmg, disulfide bonding, ionic bonding, hydrogen bonding, and electrostatic bonding "Major Histocompatibility Complex" or "MHC" is a cluster of genes that plays a role m control of the cellular interactions responsible for physiologic immune responses In humans, the MHC complex is also known as the HLA complex For a detailed description of the MHC and HLA complexes, see, Paul, FUNDAMENTAL IMMUNOLOGY, 3 RD ED , Raven Press, New York, 1993 The term "motif refers to the pattern of residues m a peptide of defined length, usually a peptide of from about 8 to about 13 ammo acids for a class I HLA motif and from about 6 to about 25 ammo acids for a class II HLA motif, which is recognized by a particular HLA molecule Peptide motifs are typically different for each protein encoded by each human HLA allele and differ m the pattern of the primary and secondary anchor residues A "negative binding residue" or "deleterious residue" is an ammo acid which, if present at certain positions (typically not pnmary anchor positions) m a peptide epitope, results m decreased bmdmg affinity of the peptide for the peptide's conespondmg HLA molecule A "non-native" sequence or "construct" refers to a sequence that is not found m nature, i e , is "non-naturally occurring" Such sequences mclude, e , peptides that are lipidated or otherwise modified, and polyepitopic compositions that contam epitopes that are not contiguous in a native protem sequence The term "peptide" is used interchangeably with "oligopeptide" m the present specification to designate a series of residues, typically -amino acids, connected one to the other, typically by peptide bonds between the α-amino and carboxyl groups of adjacent ammo acids The preferred CTL-inducing peptides of the invention are 13 residues or less m length and usually consist of between about 8 and about 11 residues, preferably 9 or 10 residues The prefened HTL-mducmg oligopeptides are less than about 50 residues m length and usually consist of between about 6 and about 30 residues, more usually between about 12 and 25, and often between about 15 and 20 residues "Pharmaceutically acceptable" refers to a generally non-toxic, inert, and/or physiologically compatible composition A "pharmaceutical excipient" comprises a mateπal such as an adjuvant, a earner, pH-adjustrng and buffermg agents, tonicity adjusting agents, wetting agents, preservative, and the like A "pnmary anchor residue" is an ammo acid at a specific position along a peptide sequence which is understood to provide a contact point between the lmmunogenic peptide and the HLA molecule One to three, usually two, pnmary anchor residues within a peptide of defined length generally defines a "motif for an immunogemc peptide These residues are understood to fit in close contact with peptide binding grooves of an HLA molecule, with their side chains buried m specific pockets of the bindmg grooves themselves In one embodiment, for example, the primary anchor residues are located at position 2 (from the amino terminal position) and at the carboxyl terminal position of a 9-resιdue peptide epitope m accordance with the invention The primary anchor positions for each motif and supermotif are set forth m Table 1 For example, analog peptides can be created by altering the presence or absence of particular residues m these primary anchor positions Such analogs are used to modulate the bmding affinity of a peptide compnsmg a particular motif or supermotif "Promiscuous recognition" is where a distmct peptide is recognized by the same T cell clone m the context of various HLA molecules Promiscuous recognition or bmdmg is synonymous with cross-reactive binding A "protective immune response" or "therapeutic immune response" refers to a CTL and/or an HTL response to an antigen derived from an infectious agent or a tumor antigen, which prevents or at least partially anests disease symptoms or progression The immune response may also include an antibody response which has been facilitated by the stimulation of helper T cells The term "residue" refers to an amino acid or ammo acid mimetic incorporated mto an oligopeptide by an amide bond or amide bond mimetic A "secondary anchor residue" is an ammo acid at a position other than a primary anchor position m a peptide which may influence peptide bmdmg A secondary anchor residue occurs at a significantly higher frequency amongst bound peptides than would be expected by random distribution of amino acids at one position The secondary anchor residues are said to occur at "secondary anchor positions " A secondary anchor residue can be identified as a residue which is present at a higher frequency among high or mtermediate affinity bindmg peptides, or a residue otherwise associated with high or intermediate affinity bindmg For example, analog peptides can be created by altermg the presence or absence of particular residues m these secondary anchor positions Such analogs are used to finely modulate the bmdmg affinity of a peptide compnsmg a particular motif or supermotif A "subdominant epitope" is an epitope which evokes little or no response upon immunization with whole antigens which comprise the epitope, but for which a response can be obtamed by immunization with an isolated peptide, and this response (unlike the case of cryptic epitopes) is detected when whole protein is used to recall the response in vitro or in vivo A "supermotif is a peptide bmdmg specificity shared by HLA molecules encoded by two or more HLA alleles Preferably, a supermotif-beanng peptide is recognized with high or mtermediate affinity (as defined herem) by two or more HLA molecules "Synthetic peptide" refers to a peptide that is man-made usmg such methods as chemical synthesis or recombinant DNA technology As used herem, a "vaccine" is a composition that contams one or more peptides of the mvention There are numerous embodiments of vaccmes m accordance with the mvention, such as by a cocktail of one or more peptides, one or more epitopes ofthe mvention comprised by a polyepitopic peptide, or nucleic acids that encode such peptides or polypeptides, e g , a minigene that encodes a polyepitopic peptide The "one or more peptides" can include any whole unit integer from 1-150, e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 , 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150 or more peptides of the invention. The peptides or polypeptides can optionally be modified, such as by lipidation, addition of targeting or other sequences. HLA class I-binding peptides of the invention can be admixed with, or linked to, HLA class II-binding peptides, to facilitate activation of both cytotoxic T lymphocytes and helper T lymphocytes. Vaccines can also comprise peptide-pulsed antigen presenting cells, e.g., dendritic cells. The nomenclature used to describe peptide compounds follows the conventional practice wherein the amino group is presented to the left (the N-terminus) and the carboxyl group to the right (the C- terminus) of each amino acid residue. When amino acid residue positions are refened to in a peptide epitope they are numbered in an amino to carboxyl direction with position one being the position closest to the amino terminal end ofthe epitope, or the peptide or protein of which it may be a part. In the formulae representing selected specific embodiments of the present invention, the amino- and carboxyl-terminal groups, although not specifically shown, are in the form they would assume at physiologic pH values, unless otherwise specified. In the amino acid structure formulae, each residue is generally represented by standard three letter or single letter designations. The L-form of an amino acid residue is represented by a capital single letter or a capital first letter of a three-letter symbol, and the D-form for those amino acids having D-forms is represented by a lower case single letter or a lower case three letter symbol. Glycine has no asymmetric carbon atom and is simply refened to as "Gly" or G. The amino acid sequences of peptides set forth herein are generally designated using the standard single letter symbol. (A, Alanine; C, Cysteine; D, Aspartic Acid; E, Glutamic Acid; F, Phenylalanine; G, Glycine; H, Histidine; I, Isoleucine; K, Lysine; L, Leucine; M, Methionine; N, Asparagine; P, Proline; Q, Glutamine; R, Arginine; S, Serine; T, Threonine; V, Valine; W, Tryptophan; and Y, Tyrosine.) In addition to these symbols, "B"in the single letter abbreviations used herein designates -amino butyric acid. IV .B. Stimulation of CTL and HTL responses The mechanism by which T cells recognize antigens has been delineated during the past ten years. Based on our understanding of the immune system we have developed efficacious peptide epitope vaccine compositions that can induce a therapeutic or prophylactic immune response to a TAA in a broad population. For an understanding ofthe value and efficacy of the claimed compositions, a brief review of immunology-related technology is provided. The review is intended to disclose the presently understood state of the art as of the filing date of the present application. Information is included in this section which was generated subsequent to the priority date of this application. Accordingly, information in this section is not intended, in any way, to delineate the priority date for the invention. A complex of an HLA molecule and a peptidic antigen acts as the ligand recognized by HLA- restricted T cells (Buus, S. et al, Cell 47: 1071, 1986; Babbitt, B. P. et al, Nature 317:359, 1985; Townsend, A. and Bodmer, H., Annu. Rev. Immunol. 7:601, 1989; Germain, R. N., Annu. Rev. Immunol. 11 :403, 1993). Through the study of single amino acid substituted antigen analogs and the sequencing of endogenously bound, naturally processed peptides, critical residues that conespond to motifs required for specific binding to HLA antigen molecules have been identified and are described herem and are set forth in Tables I, II, and III (see also, e g , Southwood, et al , J Immunol 160 3363, 1998, Rammensee, et al , Immunogenetics 41 178, 1995, Rammensee et al , SYFPEITHI, access via web at http //134 2 96 221/scπpts hlaserver dll home htm, Sette, A and Sidney, J Cuir Opin Immunol 10 478, 1998, Engelhard, V H , Curr Opin Immunol 6 13, 1994, Sette, A and Grey, H M , Curr Opin Immunol 4 79, 1992, Simgagha, F and Hammer, J Curr Biol 6 52, 1994, Ruppert et al , Cell 74 929-937, 1993, Kondo et al , J Immunol 155 4307-4312, 1995, Sidney et al , J Immunol 157 3480-3490, 1996, Sidney et al , Human Immunol 45 79-93, 1996, Sette, A and Sidney, J Immunogenetics 1999 Nov.50(3-4) 201-12 Review) Furthermore, x-ray crystallographic analysis of HLA-peptide complexes has revealed pockets within the peptide binding cleft of HLA molecules which accommodate, m an allele-specific mode, residues bome by peptide ligands, these residues in turn determine the HLA bmdmg capacity ofthe peptides m which they are present (See, e g , Madden, D R Annu Rev Immunol 13 587, 1995, Smith, et al , Immunity 4 203, 1996, Fremont et al , Immunity 8 305, 1998, Stern et al , Structure 2 245, 1994, Jones, E Y Curr Opin Immunol 9 75, 1997, Brown, J H et al , Nature 364 33, 1993, Guo, H C et al , Proc Natl Acad Sci USA 90 8053, 1993, Guo, H C et al , Nature 360 364, 1992, Silver, M L et al , Nature 360 367, 1992, Matsumura, M et al , Science 257 927, 1992, Madden et al , Cell 70 1035, 1992, Fremont, D H et al , Science 257 919, 1992, Saper, M A , Bjorkman, P J and Wiley, D C , J Mol Biol 219 277, 1991 ) Accordingly, the definition of class I and class II allele-specific HLA binding motifs, or class I or - class II supermotifs allows identification of regions withm a protem that have the potential of bmdmg particular HLA molecules The present inventors have found that the conelahon of bmdmg affinity with immunogenicity, which is disclosed herein, is an important factor to be considered when evaluating candidate peptides Thus, by a combmation of motif searches and HLA-peptide bmdmg assays, candidates for epitope-based vaccines have been identified After determining then bmdmg affinity, additional confirmatory work can be performed to select, amongst these vaccme candidates, epitopes with prefened characteristics m terms of population coverage, antigenicity, and immunogenicity Various strategies can be utilized to evaluate immunogenicity, mcludmg 1) Evaluation of pnmary T cell cultures from normal individuals (see, e g , Wentworth, P A et al , Mol Immunol 32 603, 1995, Celis, E et al , Proc Natl Acad Sci USA 91 2105, 1994, Tsai, V et al , J Immunol 158 1796, 1997, Kawashima, I et al , Human Immunol 59 1, 1998), This procedure involves the stimulation of peripheral blood lymphocytes (PBL) from normal subjects with a test peptide m the presence of antigen presenting cells in vitro over a penod of several weeks T cells specific for the peptide become activated duπng this time and are detected using, e , a ^ lQ-release assay mvolvmg peptide sensitized target cells 2) Immunization of HLA transgenic mice (see, e g , Wentworth, P A et al , J Immunol 26 97, 1996, Wentworth, P A et al nt Immunol 8 651, 1996, Alexander, J et al , J Immunol 159 4753, 1997), In this method, peptides m incomplete Freund's adjuvant are administered subcutaneously to HLA transgenic mice Several weeks following immunization, splenocytes are removed and cultured in vitro m the presence of test peptide for approximately one week Peptide-specific T cells are detected using, e , a -^Cr-release assay involving peptide sensitized target cells and target cells expressing endogenously generated antigen 3) Demonstration of recall T cell responses from patients who have been effectively vaccmated or who have a tumor, (see, e g , Rehermann, B et al , J Exp Med 181 1047, 1995, Doolan, D L et al , Immunity 7 97, 1997, Bertoni, R et al , J Clin Invest 100 503, 1997, Threlkeld, S C et al , J Immunol 159 1648, 1997, Diepolder, H M et al , J Virol 71 6011, 1997, Tsang et al , J Natl Cancer Ins t 87 982- 990, 1995, Disis et al , J Immunol 156 3151-3158, 1996) In applymg this strategy, recall responses are detected by cultunng PBL from patients with cancer who have generated an immune response "naturally", or from patients who were vaccmated with tumor antigen vaccmes PBL from subjects are cultured in vitro for 1-2 weeks in the presence of test peptide plus antigen presenting cells (APC) to allow activation of "memory" T cells, as compared to "naive" T cells At the end of the culture period, T cell activity is detected using assays for T cell activity including * *Cr release mvolvmg peptide-sensitized targets, T cell proliferation, or lymphokine release The following describes the peptide epitopes and conespondmg nucleic acids of the invention IV.C. Binding Affinity of Peptide Epitopes for HLA Molecules As indicated herein, the large degree of HLA polymorphism is an important factor to be taken into account with the epitope-based approach to vaccme development To address this factor, epitope selection encompassing identification of peptides capable of binding at high or mtermediate affinity to multiple HLA molecules is preferably utilized, most preferably these epitopes bmd at high or mtermediate affinity to two or more allele-specific HLA molecules CTL- inducing peptides of interest for vaccme compositions preferably mclude those that have an IC 5 o or binding affinity value for class I HLA molecules of 500 nM or better (; e , the value is < 500 nM) HTL-inducing peptides preferably mclude those that have an IC 50 or bmdmg affinity value for class II HLA molecules of 1000 nM or better, (z e , the value is < 1,000 nM) For example, peptide bmdmg is assessed by testing the capacity of a candidate peptide to bmd to a puπfied HLA molecule in vitro Peptides exhibiting high or intermediate affinity are then considered for further analysis Selected peptides are tested on other members of the supertype family In prefened embodiments, peptides that exhibit cross-reactive bmdmg are then used m cellular screenmg analyses or vaccmes As disclosed herem, higher HLA bmding affinity is conelated with greater immunogenicity Greater immunogenicity can be manifested in several different ways Immunogenicity conesponds to whether an immune response is elicited at all, and to the vigor of any particular response, as well as to the extent of a population in which a response is elicited For example, a peptide might elicit an immune response m a diverse anay ofthe population, yet in no instance produce a vigorous response Moreover, higher bmding affinity peptides lead to more vigorous immunogemc responses As a result, less peptide is required to elicit a similar biological effect if a high or mtermediate affinity bmdmg peptide is used Thus, m prefened embodiments ofthe mvention, high or intermediate affinity bindmg epitopes are particularly useful The relationship between bmdmg affinity for HLA class I molecules and immunogenicity of discrete peptide epitopes on bound antigens has been determmed for the first time in the art by the present inventors The conelation between bindmg affinity and immunogenicity was analyzed in two different experimental approaches (see, e g , Sette, et al , J Immunol 153 5586-5592, 1994) In the first approach, the immunogenicity of potential epitopes ranging m HLA bmdmg affinity over a 10,000- fold range was analyzed in HLA-A*0201 transgenic mice In the second approach, the antigenicity of approximately 100 different hepatitis B virus (HBV)-deπved potential epitopes, all carrying A*0201 bmdmg motifs, was assessed by using PBL from acute hepatitis patients Pursuant to these approaches, it was determmed that an affinity threshold value of approximately 500 nM (preferably 50 nM or less) determines the capacity of a peptide epitope to elicit a CTL response These data are true for class I bmdmg affinity measurements for naturally processed peptides and for synthesized T cell epitopes These data also indicate the important role of determmant selection in the shaping of T cell responses (see, e g , Schaeffer et al , Proc Natl Acad Sci USA 86 4649-4653, 1989) An affinity threshold associated with immunogenicity m the context of HLA class II DR molecules has also been delineated (see, e g , Southwood et al J Immunology 160 3363-3373,1998, and co-pendmg U S S N 09/009,953 filed 1/21/98) In order to define a biologically significant threshold of DR bmdmg affinity, a database of the bindmg affinities of 32 DR-restπcted epitopes for their restricting element (i e , the HLA molecule that bmds the motif) was compiled In approximately half of the cases (15 of 32 epitopes), DR restriction was associated with high bmdmg affinities, i e bmding affinity values of 100 nM or less In the other half of the cases (16 of 32), DR restriction was associated with mtermediate affinity (bmding affinity values m the 100-1000 nM range) In only one of 32 cases was DR restriction associated with an IC 50 of 1000 nM or greater Thus, 1000 nM can be defined as an affimty threshold associated with immunogenicity m the context of DR molecules In the case of tumor-associated antigens, many CTL peptide epitopes that have been shown to induce CTL that lyse peptide-pulsed target cells and tumor cell targets endogenously expressmg the epitope exhibit binding affinity or IC 50 values of 200 nM or less In a study that evaluated the association of binding affinity and immunogenicity of such TAA epitopes, 100% (10/10) ofthe high bmders, i e , peptide epitopes bindmg at an affinity of 50 nM or less, were immunogemc and 80% (8/10) of them elicited CTLs that specifically recognized tumor cells In the 51 to 200 nM range, very similar figures were obtamed CTL inductions positive for peptide and tumor cells were noted for 86% (6/7) and 71% (5/7) of the peptides, respectively In the 201-500 nM range, most peptides (4/5 wildtype) were positive for induction of CTL recogmzmg wildtype peptide, but tumor recognition was not detected The bindmg affinity of peptides for HLA molecules can be determined as descnbed m Example 1, below IV.D. Peptide Epitope Binding Motifs and Supermotifs Through the study of smgle ammo acid substituted antigen analogs and the sequencing of endogenously bound, naturally processed peptides, critical residues required for allele-specific bindmg to HLA molecules have been identified The presence of these residues conelates with bmdmg affinity for HLA molecules The identification of motifs and/or supermotifs that conelate with high and mtermediate affinity bmdmg is an important issue with respect to the identification of immunogemc peptide epitopes for the inclusion m a vaccme Kast et al (J Immunol 152 3904-3912, 1994) have shown that motif-beanng peptides account for 90% ofthe epitopes that bind to allele-specific HLA class I molecules In this study all possible peptides of 9 ammo acids in length and overlapping by eight amino acids (240 peptides), which cover the entire sequence of the E6 and E7 protems of human papillomavirus type 16, were evaluated for binding to five allele-specific HLA molecules that are expressed at high frequency among different ethnic groups This unbiased set of peptides allowed an evaluation of the predictive value of HLA class I motifs From the set of 240 peptides, 22 peptides were identified that bound to an allele-specific HLA molecule with high or intermediate affinity Of these 22 peptides, 20 (i e 91%) were motif-bearing Thus, this study demonstrates the value of motifs for the identification of peptide epitopes for inclusion in a vaccine application of motif-based identification techniques will identify about 90% of the potential epitopes m a target antigen protein sequence Such peptide epitopes are identified in the Tables described below Peptides of the present mvention also compnse epitopes that bmd to MHC class II DR molecules A greater degree of heterogeneity m both size and bmding frame position of the motif, relative to the N and C termini of the peptide, exists for class II peptide ligands This mcreased heterogeneity of HLA class II peptide ligands is due to the structure of the bmdmg groove of the HLA class II molecule which, unlike its class I counterpart, is open at both ends Crystallographic analysis of HLA class II DRB*0101-peptιde complexes showed that the major energy of binding is contributed by peptide residues complexed with complementary pockets on the DRB*0101 molecules An important anchor residue engages the deepest hydrophobic pocket (see, e g , Madden, D R Ann Rev Immunol 13 587, 1995) and is refened to as - position 1 (PI) PI may represent the N-termmal residue of a class II bmding peptide epitope, but more typically is flanked towards the N-terminus by one or more residues Other studies have also pomted to an important role for the peptide residue in the 6 th position towards the C-terminus, relative to PI, for bmdmg to various DR molecules In the past few years evidence has accumulated to demonstrate that a large fraction of HLA class I and class II molecules can be classified into a relatively few supertypes, each characterized by largely overlapping peptide bindmg repertoires, and consensus structures ofthe main peptide bmding pockets Thus, peptides of the present invention are identified by any one of several HLA-specific ammo acid motifs (see, e , Tables I-III), or if the presence of the motif conesponds to the ability to bmd several allele- specific HLA molecules, a supermotif The HLA molecules that bmd to peptides that possess a particular amino acid supermotif are collectively refened to as an HLA "supertype " The peptide motifs and supermotifs described below, and summarized m Tables I-III, provide guidance for the identification and use of peptide epitopes in accordance with the invention Examples of peptide epitopes bearmg a respective supermotif or motif are included m Tables as designated m the description of each motif or supermotif below The Tables include a bindmg affinity ratio listing for some ofthe peptide epitopes The ratio may be converted to IC 50 by using the followmg formula IC 50 of the standard peptide/ratio = IC 50 of the test peptide (1 e , the peptide epitope) The IC 50 values of standard peptides used to determine bmdmg affinities for Class I peptides are shown m Table IV The IC 50 values of standard peptides used to determine binding affinities for Class II peptides are shown m Table V The peptides used as standards for the binding assays described herem are examples of standards, alternative standard peptides can also be used when performing bmdmg studies To obtain the peptide epitope sequences listed in each of Tables VII-XX, the ammo acid sequence of p53 was evaluated for the presence ofthe designated supermotif or motif, i e , the ammo acid sequence was searched for the presence of the primary anchor residues as set out m Table I (for Class I motifs) or Table III (for Class II motifs) for each respective motif or supermotif In the Tables, the motif- and/or supermotif-beanng ammo acid sequences are identified by the position number and the length of the epitope with reference to the p53 ammo acid sequence and numbering provided below The "pos" (position) column designates the ammo acid position m the p53 protein sequence below that conesponds to the first ammo acid residue of the epitope The "number of ammo acids" indicates the number of residues m the epitope sequence and hence, the length of the epitope For example, the first peptide epitope listed m Table VII is a sequence of 8 residues in length starting at position 229 Accordingly, the amino acid sequence of the epitope is CTTIHYNY Bmdmg data presented m Tables VII-XX is expressed as a relative bmdmg ratio, supra p53 Amino Acid Sequence 1 MEEPQSDPSV EPPLSQETFS DL KLLPENN VLSP PSQAM DDLMLSPDDI EQWFTEDPGP 60 DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS PLSSSVPSQ KTYQGSYGFR LGFLHSGTAK 120 SVTCTYSPAL NKMFCQ AKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EWRRCPHHE 180 RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVWPY EPPEVGSDCT TIHYNYMCNS 240 SCMGGMNRRP I TIITLEDS SGNL GRNSF EVRVCACPGR DRRTEEENLR KKGEPHHE P 300 PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRE NEALEL KDAQAGKEPG 360 GSRAHSΞHLK SKKGQSTSRH KKLMFKTEGP DSD 393 HLA Class I Motifs Indicative of CTL Inducing Peptide Epitopes: The primary anchor residues of the HLA class I peptide epitope supermotifs and motifs delmeated below are summarized in Table I The HLA class I motifs set out m Table 1(a) are those most particularly relevant to the mvention claimed here Primary and secondary anchor positions are summarized m Table II Allele-specific HLA molecules that comprise HLA class I supertype families are listed m Table VI In some cases, peptide epitopes are listed m both a motif and a supermotif Table because ofthe overlappmg primary anchor specificity The relationship of a particular motif and respective supermotif is indicated m the descnption ofthe individual motifs IV.D.l. HLA-A1 supermotif The HLA-A1 supermotif is characterized by the presence m peptide ligands of a small (T or S) or hydrophobic (L, I, V, or M) primary anchor residue m position 2, and an aromatic (Y, F, or W) pnmary anchor residue at the C-terminal position of the epitope The conespondmg family of HLA molecules that bmd to the Al supermotif (i e , the HLA-A1 supertype) is compnsed of at least A*0101, A*2601, A*2602, A*2501, and A*3201 (yee, e g . DiBrmo, M et al , J Immunol 151 5930, 1993, DiBrmo, M et al , J Immunol 152 620, 1994, Kondo, A et al , Immunogenetics 45 249, 1997) Other allele-specific HLA molecules predicted to be members ofthe Al superfamily are shown m Table VI Peptides bmdmg to each of the individual HLA proteins can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the supermotif Representative peptide epitopes that comprise the Al supermotif are set forth m Table VII IV.D.2. HLA-A2 supermotif Primary anchor specificities for allele-specific HLA-A2 1 molecules (see, e g , Falk et al , Nature 351 290-296, 1991, Hunt et al , Science 255 1261-1263, 1992, Parker et al , J Immunol 149 3580-3587, 1992, Ruppert et al , Cell 74 929-937, 1993) and cross-reactive bmdmg among HLA-A2 and -A28 molecules have been described (See, e g , Fruci et al , Human Immunol 38 187-192, 1993, Tamgaki et al , Human Immunol 39 155-162, 1994, Del Guercio et al , J Immunol 154 685-693, 1995, Kast et al , J Immunol 152 3904-3912, 1994 for reviews of relevant data ) These primary anchor residues define the HLA-A2 supermotif, which presence m peptide ligands conesponds to the ability to bmd several different HLA-A2 and -A28 molecules The HLA-A2 supermotif compnses peptide ligands with L, I, V, M, A, T, or Q as a pnmary anchor residue at position 2 and L, I, V, M, A, or T as a pnmary anchor residue at the C- termmal position of the epitope The conespondmg family of HLA molecules (i e , the HLA-A2 supertype that binds these peptides) is compnsed of at least A*0201, A*0202, A*0203, A*0204, A*0205, A*0206, A*0207, A*0209, A*0214, A*6802, and A*6901 Other allele-specific HLA molecules predicted to be members of the A2 superfamily are shown in Table VI As explained m detail below, binding to each of the individual allele-specific HLA molecules can be modulated by substitutions at the primary anchor and/or secondary anchor positions, preferably choosmg respective residues specified for the supermotif Representative peptide epitopes that comprise an A2 supermotif are set forth m Table VIII The motifs comprising the primary anchor residues V, A, T, or Q at position 2 and L, I, V, A, or T at the C- terminal position are those most particularly relevant to the mvention claimed herein IV.D.3. HLA-A3 supermotif The HLA-A3 supermotif is characterized by the presence in peptide ligands of A, L, I, V, M, S, or, T as a primary anchor at position 2, and a positively charged residue, R or K, at the C-terminal position of the epitope, e g , m position 9 of 9-mers (see, e g , Sidney et al , Hum Immunol 45 79, 1996) Exemplary members ofthe conespondmg family of HLA molecules (the HLA- A3 supertype) that bind the A3 supermotif include at least A*0301, A* 1101, A*3101, A*3301, and A*6801 Other allele-specific HLA molecules predicted to be members of the A3 supertype are shown m Table VI As explamed m detail below, peptide bindmg to each of the individual allele-specific HLA protems can be modulated by substitutions of ammo acids at the pnmary and/or secondary anchor positions of the peptide, preferably choosmg respective residues specified for the supermotif Representative peptide epitopes that comprise the A3 supermotif are set forth m Table IX IV.D.4. HLA-A24 supermotif The HLA-A24 supermotif is characterized by the presence m peptide ligands of an aromatic (F, W, or Y) or hydrophobic aliphatic (L, I, V, M, or T) residue as a pnmary anchor m position 2, and Y, F, W, L, I, or M as pnmary anchor at the C-terminal position of the epitope (see, e g , Sette and Sidney, Immunogenetics 1999 Nov, 50(3-4) 201-12, Review) The conespondmg family of HLA molecules that bmd to the A24 supermotif (i e , the A24 supertype) includes at least A*2402, A*3001, and A*2301 Other allele-specific HLA molecules predicted to be members ofthe A24 supertype are shown m Table VI Peptide bmdmg to each of the allele-specific HLA molecules can be modulated by substitutions at primary and or secondary anchor positions, preferably choosmg respective residues specified for the supermotif Representative peptide epitopes that comprise the A24 supermotif are set forth m Table X IV.D.5. HLA-B7 supermotif The HLA-B7 supermotif is charactenzed by peptides bearing proline m position 2 as a primary anchor, and a hydrophobic or aliphatic ammo acid (L, I, V, M, A, F, W, or Y) as the primary anchor at the C-terminal position of the epitope The conespondmg family of HLA molecules that bmd the B7 supermotif (; e , the HLA-B7 supertype) is comprised of at least twenty six HLA-B proteins comprising at least B*0702, B*0703, B*0704, B*0705, B* 1508, B*3501, B*3502, B*3503, B*3504, B*3505, B*3506, B*3507, B*3508, B*5101, B*5102, B*5103, B*5104, B*5105, B*5301, B*5401, B*5501, B*5502, B*5601, B*5602, B*6701, and B*7801 (see, e g , Sidney, et al , J Immunol 154 247, 1995, Barber, et al , - Curr Biol 5 179, 1995, Hill, et al , Nature 360 434, 1992, Rammensee, et al , Immunogenetics 41 178, 1995 for reviews of relevant data) Other allele-specific HLA molecules predicted to be members of the B7 supertype are shown m Table VI As explamed m detail below, peptide bmdmg to each of the individual allele-specific HLA proteins can be modulated by substitutions at the pnmary and/or secondary anchor positions of the peptide, preferably choosmg respective residues specified for the supermotif Representative peptide epitopes that comprise the B7 supermotif are set forth in Table XI IV.D.6. HLA-B27 supermotif The HLA-B27 supermotif is charactenzed by the presence m peptide ligands of a positively charged (R, H, or K) residue as a pnmary anchor at position 2, and a hydrophobic (F, Y, L, W, M, I, A, or V) residue as a primary anchor at the C-terminal position of the epitope (see, e g , Sidney and Sette, Immunogenetics 1999 Nov, 50(3-4) 201-12, Review) Exemplary members ofthe conespondmg family of HLA molecules that bind to the B27 supermotif (; e , the B27 supertype) mclude at least B* 1401, B*1402, B*1509, B*2702, B*2703, B*2704, B*2705, B*2706, B*3801, B*3901, B*3902, and B*7301 Other allele-specific HLA molecules predicted to be members of the B27 supertype are shown in Table VI Peptide bindmg to each of the allele-specific HLA molecules can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosmg respective residues specified for the supermotif Representative peptide epitopes that compπse the B27 supermotif are set out m Table XII IV.D.7. HLA-B44 supermotif The HLA-B44 supermotif is characterized by the presence m peptide ligands of negatively charged (D or E) residues as a primary anchor in position 2, and hydrophobic residues (F, W, Y, L, I, M, V, or A) as a primary anchor at the C-terminal position of the epitope (see, e g , Sidney et al , Immunol Today 17 261, 1996) Exemplary members of the conespondmg family of HLA molecules that bind to the B44 supermotif (i e , the B44 supertype) include at least B* 1801, B* 1802, B*3701, B*4001, B*4002, B*4006, B*4402, B*4403, and B*4404 Peptide bmding to each of the allele-specific HLA molecules can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosmg respective residues specified for the supermotif IV.D.8. HLA-B58 supermotif The HLA-B58 supermotif is characterized by the presence m peptide ligands of a small aliphatic residue (A, S, or T) as a pnmary anchor residue at position 2, and an aromatic or hydrophobic residue (F, W, Y, L, I, V, M, or A) as a primary anchor residue at the C-terminal position of the epitope (see, e g , Sidney and Sette, Immunogenetics 1999 Nov, 50(3-4) 201-12, Review) Exemplary members of the conespondmg family of HLA molecules that bmd to the B58 supermotif (; e , the B58 supertype) mclude at least B*1516, B*1517, B*5701, B*5702, and B*5801 Other allele-specific HLA molecules predicted to be members of the B58 supertype are shown in Table VI Peptide bmdmg to each ofthe allele-specific HLA molecules can be modulated by substitutions at primary and/or secondary anchor positions, preferably _ choosing respective residues specified for the supermotif Representative peptide epitopes that comprise the B58 supermotif are set forth m Table XIII IV.D.9. HLA-B62 supermotif The HLA-B62 supermotif is characterized by the presence m peptide ligands of the polar aliphatic residue Q or a hydrophobic aliphatic residue (L, V, M, I, or P) as a pnmary anchor m position 2, and a hydrophobic residue (F, W, Y, M, I, V, L, or A) as a pnmary anchor at the C-termmal position ofthe epitope (see, e g , Sidney and Sette, Immunogenetics 1999 Nov, 50(3-4) 201-12, Review) Exemplary members ofthe conespondmg family of HLA molecules that bmd to the B62 supermotif (; e , the B62 supertype) mclude at least B* 1501, B*1502, B*1513, and B5201 Other allele-specific HLA molecules predicted to be members of the B62 supertype are shown m Table VI Peptide bindmg to each ofthe allele- specific HLA molecules can be modulated by substitutions at pnmary and/or secondary anchor positions, preferably choosing respective residues specified for the supermotif Representative peptide epitopes that compnse the B62 supermotif are set forth m Table XIV IV.D.10. HLA-A1 motif The HLA-A1 motif is characterized by the presence m peptide ligands of T, S, or M as a primary anchor residue at position 2 and the presence of Y as a pnmary anchor residue at the C-termmal position of the epitope An alternative allele-specific Al motif is charactenzed by a pnmary anchor residue at position 3 rather than position 2 This motif is characterized by the presence of D, E, A, or S as a pnmary anchor residue in position 3, and a Y as a primary anchor residue at the C-termmal position ofthe epitope (see, e g , DiBrmo et al , J Immunol , 152 620, 1994, Kondo et al , Immunogenetics 45 249, 1997, and Kubo et al , J Immunol 152 3913, 1994 for reviews of relevant data) Peptide bmdmg to HLA-A1 can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the motif Representative peptide epitopes that compnse either Al motif are set forth in Table XV Those epitopes comprising T, S, or M at position 2 and Y at the C-terminal position are also mcluded m the listing of HLA -A 1 supermotif-beanng peptide epitopes listed in Table VII, as these residues are a subset of the Al supermotif primary anchors IV.D.11. HLA-A*0201 motif An HLA-A2*0201 motif was determmed to be characterized by the presence m peptide ligands of L or M as a primary anchor residue in position 2, and L or V as a primary anchor residue at the C-terminal position of a 9-resιdue peptide (see, e g , Falk et al , Nature 351 290-296, 1991) and was further found to compnse an I at position 2 and I or A at the C-terminal position of a nme ammo acid peptide (see, e g , Hunt et al , Science 255 1261-1263, March 6, 1992, Parker et al , J Immunol 149 3580-3587, 1992) The A*0201 allele-specific motif has also been defined by the present inventors to additionally comprise V, A, T, or Q as a primary anchor residue at position 2, and M or T as a pnmary anchor residue at the C-termmal position of the epitope (see, e g , Kast et al , J Immunol 152 3904-3912, 1994) Thus, the HLA-A*0201 motif compnses peptide ligands with L, I, V, M, A, T, or Q as pnmary anchor residues at position 2 and L, - I, V, M, A, or T as a primary anchor residue at the C-termmal position ofthe epitope The prefened and tolerated residues that characterize the primary anchor positions of the HLA-A*0201 motif are identical to the residues descnbmg the A2 supermotif (For reviews of relevant data, .see, e , del Guercio et al , J Immunol 154 685-693, 1995, Ruppert et al , Cell 74 929-937, 1993, Sidney et al , Immunol Today 17 261- 266, 1996, Sette and Sidney, Curr Opin in Immunol 10 478-482, 1998) Secondary anchor residues that characterize the A*0201 motif have additionally been defined (see, e , Ruppert et al , Cell 74 929-937, 1993) These are shown m Table II Peptide bmdmg to HLA-A*0201 molecules can be modulated by substitutions at pnmary and/or secondary anchor positions, preferably choosmg respective residues specified for the motif Representative peptide epitopes that comprise an A*0201 motif are set forth in Table VIII The A*0201 motifs compnsmg the primary anchor residues V, A, T, or Q at position 2 and L, I, V, A, or T at the C-termmal position are those most particularly relevant to the mvention claimed herem IV.D.12. HLA-A3 motif The HLA- A3 motif is charactenzed by the presence m peptide ligands of L, M, V, I, S, A, T, F, C, G, or D as a pnmary anchor residue at position 2, and the presence of K, sY, R, H, F, or A as a primary anchor residue at the C-termmal position ofthe epitope (see, e g , DiBrmo et al , Proc Natl Acad Sci USA 90 1508, 1993, and Kubo et al , J Immunol 152 3913-3924, 1994) Peptide bmdmg to HLA-A3 can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosmg respective residues specified for the motif Representative peptide epitopes that compnse the A3 motif are set forth m Table XVI Those peptide epitopes that also comprise the A3 supermotif are also listed m Table IX The A3 supermotif primary anchor residues comprise a subset of the A3- and Al 1 -allele specific motif primary anchor residues IV.D.13. HLA-411 motif The HLA- A 11 motif is characterized by the presence m peptide ligands of V, T, M, L, I, S, A, G, N, C, D, or F as a primary anchor residue in position 2, and K, R, Y, or H as a primary anchor residue at the C-temunal position of the epitope (see, e g , Zhang et al , Proc Natl Acad Set USA 90 2217-2221, 1993, and Kubo et al , J Immunol 152 3913-3924, 1994) Peptide bmdmg to HLA-Al 1 can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the motif Representative peptide epitopes that compnse the Al 1 motif are set forth in Table XVII, peptide epitopes compnsmg the A3 allele-specific motif are also present m this Table because of the extensive overlap between the A3 and Al 1 motif pnmary anchor specificities Further, those peptide epitopes that comprise the A3 supermotif are also listed in Table IX IV.D.14. HLA-A24 motif The HLA-A24 motif is charactenzed by the presence m peptide ligands of Y, F, W, or M as a primary anchor residue in position 2, and F, L, I, or W as a pnmary anchor residue at the C-termmal position ofthe epitope (see, e , Kondo et al , J Immunol 155 4307-4312, 1995, and Kubo et al , J Immunol 152 3913-3924, 1994) Peptide bmdmg to HLA-A24 molecules can be modulated by substitutions at primary and or secondary anchor positions, preferably choosing respective residues specified for the motif Representative peptide epitopes that comprise the A24 motif are set forth m Table XVIII These epitopes are also listed in Table X, which sets forth HLA-A24-supermotιf-beaπng peptide epitopes, as the primary anchor residues characteπzmg the A24 allele-specific motif compnse a subset ofthe A24 supermotif pnmary anchor residues Motifs Indicative of Class II HTL Inducing Peptide Epitopes The pnmary and secondary anchor residues of the HLA class II peptide epitope supermotifs and motifs delineated below are summarized in Table III IV.D.15. HLA DR-1-4-7 supermotif Motifs have also been identified for peptides that bmd to three common HLA class II allele- specific HLA molecules HLA DRB 1 *0401, DRB1*0101, and DRB 1 *0701 (see, e g , the review by Southwood et al J Immunology 160 3363-3373,1998) Collectively, the common residues from these motifs delmeate the HLA DR-1-4-7 supermotif Peptides that bmd to these DR molecules carry a supermotif charactenzed by a large aromatic or hydrophobic residue (Y, F, W, L, I, V, or M) as a pnmary anchor residue m position 1, and a small, non-charged residue (S, T, C, A, P, V, I, L, or M) as a primary anchor residue m position 6 of a 9-mer core region Allele-specific secondary effects and secondary anchors for each of these HLA types have also been identified (Southwood et al , supra) These are set forth m Table III Peptide binding to HLA- DRB 1 *0401, DRB 1 *0101, and/or DRB 1 *0701 can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosmg respective residues specified for the supermotif Potential epitope 9-mer core regions compnsmg the DR-1-4-7 supermotif, where position 1 of the supermotif is at position 1 of the nine-residue core, are set forth m Table XIX Respective exemplary peptide epitopes of 15 amino acid residues in length, each of which comprise the nme residue core, are also shown in the Table along with cross-reactive bmding data for the exemplary 15-resιdue supermotif-beanng peptides IV.D.16. HLA DR3 motifs Two alternative motifs (i e , submotifs) characterize peptide epitopes that bind to HLA-DR3 molecules (see, e g , Geluk et al , J Immunol 152 5742, 1994) In the first motif (submotif DR3a) a large, hydrophobic residue (L, I, V, M, F, or Y) is present in anchor position 1 of a 9-mer core, and D is present as an anchor at position 4, towards the carboxyl termmus of the epitope As m other class II motifs, core position 1 may or may not occupy the peptide N-termmal position The alternative DR3 submotif provides for lack of the large, hydrophobic residue at anchor position 1, and/or lack ofthe negatively charged or amide-like anchor residue at position 4, by the presence ~ of a positive charge at position 6 towards the carboxyl termmus of the epitope Thus, for the alternative allele-specific DR3 motif (submotif DR3b) L, I, V, M, F, Y, A, or Y is present at anchor position 1, D, N, Q, E, S, or T is present at anchor position 4, and K, R, or H is present at anchor position 6 Peptide bmdmg to HLA-DR3 can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosmg respective residues specified for the motif Potential peptide epitope 9-mer core regions conespondmg to a nme residue sequence compnsmg the DR3a submotif (wherein position 1 of the motif is at position 1 of the nme residue core) are set forth m Table XXa Respective exemplary peptide epitopes of 15 ammo acid residues m length, each of which comprise the nme residue core, are also shown in Table XXa along with bmdmg data for the exemplary DR3 submotif a-bearmg peptides Potential peptide epitope 9-mer core regions compnsmg the DR3b submotif and respective exemplary 15-mer peptides comprising the DR3 submotif-b epitope are set forth in Table XXb along with bmdmg data for the exemplary DR3 submotif b-bearmg peptides Each ofthe HLA class I or class II peptide epitopes set out m the Tables herem are deemed smgly to be an mventive aspect of this application Further, it is also an mventive aspect of this application that each peptide epitope may be used in combination with any other peptide epitope IV.E. Enhancing Population Coverage of the Vaccine Vaccmes that have broad population coverage are prefened because they are more commercially viable and generally applicable to the most people Broad population coverage can be obtamed usmg the peptides of the mvention (and nucleic acid compositions that encode such peptides) through selectmg peptide epitopes that bind to HLA alleles which, when considered m total, are present in most of the population Table XXI lists the overall frequencies of the HLA class I supertypes in various ethnicities (Table XXIa) and the combined population coverage achieved by the A2-, A3-, and B7-supertypes (Table XXIb) The A2-, A3-, and B7 supertypes are each present on the average of over 40% in each of these five major ethnic groups Coverage in excess of 80% is achieved with a combination of these supermotifs These results suggest that effective and non-ethmcally biased population coverage is achieved upon use of a limited number of cross-reactive peptides Although the population coverage reached with these three mam peptide specificities is high, coverage can be expanded to reach 95% population coverage and above, and more easily achieve truly multispecific responses upon use of additional supermotif or allele-specific motif bearing peptides The B44-, A1-, and A24-supertypes are each present, on average, m a range from 25% to 40% m these major ethnic populations (Table XXIa) While less prevalent overall, the B27-, B58-, and B62 supertypes are each present with a frequency >25% in at least one major ethnic group (Table XXIa) Table XXIb summanzes the estimated prevalence of combmations of HLA supertypes that have been identified m five major ethnic groups The mcremental coverage obtained by the inclusion of Al,- A24-, and B44- supertypes to the A2, A3, and B7 coverage and coverage obtamed with all ofthe supertypes descπbed herem, is shown The data presented herem, together with the previous definition of the A2-, A3-, and B7- supertypes, mdicates that all antigens, with the possible exception of A29, B8, and B46, can be classified mto a total of nme HLA supertypes By mcluding epitopes from the six most frequent supertypes, an average population coverage of 99% is obtamed for five major ethnic groups IV.F. Immune Response-Stimulating Peptide Analogs In general, CTL and HTL responses are not directed agamst all possible epitopes Rather, they are restncted to a few "lmmunodominant" determinants (Zinkernagel, et al , Adv Immunol 27 5159, 1979, Bennink, et al , J Exp Med 168 19351939, 1988, Rawle, et al , J Immunol 146 3977-3984, 1991) It has been recognized that immunodominance (Benacenaf, et al , Science 175 273-279, 1972) could be explamed by either the ability of a given epitope to selectively bmd a particular HLA protem (determmant selection theory) (Vitiello, et al , J Immunol 131 1635, 1983), Rosenthal, et al , Nature 267 156-158, 1977), or to be selectively recognized by the existing TCR (T cell receptor) specificities (repertoire theory) (Klem, J , IMMUNOLOGY, THE SCIENCE OF SELF/NONSELF DISCRIMINATION, John Wiley & Sons, New York, pp 270- 310, 1982) It has been demonstrated that additional factors, mostly linked to processing events, can also play a key role m dictatmg, beyond strict unmunogemcity, which ofthe many potential determinants will be presented as immuno dominant (Sercarz, et al , Annu Rev Immunol 11 729-766, 1993) Because tissue specific and developmental TAAs are expressed on normal tissue at least at some point m time or location within the body, it may be expected that T cells to them, particularly dommant epitopes, are eliminated during immunological surveillance and that tolerance is mduced However, CTL responses to tumor epitopes m both normal donors and cancer patient has been detected, which may mdicate that tolerance is mcomplete (see, e g , Kawashima et al , Hum Immunol 59 1, 1998, Tsang, J Natl Cancer Inst 87 82-90, 1995, Rongcun et al , J Immunol 163 1037, 1999) Thus, immune tolerance does not completely eliminate or inactivate CTL precursors capable of recognizmg high affinity HLA class I binding peptides An additional strategy to overcome tolerance is to use analog peptides Without intendmg to be bound by theory, it is believed that because T cells to dominant epitopes may have been clonally deleted, selecting subdominant epitopes may allow existing T cells to be recruited, which will then lead to a therapeutic or prophylactic response However, the binding of HLA molecules to subdominant epitopes is often less vigorous than to dommant ones Accordmgly, there is a need to be able to modulate the bmdmg affinity of particular immunogemc epitopes for one or more HLA molecules, and thereby to modulate the immune response elicited by the peptide, for example to prepare analog peptides which elicit a more vigorous response Although peptides with suitable cross-reactivity among all alleles of a superfamily are identified by the screening procedures described above, cross-reactivity is not always as complete as possible, and m certain cases procedures to mcrease cross-reactivity of peptides can be useful, moreover, such procedures can also be used to modify other properties of the peptides such as bmdmg affinity or peptide stability Havmg established the general rules that govern cross-reactivity of peptides for HLA alleles within a given motif or supermotif, modification (; e , analogmg) of the structure of peptides of particular interest m order to achieve broader (or otherwise modified) HLA binding capacity can be performed More specifically, peptides which exhibit the broadest cross-reactivity patterns, can be produced in accordance with the teachmgs herein The present concepts related to analog generation are set forth in greater detail in co- pending U S S N 09/226,775 filed 1/6/99 In brief, the strategy employed utilizes the motifs or supermotifs which conelate with bmdmg to certain HLA molecules The motifs or supermotifs are defined by havmg pnmary anchors, and m many cases secondary anchors Analog peptides can be created by substituting ammo acid residues at pnmary anchor, secondary anchor, or at primary and secondary anchor positions Generally, analogs are made for peptides that already bear a motif or supermotif Prefened secondary anchor residues of supermotifs and motifs that have been defined for HLA class I and class II bmdmg peptides are shown m Tables II and III, respectively For a number of the motifs or supermotifs in accordance with the invention, residues are defined which are deleterious to binding to allele-specific HLA molecules or members of HLA supertypes that bind the respective motif or supermotif (Tables II and III) Accordmgly, removal of such residues that are detrimental to bmdmg can be performed m accordance with the present mvention For example, m the case of the A3 supertype, when all peptides that have such deleteπous residues are removed from the population of peptides used m the analysis, the mcidence of cross-reactivity mcreased from 22% to 37% (see, e g , Sidney, J et al , Hu Immunol 45 79, 1996) Thus, one strategy to improve the cross-reactivity of peptides withm a given supermotif is simply to delete one or more of the deletenous residues present withm a peptide and substitute a small "neutral" residue such as Ala (that may not influence T cell recognition of the peptide) An enhanced likelihood of cross-reactivity is expected if, together with elimination of detnmental residues withm a peptide, "prefened" residues associated with high affinity bmding to an allele-specific HLA molecule or to multiple HLA molecules withm a superfamily are inserted To ensure that an analog peptide, when used as a vaccme, actually elicits a CTL response to the native epitope in vivo (or, in the case of class II epitopes, elicits helper T cells that cross-react with the wild type peptides), the analog peptide may be used to immunize T cells in vitro from individuals ofthe appropriate HLA allele Thereafter, the immunized cells' capacity to mduce lysis of wild type peptide sensitized target cells is evaluated It will be desirable to use as antigen presenting cells, cells that have been either infected, or transfected with the appropriate genes, or, m the case of class II epitopes only, cells that have been pulsed with whole protein antigens, to establish whether endogenously produced antigen is also recognized by the relevant T cells Another embodiment of the mvention is to create analogs of weak binding peptides, to thereby ensure adequate numbers of cross-reactive cellular bmders Class I bmdmg peptides exhibitmg bmdmg affinities of 500-5000 nM, and carrying an acceptable but suboptimal pnmary anchor residue at one or both positions can be "fixed" by substituting prefened anchor residues m accordance with the respective supertype The analog peptides can then be tested for crossbmdmg activity Another embodiment for generatmg effective peptide analogs mvolves the substitution of residues that have an adverse impact on peptide stability or solubility m, e g , a liquid environment This substitution may occur at any position of the peptide epitope For example, a cysteine can be substituted out in favor of α-amino butyric acid ("B" m the single letter abbreviations for peptide sequences listed herem) Due to its chemical nature, cysteme has the propensity to form disulfide bndges and sufficiently alter the peptide structurally so as to reduce bindmg capacity Substituting -ammo butync acid for cysteme not only alleviates this problem, but actually improves bmdmg and crossbmdmg capability m certain instances (see, e g , the review by Sette et al , In Persistent Viral Infections. Eds R Ahmed and I Chen, John Wiley & Sons, England, 1999) Representative analog peptides are set forth m Tables XXII-XXVII The Table indicates the length and sequence ofthe analog peptide as well as the motif or supermotif, if appropnate The "source" column mdicates the residues substituted at the indicated position numbers for the respective analog IV.G. Computer Screening of Protein Sequences from Disease-Related Antigens for Supermotif- or Motif-Beaπng Peptides In order to identify supermotif- or motif-beanng epitopes m a target antigen, a native protem sequence, e g , a tumor-associated antigen, or sequences from an mfectious organism, or a donor tissue for transplantation, is screened using a means for computmg, such as an intellectual calculation or a computer, to determine the presence of a supermotif or motif within the sequence The information obtamed from the analysis of native peptide can be used directly to evaluate the status ofthe native peptide or may be utilized subsequently to generate the peptide epitope Computer programs that allow the rapid screenmg of protem sequences for the occuπence ofthe subject supermotifs or motifs are encompassed by the present mvention, as are programs that permit the generation of analog peptides These programs are implemented to analyze any identified ammo acid sequence or operate on an unknown sequence and simultaneously determine the sequence and identify motif-bearmg epitopes thereof, analogs can be simultaneously determmed as well Generally, the identified sequences will be from a pathogenic organism or a tumor-associated peptide For example, the target TAA molecules include, without limitation, CEA, MAGE, p53 and HER2/neu It is important that the selection criteria utilized for prediction of peptide bmdmg are as accurate as possible, to conelate most efficiently with actual bmdmg Prediction of peptides that bmd, for example, to HLA-A*0201, on the basis of the presence of the appropnate pnmary anchors, is positive at about a 30% rate (see, e g , Ruppert, J et al Cell 74 929, 1993) However, by extensively analyzing peptide-HLA binding data disclosed herem, data m lelated patent applications, and data m the art, the present inventors have developed a number of allele-specific polynomial algorithms that dramatically increase the predictive value over identification on the basis of the presence of primary anchor residues alone These algorithms take into account not only the presence or absence of pnmary anchors, but also consider the positive or deleteπous presence of secondary anchor residues (to account for the impact of different ammo acids at different positions) The algonthms are essentially based on the premise that the overall affinity (or ΔG) of peptide- HLA mteractions can be approximated as a lmear polynomial function of the type ΔG = a^ x a 2 ι χ a 3_ x a n , where a,, is a coefficient that represents the effect of the presence of a given ammo acid (/) at a given position (i) along the sequence of a peptide of n ammo acids An important assumption of this method is that the effects at each position are essentially mdependent of each other This assumption is justified by studies that demonstrated that peptides are bound to HLA molecules and recognized by T cells in essentially an extended conformation Denvation of specific algonthm coefficients has been descπbed, for - example, in Gulukota, K et al , J Mol Biol 267 1258, 1997 Additional methods to identify prefened peptide sequences, which also make use of specific motifs, include the use of neural networks and molecular modelmg programs (see, e g , Milik et al , Nature Biotechnology 16 753, 1998, Altuvia et al , Hum Immunol 58 1, 1997, Altuvia et al, J Mol Biol 249 244, 1995, Buus, S Curr Opin Immunol 11 209-213, 1999, Brusic, V et al , Bioinformatics 14 121-130, 1998, Parker et al , J Immunol 152 163, 1993, Meister et al , Vaccine 13 581, 1995, Hammer et al , J Exp Med 180 2353, 1994, Sturmolo et al , Nature Biotechnol 17 555 1999) For example, it has been shown that m sets of A*0201 motif-beanng peptides contammg at least one prefened secondary anchor residue while avoidmg the presence of any deletenous secondary anchor residues, 69% ofthe peptides will bind A*0201 with an IC 50 less than 500 nM (Ruppert, J et al Cell 74 929, 1993) These algonthms are also flexible in that cut-off scores may be adjusted to select sets of peptides with greater or lower predicted bindmg properties, as desired In utilizing computer screenmg to identify peptide epitopes, a protein sequence or translated sequence may be analyzed usmg software developed to search for motifs, for example the "FINDPATTERNS' program (Devereux, et al Nucl Acids Res 12 387-395, 1984) or MotifSearch 1 4 software program (D Brown, San Diego, CA) to identify potential peptide sequences contammg appropriate HLA bmdmg motifs The identified peptides can be scored usmg customized polynomial algonthms to predict their capacity to bmd specific HLA class I or class II alleles As appreciated by one of ordinary skill m the art, a large anay of computer programming software and hardware options are available in the relevant art which can be employed to implement the motifs of the mvention in order to evaluate (e , without limitation, to identify epitopes, identify epitope concentration per peptide length, or to generate analogs) known or unknown peptide sequences In accordance with the procedures described above, p53 peptide epitopes and analogs thereof that are able to bmd HLA supertype groups or allele-specific HLA molecules have been identified (Tables VII- XX, Table XXII-XXXI) IV.H. Preparation of Peptide Epitopes Peptides in accordance with the mvention can be prepared synthetically, by recombmant DNA technology or chemical synthesis, or from natural sources such as native tumors or pathogenic organisms Peptide epitopes may be synthesized individually or as polyepitopic peptides Although the peptide will preferably be substantially free of other naturally occunmg host cell protems and fragments thereof, in some embodiments the peptides may be synthetically conjugated to native fragments or particles The peptides m accordance with the invention can be a vanety of lengths, and either m their neutral (uncharged) forms or m forms which are salts The peptides m accordance with the mvention are either free of modifications such as glycosylation, side cham oxidation, or phosphorylation, or they contam these modifications, subject to the condition that modifications do not destroy the biological activity of the peptides as descnbed herein When possible, it may be desirable to optimize HLA class I bmdmg epitopes ofthe invention, such as can be used m a polyepitopic construct, to a length of about 8 to about 13 ammo acid residues, often 8 to - 11, preferably 9 to 10 HLA class II bindmg peptide epitopes of the mvention may be optimized to a length of about 6 to about 30 amino acids in length, preferably to between about 13 and about 20 residues Preferably, the peptide epitopes are commensurate m size with endogenously processed pathogen-derived peptides or tumor cell peptides that are bound to the relevant HLA molecules, however, the identification and preparation of peptides that compnse epitopes of the mvention can also be earned out usmg the techniques described herem In alternative embodiments, epitopes of the mvention can be linked as a polyepitopic peptide, or as a minigene that encodes a polyepitopic peptide In another embodiment, it is prefened to identify native peptide regions that contam a high concentration of class I and/or class II epitopes Such a sequence is generally selected on the basis that it contams the greatest number of epitopes per ammo acid length It is to be appreciated that epitopes can be present in a nested or overlappmg manner, e g a 10 ammo acid long peptide could contam two 9 ammo acid long epitopes and one 10 ammo acid long epitope, upon intracellular processmg, each epitope can be exposed and bound by an HLA molecule upon administration of such a peptide This larger, preferably multi-epitopic, peptide can be generated synthetically, recombmantly, or via cleavage from the native source The peptides of the mvention can be prepared m a wide vanety of ways For the prefened relatively short size, the peptides can be synthesized m solution or on a solid support m accordance with conventional techniques Vanous automatic synthesizers are commercially available and can be used m accordance with known protocols (See, for example, Stewart & Young, SOLID PHASE PEPTIDE SYNTHESIS, 2D ED , Pierce Chemical Co , 1984) Further, individual peptide epitopes can be joined using chemical ligation to produce larger peptides that are still withm the bounds of the mvention Alternatively, recombmant DNA technology can be employed wherein a nucleotide sequence which encodes an immunogemc peptide of interest is inserted mto an expression vector, transformed or transfected into an appropriate host cell and cultivated under conditions suitable for expression These procedures are generally known m the art, as descnbed generally m Sambrook et al , MOLECULAR CLONING, A LABORATORY MANUAL, Cold Spring Harbor Press, Cold Spring Harbor, New York (1989) Thus, recombmant polypeptides which comprise one or more peptide sequences of the mvention can be used to present the appropriate T cell epitope The nucleotide coding sequence for peptide epitopes of the prefened lengths contemplated herem can be synthesized by chemical techniques, for example, the phosphotriester method of Matteucci, et al , J Am Chem Soc 103 3185 (1981) Peptide analogs can be made simply by substituting the appropriate and desired nucleic acid base(s) for those that encode the native peptide sequence, exemplary nucleic acid substitutions are those that encode an ammo acid defined by the motifs/supermotifs herem The codmg sequence can then be provided with appropnate linkers and ligated mto expression vectors commonly available in the art, and the vectors used to transform suitable hosts to produce the desired fusion protem A number of such vectors and suitable host systems are now available For expression of the fusion protems, the coding sequence will be provided with operably linked start and stop codons, promoter and terminator regions and usually a replication system to provide an expression vector for expression m the desired cellular host For example, promoter sequences compatible with bacterial hosts are provided m plasmids contammg convenient restriction sites for insertion ofthe desired codmg sequence The resulting expression vectors are transformed mto suitable bacterial hosts Of course, yeast, msect or mammalian cell hosts may also be used, employmg suitable vectors and control sequences IV.I. Assays to Detect T-Cell Responses Once HLA binding peptides are identified, they can be tested for the ability to elicit a T-cell response The preparation and evaluation of motif-beaπng peptides are descnbed m PCT publications WO 94/20127 and WO 94/03205 Bnefly, peptides compnsmg epitopes from a particular antigen are synthesized and tested for their ability to bmd to the appropnate HLA protems These assays may mvolve evaluatmg the bmdmg of a peptide of the mvention to punfied HLA class I molecules in relation to the bindmg of a radioiodinated reference peptide Alternatively, cells expressmg empty class I molecules (i e lacking peptide therein) may be evaluated for peptide bindmg by lmmunofluorescent staining and flow microfluoπmetry Other assays that may be used to evaluate peptide bmdmg mclude peptide-dependent class I assembly assays and/or the inhibition of CTL recogmtion by peptide competition Those peptides that bmd to the class I molecule, typically with an affinity of 500 nM or less, are further evaluated for their ability to serve as targets for CTLs derived from infected or immunized individuals, as well as for their capacity to mduce primary in vitro or in vivo CTL responses that can give πse to CTL populations capable of reactmg with selected target cells associated with a disease Conespondmg assays are used for evaluation of HLA class II bmdmg peptides HLA class II motif-beanng peptides that are shown to bmd, typically at an affinity of 1000 nM or less, are further evaluated for the ability to stimulate HTL responses Conventional assays utilized to detect T cell responses mclude proliferation assays, lymphokme secretion assays, direct cytotoxicity assays, and limiting dilution assays For example, antigen-presenting cells that have been mcubated with a peptide can be assayed for the ability to mduce CTL responses m responder cell populations Antigen-presentmg cells can be normal cells such as penpheral blood mononuclear cells or dendritic cells Alternatively, mutant non-human mammalian cell lmes that are deficient in their ability to load class I molecules with internally processed peptides and that have been transfected with the appropriate human class I gene, may be used to test for the capacity ofthe peptide to induce in vitro primary CTL responses Peripheral blood mononuclear cells (PBMCs) may be used as the responder cell source of CTL precursors The appropriate antigen-presentmg cells are incubated with peptide, after which the peptide- loaded antigen-presentmg cells are then incubated with the responder cell population under optimized culture conditions Positive CTL activation can be determined by assaying the culture for the presence of CTLs that kill radio-labeled target cells, both specific peptide-pulsed targets as well as target cells expressing endogenously processed forms of the antigen from which the peptide sequence was derived More recently, a method has been devised which allows direct quantification of antigen-specific T cells by staining with Fluorescein-labelled HLA tetrameπc complexes (Airman, J D et al , Proc Natl Acad Sci USA 90 10330, 1993, Altaian, J Ω et al , Science 274 94, 1996) Other relatively recent technical developments mclude stammg for intracellular lymphokines, and interferon-γ release assays or ELISPOT assays Tetramer stammg, intracellular lymphokme staining and ELISPOT assays all appear to - be at least 10-fold more sensitive than more conventional assays (Lalvam, A et al , J Exp Med 186 859, 1997, Dunbar, P R et al , Curr Biol 8 413, 1998, Murah-Knshna, K et al , Immunity 8 177, 1998) HTL activation may also be assessed usmg such techniques known to those m the art such as T cell proliferation and secretion of lymphokmes, e g IL-2 (see, e g Alexander et al , Immunity 1 751 -761 , 1994) Alternatively, immunization of HLA transgenic mice can be used to determine immunogenicity of peptide epitopes Several transgenic mouse models mcludmg mice with human A2 1, Al 1 (which can additionally be used to analyze HLA-A3 epitopes), and B7 alleles have been characterized and others (e g , transgenic mice for HLA-Al and A24) are bemg developed HLA-DR1 and HLA-DR3 mouse models have also been developed Additional transgenic mouse models with other HLA alleles may be generated as necessary Mice may be immunized with peptides emulsified m Incomplete Freund's Adjuvant and the resulting T cells tested for their capacity to recognize peptide-pulsed target cells and target cells transfected with appropnate genes CTL responses may be analyzed usmg cytotoxicity assays descnbed above Similarly, HTL responses may be analyzed usmg such assays as T cell proliferation or secretion of lymphokines IV.J. Use of Peptide Epitopes as Diagnostic Agents and for Evaluating Immune Responses In one embodiment of the invention, HLA class I and class II bmdmg peptides as descnbed herem are used as reagents to evaluate an immune response The immune response to be evaluated is mduced by usmg as an immunogen any agent that may result m the production of antigen-specific CTLs or HTLs that recognize and bmd to the peptide epιtope(s) to be employed as the reagent The peptide reagent need not be used as the immunogen Assay systems that are used for such an analysis include relatively recent technical developments such as tetramers, staining for intracellular lymphokmes and interferon release assays, or ELISPOT assays For example, a peptide of the invention may be used m a tetramer stammg assay to assess peripheral blood mononuclear cells for the presence of antigen-specific CTLs following exposure to a tumor cell antigen or an immunogen The HLA-tetrameπc complex is used to directly visualize antigen- specific CTLs (see, e g , Ogg et al , Science 279 2103-2106, 1998, and Altaian et al , Science 174 94-96, 1996) and determine the frequency of the antigen-specific CTL population m a sample of peripheral blood mononuclear cells A tetramer reagent using a peptide of the mvention may be generated as follows A peptide that bmds to an HLA molecule is refolded m the presence of the conespondmg HLA heavy cham and β -mιcroglobulιn to generate a tπmolecular complex The complex is biotinylated at the carboxyl terminal end of the heavy chain at a site that was previously engmeered into the protein Tetramer formation is then induced by the addition of streptavidin By means of fluorescently labeled streptavidin, the tetramer can be used to stam antigen-specific cells The cells may then be identified, for example, by flow cytometry Such an analysis may be used for diagnostic or prognostic purposes Peptides of the mvention are also used as reagents to evaluate immune recall responses (see, e g , Bertom et al , J Clin Invest 100 503-513, 1997 and Penna et al . J Exp Med 174 1565-1570, 1991) For example, patient PBMC samples from individuals with cancer may be analyzed for the presence of antigen- specific CTLs or HTLs usmg specific peptides A blood sample contammg mononuclear cells may be evaluated by cultivating the PBMCs and stimulating the cells with a peptide of the mvention After an appropriate cultivation period, the expanded cell population may be analyzed, for example, for CTL or for HTL activity The peptides are also used as reagents to evaluate the efficacy of a vaccme PBMCs obtamed from a patient vaccinated with an immunogen may be analyzed usmg, for example, either of the methods described above The patient is HLA typed, and peptide epitope reagents that recognize the allele-specific molecules present in that patient are selected for the analysis The unmunogemcity ofthe vaccme is indicated by the presence of epitope-specific CTLs and or HTLs m the PBMC sample The peptides of the mvention are also used to make antibodies, using techniques well known m the art (see, e g CURRENT PROTOCOLS IN IMMUNOLOGY, Wiley/Greene, NY, and Antibodies A Laboratory Manual, Harlow and Lane, Cold Sprmg Harbor Laboratory Press, 1989), which may be useful as reagents to diagnose or monitor cancer Such antibodies include those that recognize a peptide in the context of an HLA molecule, i e , antibodies that bmd to a peptide-MHC complex IV.K. Vaccine Compositions Vaccines and methods of preparing vaccmes that contam an unmunogenically effective amount of one or more peptides as described herein are further embodiments ofthe invention Once appropnately immunogemc epitopes have been defined, they can be sorted and delivered by vanous means, herem refened to as "vaccme" compositions Such vaccme compositions can mclude, for example, popeptides (e g .Vitiello, A et al , J Clin Invest 95 341, 1995), peptide compositions encapsulated ιn poly(DL- lactide-co-glycolide) ("PLG") microspheres ( ee, eg , Eldndge, et al , Molec Immunol 28 287-294, 1991 Alonso et al , Vaccine 12 299-306, 1994, Jones et al , Vaccine 13 675-681, 1995), peptide compositions contained in immune stimulating complexes (ISCOMS) (see, e g , Takahashi et al , Nature 344 873-875, 1990, Hu et al , Clin Exp Immunol 1 13 235-243, 1998), multiple antigen peptide systems (MAPs) (see e g , Tarn, J P , Proc Natl Acad Sci U A 85 5409-5413, 1988, Tam, J P , J Immunol Methods 196 17-32, 1996), peptides formulated as multivalent peptides, peptides for use m ballistic delivery systems, typically crystallized peptides, viral delivery vectors (Perkus, M E et al , ln Concepts in vaccine development, Kaufmann, S H E , ed , p 379, 1996, Chakrabarti, S et al , Natui e 320 535, 1986, Hu, S L et al , Nature 320 537, 1986, Kieny, M -P et al , AIDS Bio/Technology 4 790, 1986, Top, F H et al , J Infect Dis 124 148, 1971 , Chanda, P K et al , Virology 175 535, 1990), particles of viral or synthetic oπgm (e g , Kofler, N et al , J Immunol Methods 192 25, 1996, Eldndge, J H et al , Sem Hematol 30 16, 1993, Falo, L D , Jr et al , Nature Med 7 649, 1995), adjuvants (Wanen, H S , Vogel, F R , and Chedid, L A Annu Rev Immunol 4 369, 1986, Gupta, R K et al , Vaccine 1 1 293, 1993), liposomes (Reddy, R et al , J Immunol 148 1585, 1992, Rock, K L , Immunol Today 17 131, 1996), or, naked or particle absorbed cDNA (Ulmer, J B et al , Science 259 1745, 1993, Robmson, H L , Hunt, L A , and Webster, R G , Vaccine 11 957, 1993, Shiver, J W et al , In Concepts in vaccine development, Kaufmann, S H E , ed , p 423, 1996, Cease, K B , and Berzofsky, J A , Annu Rev Immunol 12 923, 1994 and Eldndge, J H et al , Sem Hematol 30 16, 1993) Toxm-targeted delivery technologies, also known as receptor mediated targetmg, such as those of Avant Immunotherapeutics, Inc (Needham, Massachusetts) may also be used Vaccmes ofthe mvention include nucleic acid-mediated modalities DNA or RNA encoding one - or more ofthe peptides ofthe mvention can also be administered to a patient This approach is described, for mstance, m Wolff et al , Science 247 1465 (1990) as well as U S Patent Nos 5,580,859, 5,589,466, 5,804,566, 5,739,118, 5,736,524, 5,679,647, WO 98/04720, and more detail below Examples of DNA- based delivery technologies mclude "naked DNA", facilitated (bupivicarne, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated ("gene gun") or pressure-mediated delivery (see, e g , U S Patent No 5,922,687) For therapeutic or prophylactic immunization purposes, the peptides ofthe mvention can also be expressed by viral or bacteπal vectors Examples of expression vectors mclude attenuated vnal hosts, such as vaccmia or fowlpox As an example of this approach, vaccmia virus is used as a vector to express nucleotide sequences that encode the peptides of the invention Upon introduction into a host bearing a tumor, the recombmant vaccmia virus expresses the immunogemc peptide, and thereby elicits a host CTL and/or HTL response Vaccmia vectors and methods useful m immunization protocols are descnbed m, e g , U S Patent No 4,722,848 Another vector is BCG (Bacille Calmette Gueπn) BCG vectors are described m Stover et al , Nature 351 456-460 (1991) A wide vanety of other vectors useful for therapeutic administration or immunization of the peptides of the mvention, e g adeno and adeno- associated virus vectors, retroviral vectors, Salmonella typhi vectors, detoxified anthrax toxm vectors, and the like, will be apparent to those skilled m the art from the descπption herem Furthermore, vaccines m accordance with the invention encompass compositions of one or more of the claimed ρeptιde(s) The peptιde(s) can be individually linked to its own earner, alternatively, the peptιde(s) can exist as a homopolymer or heteropolymer of active peptide units Such a polymer has the advantage of mcreased immunological reaction and, where different peptide epitopes are used to make up the polymer, the additional ability to induce antibodies and/or CTLs that react with different antigenic determinants of the pathogenic organism or tumor-related peptide targeted for an immune response The composition may be a naturally occunmg region of an antigen or may be prepared, e , recombinantly or by chemical synthesis Camers that can be used with vaccines of the invention are well known in the art, and mclude, e g , thyroglobulm, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly L- lysine, poly L-glutamic acid, influenza, hepatitis B virus core protein, and the like The vaccmes can contain a physiologically tolerable (i e , acceptable) diluent such as water, or salme, preferably phosphate buffered saline The vaccmes also typically mclude an adjuvant Adjuvants such as mcomplete Freund's adjuvant, aluminum phosphate, alummum hydroxide, or alum are examples of mateπals well known in the art Additionally, as disclosed herein, CTL responses can be pruned by conjugatmg peptides ofthe mvention to hpids, such as tπpalmitoyl-S-glycerylcystemlyseryl- serine (P 3 CSS) As disclosed in greater detail herem, upon immunization with a peptide composition m accordance with the invention, via injection, aerosol, oral, transdermal, transmucosal, mtrapleural, mtrathecal, or other suitable routes, the immune system of the host responds to the vaccme by producing large amounts of CTLs and or HTLs specific for the desired antigen Consequently, the host becomes at least partially immune to later infection, or at least partially resistant to developing an ongomg chronic infection, or denves at least some therapeutic benefit when the antigen was tumor-associated In some embodiments, it may be desirable to combme the class I peptide components with components that mduce or facilitate neutralizing antibody and or helper T cell responses to the target antigen of interest A prefened embodiment of such a composition compnses class I and class II epitopes m accordance with the invention An alternative embodiment of such a composition comprises a class I and/or class II epitope m accordance with the invention, along with a cross-bmdmg HLA class II epitope such as PADRE™ (Epimmune, San Diego, CA) molecule (descnbed, for example, m U S Patent Number 5,736,142) A vaccme of the mvention can also include antigen-presentmg cells (APC), such as dendritic cells (DC), as a vehicle to present peptides ofthe mvention Vaccme compositions can be created in vitro, following dendritic cell mobilization and harvesting, whereby loadmg of dendritic cells occurs in vitro For example, dendπtic cells are transfected, e , with a minigene m accordance with the mvention, or are pulsed with peptides The dendritic cell can then be admmistered to a patient to elicit immune responses in Vaccme compositions, either DNA- or peptide-based, can also be administered in vivo in combination with dendritic cell mobilization whereby loading of dendntic cells occurs in vivo Antigenic peptides are used to elicit a CTL and/or HTL response ex vivo, as well The resulting CTL or HTL cells, can be used to treat tumors m patients that do not respond to other conventional forms of therapy, or will not respond to a therapeutic vaccme peptide or nucleic acid m accordance with the mvention Ex vivo CTL or HTL responses to a particular tumor-associated antigen are mduced by mcubating m tissue culture the patient's, or genetically compatible, CTL or HTL precursor cells together with a source of antigen-presentmg cells, such as dendritic cells, and the appropnate immunogemc peptide After an appropnate incubation time (typically about 7-28 days), m which the precursor cells are activated and expanded into effector cells, the cells are infused back into the patient, where they will destroy (CTL) or facilitate destruction (HTL) of their specific target cell (an infected cell or a tumor cell) Transfected dendritic cells may also be used as antigen presenting cells The vaccine compositions of the invention can also be used m combination with other treatments used for cancer, mcluding use in combination with immune adjuvants such as IL-2, IL-12, GM-CSF, and Preferably, the following principles are utilized when selectmg an anay of epitopes for inclusion in a polyepitopic composition for use in a vaccine, or for selecting discrete epitopes to be mcluded m a vaccine and or to be encoded by nucleic acids such as a minigene Exemplary epitopes that may be utilized in a vaccme to treat or prevent cancer are set out in Tables XXIII-XXVII and XXXI It is prefened that each of the followmg principles are balanced in order to make the selection The multiple epitopes to be incorporated m a given vaccine composition can be, but need not be, contiguous m sequence in the native antigen from which the epitopes are derived 1 ) Epitopes are selected which, upon administration, mimic immune responses that have been observed to be conelated with tumor clearance For HLA Class I this includes 3-4 epitopes that come from at least one TAA For HLA Class II a similar rationale is employed, again 3-4 epitopes are selected from at least one TAA (see e g , Rosenberg et al , Science 278 1447-1450) Epitopes from one TAA may be used m combination with epitopes from one or more additional TAAs to produce a vaccine that targets tumors with varying expression patterns of frequently-expressed TAAs as described, e , m Example 15 2 ) Epitopes are selected that have the requisite bmdmg affinity established to be conelated with immunogenicity for HLA Class I an IC 50 of 500 nM or less, or for Class II an IC 50 of 1000 nM or less 3 ) Sufficient supermotif beaπng-peptides, or a sufficient anay of allele-specific mohf- bearmg peptides, are selected to give broad population coverage For example, it is preferable to have at least 80% population coverage A Monte Carlo analysis, a statistical evaluation known in the art, can be employed to assess the breadth, or redundancy of, population coverage 4 ) When selectmg epitopes from cancer-related antigens it is often useful to select analogs because the patient may have developed tolerance to the native epitope When selectmg epitopes for infectious disease-related antigens it is preferable to select either native or analoged epitopes 5 ) Of particular relevance are epitopes refened to as "nested epitopes " Nested epitopes occur where at least two epitopes overlap in a given peptide sequence A nested peptide sequence can compnse both HLA class I and HLA class II epitopes When providmg nested epitopes, a general objective is to provide the greatest number of epitopes per sequence Thus, an aspect is to avoid providmg a peptide that is any longer than the amino termmus of the amino termmal epitope and the carboxyl termmus ofthe carboxyl termmal epitope m the peptide When providmg a multi-epitopic sequence, such as a sequence compnsmg nested epitopes, it is generally important to screen the sequence m order to insure that it does not have pathological or other deleterious biological properties 6 ) If a polyepitopic protem is created, or when creating a minigene, an objective is to generate the smallest peptide that encompasses the epitopes of mterest This principle is similar, if not the same as that employed when selectmg a peptide comprising nested epitopes However, with an artificial polyepitopic peptide, the size minimization objective is balanced against the need to integrate any spacer sequences between epitopes in the polyepitopic protein. Spacer amino acid residues can, for example, be introduced to avoid junctional epitopes (an epitope recognized by the immune system, not present in the target antigen, and only created by the man-made juxtaposition of epitopes), or to facilitate cleavage between epitopes and thereby enhance epitope presentation. Junctional epitopes are generally to be avoided because the recipient may generate an immune response to that non-native epitope. Of particular concern is a junctional epitope that is a "dominant epitope." A dominant epitope may lead to such a zealous response that immune responses to other epitopes are diminished or suppressed. I V.K.I. Minigene Vaccines A number of different approaches are available which allow simultaneous delivery of multiple epitopes. Nucleic acids encoding the peptides of the invention are a particularly useful embodiment of the invention. Epitopes for inclusion in a minigene are preferably selected according to the guidelines set forth in the previous section. A prefened means of administering nucleic acids encoding the peptides ofthe invention uses minigene constructs encoding a peptide comprising one or multiple epitopes ofthe invention. The use of multi-epitope minigenes is described below and in, e.g., co-pending application U.S.S.N. 09/311,784; Ishiokz et al. , J. Immunol. 162:3915-3925, 1999; An, L. and Whitton, J. L., J. Virol 71:2292, 1997; Thomson, S. A. et al, J. Immunol. 157:822, 1996; Whitton, J. L. et al, J. Virol. 67:348, 1993; Hanke, R. et al, Vaccine 16:426, 1998. For example, a multi-epitope DNA plasmid encoding supermotif- and/or motif-bearing ρ53 epitopes derived from multiple regions of p53, the PADRE™ universal helper T cell epitope (or multiple HTL epitopes from p53), and an endoplasmic reticulum- translocating signal sequence can be engineered. A vaccine may also comprise epitopes, in addition to p53 epitopes, that are derived from other TAAs. The immunogenicity of a multi-epitopic minigene can be tested in transgenic mice to evaluate the magnitude of CTL induction responses against the epitopes tested. Further, the immunogenicity of DNA- encoded epitopes in vivo can be conelated with the in vitro responses of specific CTL lines against target cells transfected with the DNA plasmid. Thus, these experiments can show that the minigene serves to both: 1.) generate a CTL response and 2.) that the induced CTLs recognized cells expressing the encoded epitopes. For example, to create a DNA sequence encoding the selected epitopes (minigene) for expression in human cells, the amino acid sequences of the epitopes may be reverse translated. A human codon usage table can be used to guide the codon choice for each amino acid. These epitope-encoding DNA sequences may be directly adjoined, so that when translated, a continuous polypeptide sequence is created. To optimize expression and/or immunogenicity, additional elements can be incorporated into the minigene design. Examples of amino acid sequences that can be reverse translated and included in the minigene sequence include: HLA class I epitopes, HLA class II epitopes, a ubiquitination signal sequence, and/or an endoplasmic reticulum targeting signal. In addition, HLA presentation of CTL and HTL epitopes may be improved by including synthetic (e.g. poly-alanine) or naturally-occurring flanking sequences adjacent to the CTL or HTL epitopes, these larger peptides comprising the epιtope(s) are withm the scope ofthe invention The mmigene sequence may be converted to DNA by assemblmg oligonucleotides that encode the plus and minus strands of the minigene Overlappmg oligonucleotides (30-100 bases long) may be synthesized, phosphorylated, purified and annealed under appropnate conditions using well known techniques The ends of the oligonucleotides can be joined, for example, using T4 DNA ligase This synthetic minigene, encodmg the epitope polypeptide, can then be cloned into a desired expression vector Standard regulatory sequences well known to those of skill in the art are preferably mcluded in the vector to ensure expression m the target cells Several vector elements are desirable a promoter with a down-stream cloning site for mmigene insertion, a polyadenylation signal for efficient transcription termination, an E coli origin of replication, and an E coli selectable marker (e g ampicillin or kanamycin resistance) Numerous promoters can be used for this purpose, e g the human cytomegalovirus (hCMV) promoter See, e g , U S Patent Nos 5,580,859 and 5,589,466 for other suitable promoter sequences Additional vector modifications may be desired to optimize mmigene expression and immunogenicity In some cases, introns are required for efficient gene expression, and one or more synthetic or naturally-occumng mtrons could be incorporated mto the transcribed region of the mmigene The inclusion of mRNA stabilization sequences and sequences for replication m mammalian cells may also be considered for mcreasmg mmigene expression Once an expression vector is selected, the minigene is cloned into the polylinker region downstream ofthe promoter This plasmid is transformed mto an appropnate E coli strain, and DNA is prepared using standard techniques The onentation and DNA sequence of the mmigene, as well as all other elements mcluded in the vector, are confirmed using restπction mapping and DNA sequence analysis Bactenal cells harboring the conect plasmid can be stored as a master cell bank and a working cell bank In addition, immunostimulatory sequences (ISSs or CpGs) appear to play a role in the unmunogemcity of DNA vaccines These sequences may be mcluded m the vector, outside the mmigene coding sequence, if desired to enhance unmunogemcity In some embodiments, a bi-cistromc expression vector which allows production of both the minigene-encoded epitopes and a second protem (mcluded to enhance or decrease unmunogemcity) can be used Examples of protems or polypeptides that could beneficially enhance the immune response if co- expressed include cytokines (e g , IL-2, IL-12, GM-CSF), cytokine-inducing molecules (e , LeIF), costrmulatory molecules, or for HTL responses, pan-DR bmdmg protems (PADRE™, Epimmune, San Diego, CA) Helper (HTL) epitopes can be jomed to mtracellular targetmg signals and expressed separately from expressed CTL epitopes, this allows direction of the HTL epitopes to a cell compartment different than that ofthe CTL epitopes If required, this could facilitate more efficient entry of HTL epitopes mto the HLA class II pathway, thereby improvmg HTL induction In contrast to HTL or CTL mduction, specifically decreasing the immune response by co-expression of immunosuppressive molecules (e g TGF- β) may be beneficial m certain diseases Therapeutic quantities of plasmid DNA can be produced for example, by fermentation m E coli, followed by punfication Ahquots from the working cell bank are used to moculate growth medium, and grown to saturation in shaker flasks or a bioreactor accordmg to well known techniques Plasmid DNA can be purified using standard bioseparation technologies such as solid phase anion-exchange resms supplied by QIAGEN, Inc (Valencia, California) If required, supercoiled DNA can be isolated from the open circular and linear forms using gel electrophoresis or other methods Purified plasmid DNA can be prepared for injection usmg a vanety of formulations The simplest of these is reconstitution of lyophilized DNA in sterile phosphate-buffered saline (PBS) This approach, known as "naked DNA," is cunently being used for intramuscular (IM) administration m clinical tnals To maximize the immuno therapeutic effects of mmigene DNA vaccmes, an alternative method for formulating puπfied plasmid DNA may be desirable A variety of methods have been described, and new techniques may become available Cationic lipids, glycohpids, and fusogemc liposomes can also be used in the formulation (see, e g , as described by WO 93/24640, Mannino & Gould-Fogeπte, BioTechniques 6(7) 682 (1988), U S Pat No 5,279,833, WO 91/06309, and Feigner, et al , Proc Nat 'I Acad Sc USA 84 7413 (1987) In addition, peptides and compounds refened to collectively as protective, mteractive, non- condensing compounds (PINC) could also be complexed to punfied plasmid DNA to influence variables such as stability, intramuscular dispersion, or trafficking to specific organs or cell types Target cell sensitization can be used as a functional assay for expression and HLA class I presentation of minigene-encoded CTL epitopes For example, the plasmid DNA is introduced mto a mammalian cell lme that is suitable as a target for standard CTL chromium release assays The transfection method used will be dependent on the final formulation Electroporation can be used for "naked" DNA, whereas cationic lipids allow direct in vitro transfection A plasmid expressing green fluorescent protem (GFP) can be co-transfected to allow enrichment of transfected cells usmg fluorescence activated cell sorting (FACS) These cells are then chromιum-51 ( 51 Cr) labeled and used as target cells for epitope- specific CTL lmes, cytolysis, detected by 51 Cr release, indicates both production of, and HLA presentation of, rmnigene-encoded CTL epitopes Expression of HTL epitopes may be evaluated m an analogous manner using assays to assess HTL activity In vivo unmunogemcity is a second approach for functional testmg of mmigene DNA formulations Transgenic mice expressmg appropnate human HLA protems are immunized with the DNA product The dose and route of administration are formulation dependent ( , IM for DNA in PBS, lntrapeπtoneal (IP) for lipid-complexed DNA) Twenty-one days after immunization, splenocytes are harvested and restimulated for one week m the presence of peptides encoding each epitope bemg tested Thereafter, for CTL effector cells, assays are conducted for cytolysis of peptide-loaded, 51 Cr-labeled target cells using standard techniques Lysis of target cells that were sensitized by HLA loaded with peptide epitopes, conespondmg to minigene-encoded epitopes, demonstrates DNA vaccme function for in vivo mduction of CTLs Immunogenicity of HTL epitopes is evaluated m transgenic mice m an analogous manner Alternatively, the nucleic acids can be admmistered usmg ballistic delivery as descnbed, for mstance, in U S Patent No 5,204,253 Usmg this technique, particles comprised solely of DNA are admmistered In a further alternative embodiment, DNA can be adhered to particles, such as gold particles Mimgenes can also be delivered usmg other bactenal or viral delivery systems well known in the art, e g , an expression construct encodmg epitopes of the mvention can be incorporated mto a viral vector such as vaccmia IV.K.2. Combinations of CTL Peptides with Helper Peptides Vaccine compositions compnsmg the peptides ofthe present mvention can be modified to provide desired attributes, such as improved serum half-life, or to enhance unmunogemcity For mstance, the ability of a peptide to induce CTL activity can be enhanced by linking the peptide to a sequence which contams at least one epitope that is capable of mducmg a T helper cell response The use of T helper epitopes in conjunction with CTL epitopes to enhance unmunogemcity is illustrated, for example, in the co-pending applications U S S N 08/820,360, U S S N 08/197,484, and U S S N 08/464,234 Although a CTL peptide can be directly linked to a T helper peptide, often CTL epitope/HTL epitope conjugates are linked by a spacer molecule The spacer is typically comprised of relatively small, neutral molecules, such as amino acids or ammo acid mimetics, which are substantially uncharged under physiological conditions The spacers are typically selected from, e g , Ala, Gly, or other neutral spacers of nonpolar amino acids or neutral polar ammo acids It will be understood that the optionally present spacer need not be comprised of the same residues and thus may be a hetero- or homo-oligomer When present, the spacer will usually be at least one or two residues, more usually three to six residues and sometimes 10 or more residues The CTL peptide epitope can be linked to the T helper peptide epitope either directly or via a spacer either at the ammo or carboxy terminus of the CTL peptide The ammo termmus of either the immunogemc peptide or the T helper peptide may be acylated In certain embodiments, the T helper peptide is one that is recognized by T helper cells present in the majonty of the population This can be accomplished by selectmg ammo acid sequences that bmd to many, most, or all of the HLA class II molecules These are known as "loosely HLA-restncted" or "promiscuous" T helper sequences Examples of peptides that are promiscuous mclude sequences from antigens such as tetanus toxoid at positions 830-843 (QYIKANSKFIGITE), Plasmodium falciparum circumsporozoite (CS) protein at positions 378-398 (DIEKK1AKMEKASSVFNVVNS), and Streptococcus 18kD protein at positions 116 (GAVDSILGGVATYGAA) Other examples mclude peptides bearing a DR 1-4-7 supermotif, or either of the DR3 motifs Alternatively, it is possible to prepare synthetic peptides capable of stimulating T helper lymphocytes, m a loosely HLA-restncted fashion, using amino acid sequences not found m nature (see, e g , PCT publication WO 95/07707) These synthetic compounds called Pan-DR-bmding epitopes (e g , PADRE™, Epimmune, Inc , San Diego, CA) are designed to most prefenably bmd most HLA-DR (human HLA class II) molecules For mstance, a pan-DR-bmdmg epitope peptide having the formula aKXVAAWTLKAAa, where "X" is either cyclohexylalanine, phenylalanine, or tyrosine, and "a" is either D-alanme or L-alanme, has been found to bmd to most HLA-DR alleles, and to stimulate the response of T helper lymphocytes from most individuals, regardless of their HLA type An alternative of a pan-DR bmdmg epitope compnses all "L" natural ammo acids and can be provided m the form of nucleic acids that encode the epitope HTL peptide epitopes can also be modified to alter their biological properties For example, they can be modified to mclude D-ammo acids to mcrease their resistance to proteases and thus extend their serum half life, or they can be conjugated to other molecules such as lipids, protems, carbohydrates, and the like to increase their biological activity For example, a T helper peptide can be conjugated to one or more palmitic acid chains at either the ammo or carboxyl termini IV.K.3. Combinations of CTL Peptides with T Cell Priming Agents In some embodiments it may be desirable to include m the pharmaceutical compositions of the invention at least one component which primes cytotoxic T lymphocytes Lipids have been identified as agents capable of pruning CTL in vivo against viral antigens For example, palmitic acid residues can be attached to the ε-and α- amino groups of a lysine residue and then linked, e g , via one or more linking residues such as Gly, Gly-Gly-, Ser, Ser-Ser, or the like, to an immunogemc peptide The pidated peptide can then be administered either directly in a micelle or particle, incorporated into a liposome, or emulsified m an adjuvant, e g , incomplete Freund's adjuvant A prefened immunogemc composition comprises palmitic acid attached to ε- and - ammo groups of Lys, which is attached via linkage, e g , Ser-Ser, to the amino termmus of the immunogemc peptide As another example of lipid pnmmg of CTL responses, E coli hpoprotems, such as tnpalnutoyl-S- glycerylcystemlyseryl- serine (P 3 CSS) can be used to prune virus specific CTL when covalently attached to an appropriate peptide (see, e g , Deres, et al , Nature 342 561, 1989) Peptides of the mvention can be coupled to P 3 CSS, for example, and the hpopeptide administered to an individual to specifically pnme a CTL response to the target antigen Moreover, because the mduction of neutralizing antibodies can also be pruned with P 3 CSS-conjugated epitopes, two such compositions can be combined to more effectively elicit both humoral and cell-mediated responses CTL and/or HTL peptides can also be modified by the addition of ammo acids to the termini of a peptide to provide for ease of linking peptides one to another, for couplmg to a earner support or larger peptide, for modifying the physical or chemical properties of the peptide or oligopeptide, or the like Ammo acids such as tyrosine, cysteine, lysme, glutamic or aspartic acid, or the like, can be introduced at the C- or N-termmus of the peptide or oligopeptide, particularly class I peptides However, it is to be noted that modification at the carboxyl terminus of a CTL epitope may, m some cases, alter bmdmg characteristics of the peptide In addition, the peptide or oligopeptide sequences can differ from the natural sequence by bemg modified by termιnal-NH 2 acylation, e g , by alkanoyl (C|-C 2 o) or thioglycolyl acetylation, terminal-carboxyl amidation, e g , ammonia, methylamine, etc In some mstances these modifications may provide sites for linking to a support or other molecule IV.K.4. Vaccine Compositions Comprising DC Pulsed with CTL and/or HTL Peptides An embodiment of a vaccine composition m accordance with the mvention comprises ex vivo administration of a cocktail of epitope-beanng peptides to PBMC, or isolated DC therefrom, from the patient's blood A pharmaceutical to facilitate harvestmg of DC can be used, such as Progempoietm™ (Monsanto, St Louis, MO) or GM-CSF/IL-4 After pulsing the DC with peptides and pnor to rernfusion mto patients, the DC are washed to remove unbound peptides In this embodiment, a vaccme compnses peptide-pulsed DCs which present the pulsed peptide epitopes complexed with HLA molecules on their surfaces The DC can be pulsed ex vivo with a cocktail of peptides, some of which stimulate CTL response to one or more antigens of interest, e , prostate-associated antigens such as PSA, PSM, PAP, kallikrein, and the like Optionally, a helper T cell peptide such as a PADRE™ family molecule, can be included to facilitate the CTL response. IV.L. Administration of Vaccines for Therapeutic or Prophylactic Purposes The peptides of the present invention and pharmaceutical and vaccine compositions of the invention are useful for administration to mammals, particularly humans, to treat and/or prevent cancer Vaccine compositions contammg the peptides of the mvention are typically administered to a cancer patient who has a malignancy associated with expression of one or more tumor-associated antigens Alternatively, vaccme compositions can be administered to an individual susceptible to, or otherwise at nsk for developing a cancer, e g, an individual at nsk for developing breast cancer. In therapeutic applications, peptide and/or nucleic acid compositions are admmistered to a patient in an amount sufficient to elicit an effective CTL and/or HTL response to the tumor antigen and to cure or at least partially anest or slow symptoms and/or complications An amount adequate to accomplish this is defined as "therapeutically effective dose " Amounts effective for this use will depend on, e g , the particular composition admmistered, the manner of administration, the stage and severity ofthe disease being treated, the weight and general state of health ofthe patient, and the judgment of the prescπbmg physician As noted above, peptides comprising CTL and/or HTL epitopes ofthe invention-induce immune responses when presented by HLA molecules and contacted with a CTL or HTL specific for an epitope comprised by the peptide The manner in which the peptide is contacted with the CTL or HTL is not critical to the invention For mstance, the peptide can be contacted with the CTL or HTL either in vivo or in vitro. If the contacting occurs in vivo, the peptide itself can be admmistered to the patient, or other vehicles, e g , DNA vectors encodmg one or more peptides, viral vectors encodmg the peptιde(s), liposomes and the like, can be used, as descnbed herem When the peptide is contacted in vitro, the vaccinating agent can compnse a population of cells, e g , peptide-pulsed dendritic cells, or TAA-specific CTLs, which have been mduced by pulsmg antigen- presenting cells in vitro with the peptide Such a cell population is subsequently admmistered to a patient in a therapeutically effective dose For pharmaceutical compositions, the lmmunogenic peptides of the invention, or DNA encodmg them, are generally admmistered to an individual already diagnosed with cancer The peptides or DNA encoding them can be admmistered individually or as fusions of one or more peptide sequences. For therapeutic use, administration should generally begm at the first diagnosis of cancer. This is followed by boostmg doses until at least symptoms are substantially abated and for a period thereafter The embodiment of the vaccme composition (; e , mcludmg, but not limited to embodiments such as peptide cocktails, polyepitopic polypeptides, minigenes, or TAA-specific CTLs or pulsed dendritic cells) delivered to the patient may vary accordmg to the stage of the disease or the patient's health status For example, a vaccine compnsmg TAA-specific CTLs may be more efficacious m killing tumor cells in patients with advanced disease than alternative embodiments The vaccme compositions of the invention may also be used therapeutically in combination with treatments such as surgery An example is a situation in which a patient has undergone surgery to remove a primary tumor and the vaccme is then used to slow or prevent recunence and/or metastasis Where susceptible individuals, e g , individuals who may be diagnosed as being genetically pre- disposed to developing a particular type of tumor, are identified pnor to diagnosis of cancer, the composition can be targeted to them, thus minimizing the need for administration to a larger population The dosage for an initial immunization generally occurs m a unit dosage range where the lower value is about 1, 5, 50, 500, or 1,000 μg and the higher value is about 10,000, 20,000, 30,000, or 50 000 μg Dosage values for a human typically range from about 500 μg to about 50,000 μg per 70 kilogram patient Initial doses followed by boosting doses at established intervals, e g from four weeks to six months, may be required, possibly for a prolonged period of time to effectively treat a patient Boostmg dosages of between about 1 0 μg to about 50,000 μg of peptide pursuant to a boosting regimen over weeks to months may be administered depending upon the patient's response and condition as determined by measuring the specific activity of CTL and HTL obtained from the patient's blood Administration should contmue until at least clinical symptoms or laboratory tests mdicate that the tumor has been eliminated or that the tumor cell burden has been substantially reduced and for a period thereafter The dosages, routes of administration, and dose schedules are adjusted m accordance with methodologies known in the art In certain embodiments, peptides and compositions of the present invention are employed m serious disease states, that is, life-threatening or potentially life threatenmg situations In such cases, as a result of the minimal amounts of extraneous substances and the relative nontoxic nature ofthe peptides m prefened compositions of the mvention, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these peptide compositions relative to these stated dosage amounts The pharmaceutical compositions for therapeutic treatment are intended for parenteral, topical, oral, lntrathecal, or local administration Preferably, the pharmaceutical compositions are admmistered parentally, e g , intravenously, subcutaneously, intradermally, or intramuscularly Thus, the mvention provides compositions for parenteral administration which compnse a solution ofthe unmunogenic peptides dissolved or suspended m an acceptable earner, preferably an aqueous earner A variety of aqueous earners may be used, e g , water, buffered water, 0 8% salme, 0 3% glycme, hyaluromc acid and the like These compositions may be sterilized by conventional, well known stenlization techniques, or may be sterile filtered The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation bemg combmed with a sterile solution pnor to administration The compositions may contam pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH-adjusting and buffering agents, tomcity adjusting agents, wetting agents, preservatives, and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chlonde, calcium chloride, sorbitan monolaurate, tπethanolamine oleate, etc The concentration of peptides of the invention in the pharmaceutical formulations can vary widely, i e , from less than about 0 1%, usually at or at least about 2% to as much as 20% to 50% or more by weight, and will be selected pnmanly by fluid volumes, viscosities, etc , in accordance with the particular mode of administration selected A human unit dose form of the peptide composition is typically included in a pharmaceutical composition that comprises a human unit dose of an acceptable earner, preferably an aqueous earner, and is administered in a volume of fluid that is known by those of skill m the art to be used for administration of such compositions to humans (see, e g , Remington's Pharmaceutical Sciences. 17* Edition, A Gennaro, Editor, Mack Publishing Co , Easton, Pennsylvania, 1985) The peptides of the invention may also be admmistered via liposomes, which serve to target the peptides to a particular tissue, such as lymphoid tissue, or to target selectively to mfected cells, as well as to increase the half-life of the peptide composition Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like In these preparations, the peptide to be delivered is incorporated as part of a liposome, alone or m conjunction with a molecule which binds to a receptor prevalent among lymphoid cells, such as monoclonal antibodies which bind to the CD45 antigen, or with other therapeutic or lmmunogenic compositions Thus, liposomes either filled or decorated with a desired peptide ofthe mvention can be directed to the site of lymphoid cells, where the liposomes then deliver the peptide compositions Liposomes for use m accordance with the mvention are formed from standard vesicle-forming lipids, which generally mclude neutral and negatively charged phosphohpids and a sterol, such as cholesterol The selection of lipids is generally guided by consideration of, e g , liposome size, acid lability and stability of the liposomes m the blood stream A variety of methods are available for prepaπng liposomes, as described m, e g , Szoka, et al , Ann Rev Biophys Bioeng 9 467 (1980), and U S Patent Nos 4,235,871, 4,501,728, 4,837,028, and 5,019,369 For targeting cells of the immune system, a ligand to be incorporated mto the liposome can mclude, e , antibodies or fragments thereof specific for cell surface determinants of the desired immune system cells A liposome suspension contammg a peptide may be admmistered intravenously, locally, topically, etc m a dose which vanes accordmg to, inter alia, the manner of administration, the peptide bemg delivered, and the stage of the disease being treated For solid compositions, conventional nontoxic solid earners may be used which mclude, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those earners previously listed, and generally 10-95% of active ingredient, that is, one or more peptides of the mvention, and more preferably at a concentration of 25%-75% For aerosol administration, the immunogemc peptides are preferably supplied m finely divided form along with a surfactant and propellant Typical percentages of peptides are 0 01%-20% by weight, preferably 1%-10% The surfactant must, of course, be nontoxic, and preferably soluble m the propellant Representative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, Imoleic, Imolenic, olesteric and oleic acids with an aliphatic polyhydπc alcohol or its cyclic anhydride Mixed esters, such as mixed or natural glycendes may be employed The surfactant may constitute 0 l%-20% by weight ofthe composition, preferably 0 25- 5% The balance ofthe composition is ordinarily propellant A earner can also be mcluded, as desired, as with, e g , lecithin for intranasal delivery IV.M. HLA EXPRESSION: IMPLICATIONS FOR T CELL-BASED IMMUNOTHERAPY Disease progression in cancer and infectious disease It is well recognized that a dynamic interaction between exists between host and disease, both in the cancer and infectious disease settings In the mfectious disease setting, it is well established that pathogens evolve during disease The strains that predommate early m HIV mfection are different from the ones that are associated with AIDS and later disease stages (NS versus S strains) It has long been hypothesized that pathogen forms that are effective m establishing infection may differ from the ones most effective in terms of replication and chronicity Similarly, it is widely recognized that the pathological process by which an individual succumbs to a neoplastic disease is complex During the course of disease, many changes occur m cancer cells The tumor accumulates alterations which are m part related to dysfunctional regulation of growth and differentiation, but also related to maximizing its growth potential, escape from drug treatment and/or the body's immunosurveillance Neoplastic disease results m the accumulation of several different biochemical alterations of cancer cells, as a function of disease progression It also results in significant levels of lntra- and inter- cancer heterogeneity, particularly m the late, metastatic stage Familiar examples of cellular alterations affecting treatment outcomes mclude the outgrowth of radiation or chemotherapy resistant tumors dunng the course of therapy These examples parallel the emergence of drug resistant viral strains as a result of aggressive chemotherapy, e g , of chronic HBV and HIV infection, and the cunent resurgence of drug resistant organisms that cause Tuberculosis and Malana - It appears that significant heterogeneity of responses is also associated with other approaches to cancer therapy, mcludmg anti-angiogenesis drugs, passive antibody immunotherapy, and active T cell-based immunotherapy Thus, m view of such phenomena, epitopes from multiple disease-related antigens can be used m vaccmes and therapeutics thereby counteracting the ability of diseased cells to mutate and escape treatment The interplay between disease and the immune system One ofthe mam factors contnbutmg to the dynamic interplay between host and disease is the immune response mounted agamst the pathogen, mfected cell, or malignant cell In many conditions such immune responses control the disease Several animal model systems and prospective studies of natural infection in humans suggest that immune responses against a pathogen can control the pathogen, prevent progression to severe disease and/or eliminate the pathogen A common theme is the requuement for a multispecific T cell response, and that nanowly focused responses appear to be less effective These observations guide skilled artisan as to embodiments of methods and compositions ofthe present mvention that provide for a broad immune response In the cancer setting there are several findings that mdicate that immune responses can impact neoplastic growth First, the demonstration in many different animal models, that anti-tumor T cells, restπcted by MHC class I, can prevent or treat tumors Second, encouraging results have come from immunotherapy tnals Third, observations made in the course of natural disease conelated the type and composition of T cell infiltrate within tumors with positive clinical outcomes (Couhe PG, et al Antitumor immunity at work in a melanoma patient In Advances in Cancer Research. 213-242, 1999) Finally, tumors commonly have the ability to mutate, thereby changing their immunological recognition For example, the presence of monospecific CTL was also conelated with control of tumor growth, until antigen loss emerged (Riker A, et al , Immune selection after antigen-specific immunotherapy of melanoma Surgery, Aug 126(2) 112-20, 1999, Marchand M, et al , Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-Al Int J Cancer 80(2) 219-30, Jan 18, 1999) Similarly, loss of beta 2 microglobuhn was detected in 5/13 lines established from melanoma patients after receivmg immunotherapy at the NCI (Restifo NP, et al , Loss of functional Beta2 - microglobulm m metastatic melanomas from five patients receiving immunotherapy Journal of the National Cancer Institute, Vol 88 (2), 100-108, Jan 1996) It has long been recognized that HLA class I is frequently altered m various tumor types This has led to a hypothesis that this phenomenon might reflect immune pressure exerted on the tumor by means of class I restricted CTL The extent and degree of alteration m HLA class I expression appears to be reflective of past unmune pressures, and may also have prognostic value (van Dumen SG, et al , Level of HLA antigens m locoregional metastases and clinical course of the disease m patients with melanoma Cancer Research 48, 1019-1025, Feb 1988, Moller P, et al , Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcmoma Cancer Research 51, 729-736, Jan 1991) Taken together, these observations provide a rationale for immunotherapy of cancer and infectious disease, and suggest that effective strategies need to account for the complex seπes of pathological changes associated with disease The three mam types of alterations in HLA expression m tumors and their functional significance The level and pattern of expression of HLA class I antigens in tumors has been studied in many different tumor types and alterations have been reported m all types of tumors studied The molecular mechanisms underlining HLA class I alterations have been demonstrated to be quite heterogeneous They mclude alterations in the TAP/processing pathways, mutations of β2-mιcroglobulιn and specific HLA heavy chams, alterations m the regulatory elements controlling over class I expression and loss of entire chromosome sections There are several reviews on this topic, see, e g , Garndo F, et al , Natural history of HLA expression during tumour development Immunol Today 14(10) 491-499, 1993, Kaklamams L, et al , Loss of HLA class-I alleles, heavy chains and β2-mιcroglobulιn m colorectal cancer Int J Cancer, 51(3) 379-85, May 28,1992 There are three main types of HLA Class I alteration (complete loss, allele- specific loss and decreased expression) The functional significance of each alteration is discussed separately Complete loss of HLA expression Complete loss of HLA expression can result from a vanety of different molecular mechanisms, reviewed in (Algana I, er al , The HLA crossroad m tumor immunology Human Immunology 61, 65-73, 2000, Brownmg M, et al , Mechanisms of loss of HLA class I expression on colorectal tumor cells Tissue Antigens 47 364-371, 1996, Fenone S, et al , Loss of HLA class I antigens by melanoma cells molecular mechanisms, functional significance and clinical relevance Immunology Today, 16(10) 487-494, 1995, Ganido F, et al , Natural history of HLA expression during tumour development Immunology Today 14(10) 491-499, 1993, Tait, BD, HLA Class I expression on human cancer cells Implications for effective immunotherapy Hum Immunol 61, 158-165, 2000) In functional terms, this type of alteration has several important implications While the complete absence of class I expression will eliminate CTL recognition of those tumor cells, the loss of HLA class I will also render the tumor cells extraordinary sensitive to lysis from NK cells (Ohnmacht, GA, et al , Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma J Cellular Phys 182 332-338, 2000, Liunggren HG, et al , Host resistance directed selectively against H-2 deficient lymphoma variants Analysis of the mechanism J Exp Med , Dec 1 ,162(6) 1745-59, 1985, Maio M, et al , Reduction m susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after mduction of HLA class I antigen expression by transfection with B2m gene J Clin Invest 88(1) 282-9, July 1991, Schner PI, et al , Relationship between myc oncogene activation and MHC class I expression Adv Cancer Res , 60 181-246, 1993) The complementary interplay between loss of HLA expression and gam m NK sensitivity is exemplified by the classic studies of Coulie and coworkers (Coulie, PG, er al , Antitumor immunity at work in a melanoma patient In Advances in Cancer Research. 213-242, 1999) which described the evolution of a patient's immune response over the course of several years Because of mcreased sensitivity to NK lysis, it is predicted that approaches leadmg to stimulation of innate immunity m general and NK activity m particular would be of special significance An example of such approach is the mduction of large amounts of dendritic cells (DC) by various hematopoietic growth factors, such as Flt3 ligand or ProGP The rationale for this approach resides m the well known fact that dendπtic cells produce large amounts of IL- 12, one ofthe most potent stimulators for innate immunity and NK activity m particular Alternatively, IL- 12 is admmistered directly, or as nucleic acids that encode it In this light, it is mterestmg to note that Flt3 ligand treatment results m transient tumor regression of a class I negative prostate murine cancer model (Ciavana RP, et al , Flt3-Lιgand mduces transient tumor regression m an ectopic treatment model of major histocompatibility complex-negative prostate cancer Cancer Res 60 2081-84, 2000) In this context, specific anti-tumor vaccmes m accordance with the mvention synergize with these types of hematopoietic growth factors to facilitate both CTL and NK cell responses, thereby appreciably impairing a cell's ability to mutate and thereby escape efficacious treatment Thus, an embodiment of the present invention compnses a composition of the invention together with a method or composition that augments functional activity or numbers of NK cells Such an embodiment can compnse a protocol that provides a composition of the invention sequentially with an NK-inducing modality, or contemporaneous with an NK-inducing modality Secondly, complete loss of HLA frequently occurs only m a fraction of the tumor cells, while the remamder of tumor cells continue to exhibit normal expression In functional terms, the tumor would still be subject, m part, to direct attack from a CTL response, the portion of cells lackmg HLA subject to an NK response Even if only a CTL response were used, destruction ofthe HLA expressing fraction ofthe tumor has dramatic effects on survival tunes and quality of life It should also be noted that in the case of heterogeneous HLA expression, both normal HLA- expressmg as well as defective cells are predicted to be susceptible to immune destruction based on "bystander effects " Such effects were demonstrated, e g , m the studies of Rosendahl and colleagues that investigated in vivo mechanisms of action of antibody targeted superantigens (Rosendahl A, et al , Perform and IFN-gamma are involved m the antitumor effects of antibody-targeted superantigens J Immunol 160(11) 5309-13, June 1, 1998) The bystander effect is understood to be mediated by cytokmes elicited from, e g , CTLs acting on an HLA-bearmg target cell, whereby the cytokmes are m the environment of other diseased cells that are concomitantly killed A llele-spec c loss One of the most common types of alterations m class I molecules is the selective loss of certain alleles m individuals heterozygous for HLA Allele-specific alterations might reflect the tumor adaptation to immune pressure, exerted by an immunodominant response restπcted by a smgle HLA restnction element This type of alteration allows the tumor to retam class I expression and thus escape NK cell recognition, yet still be susceptible to a CTL-based vaccme m accordance with the mvention which compπses epitopes conespondmg to the remaining HLA type Thus, a practical solution to overcome the potential hurdle of allele-specific loss relies on the mduction of multispecific responses Just as the inclusion of multiple disease-associated antigens in a vaccine ofthe invention guards agamst mutations that yield loss of a specific disease antigens, simultaneously targetmg multiple HLA specificities and multiple disease-related - antigens prevents disease escape by allele-specific losses Decrease in expression (allele-specific or not) The sensitivity of effector CTL has long been demonstrated (Brower, RC, et al , Minimal requirements for peptide mediated activation of CD8+ CTL Mol Immunol , 31,1285-93, 1994, Chnustmck, ET, et al Low numbers of MHC class I-peptide complexes required to tngger a T cell response Nature 352 67-70, 1991 , Sykulev, Y, et al , Evidence that a single pepnde-MHC complex on a target cell can elicit a cytolytic T cell response Immunity, 4(6) 565-71, June 1996) Even a smgle peptide/MHC complex can result in tumor cells lysis and release of anti-tumor lymphokines The biological significance of decreased HLA expression and possible tumor escape from immune recognition is not fully known Nevertheless, it has been demonstrated that CTL recognition of as few as one MHC/peptide complex is sufficient to lead to tumor cell lysis Further, it is commonly observed that expression of HLA can be upregulated by gamma IFN, commonly secreted by effector CTL Additionally, HLA class I expression can be induced in vivo by both alpha and beta IFN (Halloran, et al Local T cell responses mduce widespread MHC expression J Immunol 148 3837, 1992, Pestka, S, et al , Interferons and their actions Annu Rev Biochem 56 727-77, 1987) Conversely, decreased levels of HLA class I expression also render cells more susceptible to NK lysis With regard to gamma IFN, Tones et al (Tones, MJ, et al , Loss of an HLA haplotype m pancreas cancer tissue and its conespondmg tumor derived cell lme Tissue Antigens 47 372-81, 1996) note that HLA expression is upregulated by gamma IFN m pancreatic cancer, unless a total loss of haplotype has occuned Similarly, Rees and Mian note that allelic deletion and loss can be restored, at least partially, by cytokmes such as IFN-gamma (Rees, R , et al Selective MHC expression in tumours modulates adaptive and innate antitumour responses Cancer Immunol Immunother 48 374-81, 1999) It has also been noted that IFN-gamma treatment results in upregulation of class I molecules in the majority of the cases studied (Browning M, et al , Mechanisms of loss of HLA class I expression on colorectal rumor cells Tissue Antigens 47 264-7 \ , 1996) Kaklamakis, et al also suggested that adjuvant immunotherapy with IFN- gamma may be beneficial m the case of HLA class I negative tumors (Kaklamams L, Loss of transporter m antigen processmg 1 transport protem and major histocompatibility complex class I molecules m metastatic versus primary breast cancer Cancer Research 55 5191-94, November 1995) It is important to underline that IFN-gamma production is induced and self-amplified by local inflammation/immunization (Halloran, et al Local T cell responses induce widespread MHC expression J Immunol 148 3837, 1992), resultmg m large increases in MHC expressions even in sites distant from the inflammatory site Finally, studies have demonstrated that decreased HLA expression can render tumor cells more susceptible to NK lysis (Ohnmacht, GA, et al , Heterogeneity m expression of human leukocyte antigens and melanoma-associated antigens m advanced melanoma J Cellular Phys 182 332-38, 2000, Liunggren HG, et al , Host resistance directed selectively agamst H-2 deficient lymphoma variants Analysis of the mechanism Exp Med , 162(6) 1745-59, December 1, 1985, Maio M, et al , Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after mduction of HLA class I antigen expression by transfection with β2m gene J Clin Invest 88(1) 282-9, July 1991 , Schπer PI, et al , Relationship between myc oncogene activation and MHC class I expression Adv Cancer Res , 60 181-246, - 1993) If decreases in HLA expression benefit a tumor because it facilitates CTL escape, but render the tumor susceptible to NK lysis, then a minimal level of HLA expression that allows for resistance to NK activity would be selected for (Ganido F, et al , Implications for immunosurveillance of altered HLA class I phenotypes m human tumours Immunol Today 18(2) 89-96, February 1997) Therefore, a therapeutic compositions or methods m accordance with the mvention together with a treatment to upregulate HLA expression and/or treatment with high affinity T-cells renders the tumor sensitive to CTL destruction Frequency of alterations in HLA expression The frequency of alterations m class I expression is the subject of numerous studies (Algana I, et al , The HLA crossroad in tumor immunology Human Immunology 61, 65-73, 2000) Rees and Mian estimate allelic loss to occur overall m 3-20% of tumors, and allelic deletion to occur in 15-50% of tumors It should be noted that each cell canies two separate sets of class I genes, each gene carrying one HLA-A and one HLA-B locus Thus, fully heterozygous individuals carry two different HLA-A molecules and two different HLA-B molecules Accordmgly, the actual frequency of losses for any specific allele could be as little as one quarter of the overall frequency They also note that, m general, a gradient of expression exists between normal cells, primary tumors and tumor metastasis In a study from Natali and coworkers (Natali PG, et al , Selective changes m expression of HLA class I polymorphic determinants m human solid tumors PNAS USA 86 6719-6723, September 1989), solid tumors were mvestigated for total HLA expression, usmg W6/32 antibody, and for allele-specific expression of the A2 antigen, as evaluated by use ofthe BB7 2 antibody Tumor samples were derived from pnmary cancers or metastasis, for 13 different tumor types, and scored as negative if less than 20%, reduced if m the 30-80% range, and normal above 80% All tumors, both primary and metastatic, were HLA positive with W6/32. In terms of A2 expression, a reduction was noted in 16.1 % of the cases, and A2 was scored as undetectable in 39.4 % ofthe cases. Garrido and coworkers (Ga ido F, er al, Natural history of HLA expression during tumour development Immunol Today 14(10):491-99, 1993) emphasize that HLA changes appear to occur at a particular step in the progression from benign to most aggressive. Jiminez et al (Jiminez P, et al, Microsatellite instability analysis in tumors with different mechanisms for total loss of HLA expression. Cancer Immunol Immunother 48:684-90, 2000) have analyzed 118 different tumors (68 colorectal, 34 laryngeal and 16 melanomas). The frequencies reported for total loss of HLA expression were 11% for colon, 18% for melanoma and 13 % for larynx. Thus, HLA class I expression is altered in a significant fraction of the tumor types, possibly as a reflection of immune pressure, or simply a reflection ofthe accumulation of pathological changes and alterations in diseased cells. Immunotherapy in the context of HLA loss A majority ofthe tumors express HLA class I, with a general tendency for the more severe alterations to be found in later stage and less differentiated tumors. This pattern is encouraging in the context of immunotherapy, especially considering that: 1) the relatively low sensitivity of immunohistochemical techniques might underestimate HLA expression in tumors; 2) class I expression can be induced in tumor cells as a result of local inflammation and lymphokme release; and, 3) class I negative cells are sensitive to lysis by NK cells. Accordingly, various embodiments ofthe present invention can be selected in view ofthe fact that there can be a degree of loss of HLA molecules, particularly in the context of neoplastic disease. For example, the treating physician can assay a patient's tumor to ascertain whether HLA is being expressed. If a percentage of tumor cells express no class I HLA, then embodiments of the present invention that comprise methods or compositions that elicit NK cell responses can be employed. As noted herein, such NK-inducing methods or composition can comprise a Flt3 ligand or ProGP which facilitate mobilization of dendritic cells, the rationale being that dendritic cells produce large amounts of IL-12. IL-12 can also be administered directly in either amino acid or nucleic acid form. It should be noted that compositions in accordance with the invention can be administered concunently with NK cell-inducing compositions, or these compositions can be administered sequentially. In the context of allele-specific HLA loss, a tumor retains class I expression and may thus escape NK cell recognition, yet still be susceptible to a CTL-based vaccine in accordance with the invention which comprises epitopes conesponding to the remaining HLA type. The concept here is analogous to embodiments ofthe invention that include multiple disease antigens to guard against mutations that yield loss of a specific antigen. Thus, one can simultaneously target multiple HLA specificities and epitopes from multiple disease-related antigens to prevent tumor escape by allele-specific loss as well as disease- related antigen loss. In addition, embodiments ofthe present invention can be combined with alternative therapeutic compositions and methods. Such alternative compositions and methods comprise, without limitation, radiation, cytotoxic pharmaceuticals, and/or compositions/methods that induce humoral antibody responses. Moreover, it has been observed that expression of HLA can be upregulated by gamma IFN, which is commonly secreted by effector CTL, and that HLA class I expression can be induced in vivo by both alpha and beta IFN Thus, embodiments ofthe invention can also comprise alpha, beta and/or gamma IFN to facilitate upregualtion of HLA IV.N. REPRIEVE PERIODS FROM THERAPIES THAT INDUCE SIDE EFFECTS: "Scheduled Treatment Interruptions or Drug Holidays" Recent evidence has shown that certain patients infected with a pathogen, whom are initially treated with a therapeutic regimen to reduce pathogen load, have been able to maintain decreased pathogen load when removed from the therapeutic regimen, I e , during a "drug holiday" (Rosenberg, E , et al , Immune control of HIV-1 after early treatment of acute infection Nature 407 523-26, Sept 28, 2000) As appreciated by those skilled m the art, many therapeutic regimens for both pathogens and cancer have numerous, often severe, side effects Dunng the drug holiday, the patient's immune system is keepmg the disease m check Methods for using compositions of the invention are used m the context of drug holidays for cancer and pathogenic infection For treatment of an infection, where therapies are not particularly immunosuppressive, compositions of the mvention are administered concunently with the standard therapy Durmg this period, the patient's immune system is directed to mduce responses agamst the epitopes comprised by the present mventive compositions Upon removal from the treatment havmg side effects, the patient is primed to respond to the mfectious pathogen should the pathogen load begm to increase Composition ofthe invention can be provided durmg the drug holiday as well For patients with cancer, many therapies are immunosuppressive Thus, upon achievement of a remission or identification that the patient is refractory to standard treatment, then upon removal from the immunosuppressive therapy, a composition m accordance with the mvention is administered Accordmgly, as the patient's immune system reconstitutes, precious immune resources are simultaneously directed agamst the cancer Composition of the invention can also be admmistered concunently with an immunosuppressive regimen if desired IV.O. Kits The peptide and nucleic acid compositions of this mvention can be provided in kit form together with instructions for vaccme administration Typically the kit would mclude desired peptide compositions in a contamer, preferably in unit dosage form and instructions for administration An alternative kit would include a mmigene construct with desired nucleic acids of the mvention m a contamer, preferably in unit dosage form together with instructions for administration Lymphokines such as IL-2 or IL-12 may also be mcluded m the kit Other kit components that may also be desuable mclude, for example, a stenle synnge, booster dosages, and other desired excipients IV.P. Overview Epitopes m accordance with the present invention were successfully used to induce an immune response Immune responses with these epitopes have been mduced by admmistermg the epitopes m various forms The epitopes have been admmistered as peptides, as nucleic acids, and as viral vectors comprising nucleic acids that encode the epιtope(s) of the mvention Upon administration of peptide-based epitope forms, immune responses have been induced by direct loading of an epitope onto an empty HLA molecule that is expressed on a cell, and via internalization of the epitope and processing via the HLA class I pathway, in either event, the HLA molecule expressmg the epitope was then able to interact with and induce a CTL response Peptides can be deh\ ered directly or using such agents as liposomes They can additionally be delivered using ballistic delivery, in which the peptides are typically m a crystalline form When DNA is used to induce an immune response, it is admmistered either as naked DNA, generally m a dose range of approximately l-5mg, or via the ballistic "gene gun" delivery, typically m a dose range of approximately 10- 100 μg The DNA can be delivered m a vanety of conformations, e , linear, circular etc Vaπous viral vectors have also successfully been used that compnse nucleic acids which encode epitopes in accordance with the mvention Accordingly compositions m accordance with the mvention exist m several forms Embodiments of each of these composition forms m accordance with the invention have been successfully used to induce an immune response One composition m accordance with the invention comprises a plurality of peptides This plurality or cocktail of peptides is generally admixed with one or more pharmaceutically acceptable excipients The peptide cocktail can comprise multiple copies of the same peptide or can comprise a mixture of peptides The peptides can be analogs of naturally occurnng epitopes The peptides can comprise artificial ammo acids and/or chemical modifications such as addition of a surface active molecule, e g , hpidation, acetylation, glycosylation, biotinylation, phosphorylation etc The peptides can be CTL or HTL epitopes In a prefened embodiment the peptide cocktail comprises a plurality of different CTL epitopes and at least one HTL epitope The HTL epitope can be naturally or non-naturally (e g , PADRE®, Epimmune Inc , San Diego, CA) The number of distmct epitopes m an embodiment of the mvention is generally a whole unit integer from one through two hundred (e g , 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 105, 107, 108, 109, 1 10, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200) An additional embodiment of a composition m accordance with the mvention comprises a polypeptide multi-epitope construct, i e , a. polyepitopic peptide Polyepitopic peptides m accordance with the mvention are prepared by use of technologies well-known m the art By use of these known technologies, epitopes in accordance with the mvention are connected one to another The polyepitopic peptides can be lmear or non-linear, e g , multivalent These polyepitopic constructs can compnse artificial ammo acids, spacmg or spacer amino acids, flanking amino acids, or chemical modifications between adjacent epitope units The polyepitopic construct can be a heteropolymer or a homopolymer The polyepitopic constructs generally comprise epitopes m a quantity of any whole unit integer between 2-200 (e , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, etc ) The polyepitopic construct can compnse CTL and/or HTL epitopes One or more of the epitopes in the construct can be modified, e g , by addition of a surface active material, e g a lipid, or chemically modified, e g , acetylation, etc Moreover, bonds in the multiepitopic construct can be other than peptide bonds, e g , covalent bonds, ester or ether bonds, disulfide bonds, hydrogen bonds, ionic bonds etc Alternatively, a composition m accordance with the mvention compnses construct which comprises a series, sequence, stretch, etc , of ammo acids that have homology to ( i e , conesponds to or is contiguous with) to a native sequence This stretch of amino acids compnses at least one subsequence of amino acids that, if cleaved or isolated from the longer series of ammo acids, functions as an HLA class I or HLA class II epitope in accordance with the invention In this embodiment, the peptide sequence is modified, so as to become a construct as defined herem, by use of any number of techniques known or to be provided m the art The polyepitopic constructs can contam homology to a native sequence m any whole unit integer increment from 70-100%, e g , 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or, 100 percent A further embodiment of a composition in accordance with the mvention is an antigen presenting cell that comprises one or more epitopes m accordance with the mvention The antigen presenting cell can be a "professional" antigen presentmg cell, such as a dendπtic cell The antigen presenting cell can comprise the epitope of the mvention by any means known or to be determined m the art Such means include pulsing of dendritic cells with one or more individual epitopes or with one or more peptides that comprise multiple epitopes, by nucleic acid administration such as ballistic nucleic acid delivery or by other techniques in the art for admmistration of nucleic acids, mcludmg vector-based, e g viral vector, delivery of nucleic acids Further embodiments of compositions in accordance with the mvention compnse nucleic acids that encode one or more peptides ofthe invention, or nucleic acids which encode a polyepitopic peptide m accordance with the invention As appreciated by one of ordinary skill m the art, vaπous nucleic acids compositions will encode the same peptide due to the redundancy of the genetic code Each of these nucleic acid compositions falls withm the scope of the present mvention This embodiment ofthe mvention comprises DNA or RNA, and m certain embodiments a combination of DNA and RNA It is to be appreciated that any composition compnsmg nucleic acids that will encode a peptide m accordance with the invention or any other peptide based composition in accordance with the mvention, falls withm the scope of this mvention It is to be appreciated that peptide-based forms of the mvention (as well as the nucleic acids that encode them) can comprise analogs of epitopes of the mvention generated usmg pnmciples already known, or to be known, m the art Principles related to analogmg are now known m the art, and are disclosed herem, moreover, analogmg principles (heterochtic analogmg) are disclosed m co-pendmg application serial number U S S N 09/226,775 filed 6 January 1999 Generally the compositions of the invention are isolated or purified The invention will be described in greater detail by way of specific examples The followmg examples are offered for illustrative purposes, and are not intended to limit the invention m any manner Those of skill m the art will readily recognize a variety of non-critical parameters that can be changed or modified to yield alternative embodiments in accordance with the mvention V. EXAMPLES The following examples illustrate identification, selection, and use of immunogemc Class I and Class II peptide epitopes for inclusion m vaccine compositions Example 1 HLA Class I and Class II Binding Assays The following example of peptide bmdmg to HLA molecules demonstrates quantification of bmdmg affinities of HLA class I and class II peptides Bmdmg assays can be performed with peptides that are either motif-bearing or not motif-bearing HLA class I and class II binding assays usmg purified HLA molecules were performed m accordance with disclosed protocols (e g , PCT publications WO 94/20127 and WO 94/03205, Sidney et al , Current Protocols in Immunology 18 3 1 (1998), Sidney, et al , J Immunol 154 247 (1995), Sette, et al , Mol Immunol 31 813 (1994)) Bnefly, punfied MHC molecules (5 to 500nM) were mcubated with vanous unlabeled peptide inhibitors and 1-lOnM 125 I-radιolabeled probe peptides as descnbed Followmg mcubation, MHC-peptide complexes were separated from free peptide by gel filtration and the fraction of peptide bound was determmed Typically, in preliminary experiments, each MHC preparation was titered m the presence of fixed amounts of radio labeled peptides to determine the concentration of HLA molecules necessary to bind 10-20% ofthe total radioactivity All subsequent inhibition and direct bmdmg assays were performed using these HLA concentrations Since under these conditions [label]<[HLA] and IC 50 >[HLA], the measured IC 50 values are reasonable approximations of the true K D values Peptide inhibitors are typically tested at concentrations rangmg from 120 μg/ml to 1 2 ng/ml, and are tested m two to four completely mdependent experiments To allow comparison ofthe data obtained m different experiments, a relative bmdmg figure is calculated for each peptide by dividing the IC 50 of a positive control for inhibition by the IC5 0 f° r eacn tested peptide (typically unlabeled versions of the radiolabeled probe peptide) For database purposes, and mter- expeπment compaπsons, relative bmdmg values are compiled These values can subsequently be converted back into IC 50 nM values by dividing the IC 50 nM of the positive controls for inhibition by the relative bmding of the peptide of interest This method of data compilation has proven to be the most accurate and consistent for comparmg peptides that have been tested on different days, or with different lots of purified MHC Bmdmg assays as outlined above can be used to analyze supermotif and/or motif-beaπng epitopes as, for example, described m Example 2 Example 2 Identification of HLA Supermotif- and Motif-Bearing CTL Candidate Epitopes Vaccine compositions ofthe invention may include multiple epitopes that comprise multiple HLA supermotifs or motifs to achieve broad population coverage This example illustrates the identification of supermotif- and motif-bearmg epitopes for the inclusion in such a vaccme composition Calculation of population coverage is performed using the strategy described below Computer searches and algorthims for identification of supermotif and/or motif-bearing epitopes The searches performed to identify the motif-bearing peptide sequences m Examples 2 and 5 employed protein sequence data for the tumor-associated antigen p53 Computer searches for epitopes bearing HLA Class I or Class II supermotifs or motifs were performed as follows All translated protein sequences were analyzed usmg a text string search software program, e g , MotifSearch 1 4 (D Brown, San Diego) to identify potential peptide sequences contammg appropriate HLA bindmg motifs, alternative programs are readily produced in accordance with information m the art in view of the motif/supermotif disclosure herem Furthermore, such calculations can be made mentally Identified A2-, A3-, and DR-supermotif sequences were scored usmg polynomial algorithms to predict their capacity to bmd to specific HLA-Class I or Class II molecules These polynomial algorithms take mto account both extended and refined motifs (that is, to account for the impact of different ammo acids at different positions), and are essentially based on the premise that the overall affinity (or ΔG) of peptide-HLA molecule interactions can be approximated as a lmear polynomial function of the type "ΔG" = a h x a 2l x a 3 , x a„, where a,, is a coefficient which represents the effect of the presence of a given ammo acid ( ) at a given position (i) along the sequence of a peptide of n ammo acids The crucial assumption of this method is that the effects at each position are essentially independent of each other (l e , mdependent bmdmg of individual side-chams) When residue occurs at position i m the peptide, it is assumed to contπbute a constant amount^, to the free energy of binding ofthe peptide inespective ofthe sequence ofthe rest ofthe peptide This assumption is justified by studies from our laboratones that demonstrated that peptides are bound to MHC and recognized by T cells m essentially an extended conformation (data omitted herem) The method of denvation of specific algonthm coefficients has been descnbed m Gulukota et al , J Mol Biol 267 1258-126, 1997, (see also Sidney et al , Human Immunol 45 79-93, 1996, and Southwood et al , J Immunol 160 3363-3373, 1998) Bnefly, for all i positions, anchor and non-anchor alike, the geometnc mean of the average relative binding (ARB) of all peptides carrying y is calculated relative to the remamder of the group, and used as the estimate ofy, For Class II peptides, if multiple alignments are possible, only the highest scormg alignment is utilized, followmg an iterative procedure To calculate an algorithm score of a given peptide m a test set, the ARB values conespondmg to the sequence of the peptide are multiplied If this product exceeds a chosen threshold, the peptide is predicted to bind Appropnate thresholds are chosen as a function of the degree of stringency of prediction desired Selection ofHLA-A2 supertype cross-reactive peptides The complete protem sequence from p53 was scanned, utilizing motif identification software, to identify 8-, 9-, 10-, and 11-mer sequences contammg the HLA-A2-supermotιf mam anchor specificity A total of 149 HLA-A2 supermotif-positive sequences were identified and conespondmg peptides synthesized These 149 peptides were then tested for their capacity to bmd purified HLA-A*0201 molecules in vitro (HLA-A*0201 is considered a prototype A2 supertype molecule) Fourteen of the peptides bound A*0201 with IC 50 values <500 nM The fourteen A*0201 -bmding peptides were subsequently tested for the capacity to bmd to additional A2-supertype molecules (A*0202, A*0203, A*0206, and A*6802) As shown m Table XXII, 10 ofthe 14 peptides were found to be A2-supertype cross-reactive bmders, bmding at least three ofthe five A2-supertyρe alleles tested One of the peptides was selected for further evaluation Selection ofHLA-A3 supermotif-beanng epitopes The protein sequences scanned above are also examined for the presence of peptides with the HLA-A3-supermotιf primary anchors usmg methodology similar to that performed to identify HLA-A2 supermotif-beanng epitopes Peptides conespondmg to the supermotif-beanng sequences are then synthesized and tested for binding to HLA-A*0301 and HLA-A* 1101 molecules, the two most prevalent A3-suρertype alleles The peptides that are found to bmd one ofthe two alleles with bmdmg affinities of <500 nM are then tested for binding cross-reactivity to the other common A3-supertype alleles (A*3101, A*3301, and A*6801) to identify those that can bmd at least three of the five HLA-A3-suρertype molecules tested Examples of HLA-A3 cross-binding supermotif-beanng peptides identified m accordance with this procedure are provided m Table XXIII Selection ofHLA-B7 supermotif bearing epitopes The same target antigen protem sequences are also analyzed to identify HLA-B7-supermotιf- bearmg sequences The conespondmg peptides are then synthesized and tested for bmdmg to HLA- B*0702, the most common B7-supertype allele (; e , the prototype B7 supertype allele) Those peptides that bmd B*0702 with IC 50 of <500 nM are then tested for bindmg to other common B7-supertype molecules (B*3501, B*5101, B*5301, and B*5401) to identify those peptides that are capable of bmdmg to three or more ofthe five B7-supertype alleles tested Examples of HLA-B 7 cross-bmdmg supermotif-beanng peptides identified in accordance with this procedure are provided m Table XXIV Selection of Al and A 24 motif-bearing epitopes To further mcrease population coverage, HLA-Al and -A24 motif-beanng epitopes can also be incorporated into potential vaccme constructs An analysis of the protein sequence data from the target antigen utilized above is also performed to identify HLA-Al- and A24-motιf-contaιnιng conserved sequences The conespondmg peptide sequence are then synthesized and tested for bindmg to the appropnate allele-specific HLA molecule, HLA-Al or HLA-24 Peptides are identified that bmd to the allele-specific HLA molecules at an IC 50 of <500 nM Examples of peptides identified in accordance with this procedure are provided m Tables XXV and XXVI Example 3 Confirmation of Immunogenicity Cross-reactive candidate CTL A2-supermotιf-beaπng peptides identified in Example 2 were selected for in vitro immunogenicity testing Testing was performed usmg the following methodology Target Cell Lines for Cellular Screening The 221A2 1 cell line, produced by transfemng the HLA-A2 1 gene mto the HLA-A, -B, -C null mutant human B-lymphoblastoid cell line 721 221, was used as the peptide-loaded target to measure activity of HLA-A2 1 -restricted CTL The breast tumor line BT549 was obtamed from the American Type Culture Collection (ATCC) (Rockville, MD) The Saos-2/175 (Saos-2 transfected with the p53 gene contammg a mutation at position 175) was obtained from Dr Levme, Princeton University, Princeton, NJ The cell lines that were obtained from ATCC were maintained under the culture conditions recommended by the supplier All other cell lines were grown m RPMI-1640 medium supplemented with antibiotics, sodium pyruvate, nonessential ammo acids and 10% (v/v) heat mactivated FCS The p53 tumor targets were treated with 20 ng/ml IFNγ and 3 ng/ml TNF for 24 hours pnor to use as targets in the 51 Cr release and in situ IFNγ assays (see, e g , Theobald et al , Proc Natl Acad Sci USA 92 11993, 1995) Primary CTL Induction Cultures: Generation of Dendritic Cells (DC) PBMCs were thawed m RPMI with 30 μg/ml DNAse, washed twice and resuspended m complete medium (RPMI-1640 plus 5% AB human serum, non-essential ammo acids, sodium pyruvate, L-glutamine and pemcillin/strpetomycin) The monocytes were purified by plat g 10 x 10 6 PBMC/well m a 6-well plate After 2 hours at 37°C, the non-adherent cells were removed by gently shakmg the plates and aspirating the supernatants The wells were washed a total of three times with 3 ml RPMI to remove most ofthe non-adherent and loosely adherent cells Three ml of complete medium contammg 50 ng/ml of GM-CSF and 1,000 U/ml of IL-4 were then added to each well DC were used for CTL mduction cultures followmg 7 days of culture Induction of CTL with DC and Peptide CD8+ T-cells were isolated by positive selection with Dynal lmmunomagnetic beads (Dynabeads® M-450) and the detacha-bead® reagent Typically about 200- 250xl0 6 PBMC were processed to obtam 24x10 s CD8 + T-cells (enough for a 48-well plate culture) Briefly, the PBMCs were thawed m RPMI with 30μg/ml DNAse, washed once with PBS contammg 1% human AB serum and resuspended m PBS/1% AB serum at a concentration of 20xl0 6 cells/ml The magnetic beads were washed 3 times with PBS/AB serum, added to the cells (140μl beads/20xl0 6 cells) and incubated for 1 hour at 4°C with contmuous mixing The beads and cells were washed 4x with PBS/AB serum to remove the nonadherent cells and resuspended at lOOxlO 6 cells/ml (based on the onginal cell number) in PBS/AB serum contammg lOOμl/ml detacha-bead® reagent and 30μg/ml DNAse The mixture is mcubated for 1 hour at room temperature with continuous mixing The beads were washed agam with PBS/AB/DNAse to collect the CD8+ T-cells The DC were collected and centrifuged at 1300 φm for 5-7 minutes, washed once with PBS with 1% BSA, counted and pulsed with 40μg/ml of peptide at a cell concentration of l-2xl0 6 /ml m the presence of 3 μg/ml β 2 - microglobulm for 4 hours at 20°C The DC were then uradiated (4,200 rads), washed 1 tune with medium and counted agam Setting up induction cultures 0 25 ml cytokine-generated DC (@lxl0 5 cells/ml) were co-cultured with 0 25ml of CD8+ T-cells (@2xl0 6 cell/ml) in each well of a 48-well plate m the presence of 10 ng/ml of IL-7 rHuman IL10 was added the next day at a final concentration of 10 ng/ml and rhuman IL2 was added 48 hours later at lOIU/ml Restimulation ofthe induction cultures with peptide-pulsed adherent cells Seven and fourteen days after the primary induction the cells were reshmulated with peptide-pulsed adherent cells The PBMCS were thawed and washed twice with RPMI and DNAse The cells were resuspended at 5\10 6 cells/ml and inadiated at ~4200 rads The PBMCs were plated at 2xl0 6 in 0 5ml complete medium per well and incubated for 2 hours at 37°C The plates were washed twice with RPMI by tappmg the plate gently to remove the nonadherent cells and the adherent cells pulsed with lOμg/ml of peptide m the presence of 3 μg/ml β 2 microglobulm in 0 25ml RPMI/5%AB per well for 2 hours at 37°C Peptide solution from each well was aspirated and the wells were washed once with RPMI Most of the media was aspuated from the mduction cultures (CD8+ cells) and brought to 0 5 ml with fresh media The cells were then transfened to the wells contammg the peptide-pulsed adherent cells Twenty four hours later rhuman IL10 was added at a final concentration of lOng/ml and rhuman IL2 was added the next day and again 2-3 days later at 50IU/ml (Tsai et al , Critical Reviews in Immunology 18(1-2) 65-75, 1998) Seven days later the cultures were assayed for CTL activity in a 51 Cr release assay In some experiments the cultures were assayed for peptide-specific recognition in the in situ IFNγ ELISA at the time ofthe second restimulation followed by assay of endogenous recognition 7 days later After expansion, activity was measured m both assays for a side by side companson Measurement of CTL lytic activity by sl Cr release. Seven days after the second restimulation, cytotoxicity was determmed m a standard (5hr) 5l Cr release assay by assaying individual wells at a single E T Peptide-pulsed targets were prepared by mcubatmg the cells with lOμg/ml peptide overnight at 37°C Adherent target cells were removed from culture flasks with trypsm-EDTA Target cells were labelled with 200μCι of 51 Cr sodium chromate (Dupont, Wilmington, DE) for 1 hour at 37°C Labelled target cells are resuspended at 10 6 per ml and diluted 1 10 with K562 cells at a concentration of 3 3xl0 6 /ml (an NK-sensitive erythroblastoma cell lme used to reduce non-specific lysis) Target cells (100 μl) and lOOμl of effectors were plated in 96 well round-bottom plates and mcubated for 5 hours at 37°C At that tune, 100 μl of supernatant were collected from each well and percent lysis was determined according to the formula [(cpm ofthe test sample- cpm ofthe spontaneous "Cr release sample)/(cpm of the maximal 51 Cr release sample- cpm of the spontaneous 51 Cr release sample)] x 100 Maximum and spontaneous release were determined by incubating the labelled targets with 1% Tntion X-100 and media alone, respectively A positive culture was defined as one m which the specific lysis (sample- background) was 10% or higher m the case of individual wells and was 15% or more at the 2 highest E T ratios when expanded cultures were assayed In situ Measurement of Human IFNγ Production as an Indicator of Peptide-specific and Endogenous Recognition Immulon 2 plates were coated with mouse anti-human IFNγ monoclonal antibody (4 μg/ml 0 IM NaHC0 3 , pH8 2) overnight at 4°C The plates were washed with Ca 2+ , Mg 2+ -free PBS/0 05% Tween 20 and blocked with PBS/10% FCS for 2 hours, after which the CTLs (100 μl/well) and targets (100 μl/well) were added to each well, leaving empty wells for the standards and blanks (which received media only) The target cells, either peptide-pulsed or endogenous targets, were used at a concentration of lxl 0 6 cells/ml The plates were incubated for 48 hours at 37°C with 5% C0 2 Recombinant human IFNγ was added to the standard wells starting at 400 pg or 1200pg/100μl well and the plate incubated for 2 hours at 37°C The plates were washed and 100 μl of biotinylated mouse anti-human IFNγ monoclonal antibody (4μg/ml m PBS/3 %FCS/0 05% Tween 20) were added and incubated for 2 hours at room temperature After washmg agam, 100 μl HRP-streptavidin were added and mcubated for 1 hour at room temperature The plates were then washed 6x with wash buffer, lOOμl/well developing solution (TMB 1 1) were added, and the plates allowed to develop for 5-15 minutes The reaction was stopped with 50 μl well IM H 3 P0 4 and read at OD450 A culture was considered positive if it measured at least 50 pg of IFNγ/well above background and was twice the background level of expression CTL Expansion Those cultures that demonstrated specific lytic activity agamst peptide- pulsed targets and/or tumor targets were expanded over a two week period with antι-CD3 Bnefly, 5xl0 4 CD8+ cells were added to a T25 flask contammg the followmg lxlO 6 irradiated (4,200 rad) PBMC (autologous or allogeneic) per ml, 2xl0 5 madiated (8,000 rad) EBV- transformed cells per ml, and OKT3 (antι-CD3) at 30ng per ml m RPMI-1640 containing 10% (v/v) human AB serum, non-essential amino acids, sodium pyruvate, 25 μM 2-mercaptoethanol, L-glutamme and penicillin/streptomycin rHuman IL2 was added 24 hours later at a final concentration of 200IU/ml and every 3 days thereafter with fresh media at 50IU/ml The cells were split if the cell concentration exceeded lxl0 6 /ml and the cultures were assayed between days 13 and 15 at E T ratios of 30, 10, 3 and 1 1 m the 51 Cr release assay or at lxl0 6 /ml in the in situ IFNγ assay usmg the same targets as before the expansion Immunogenicity of A2 supermotif-beanng peptides The A2-supermotιf cross-reactive bindmg peptides (and analogs of those peptides, which were engmeered as described herem) that were selected for further evaluation were tested m the cellular assay for the ability to mduce peptide-specific CTL m normal individuals In this analysis, a peptide was considered to be an epitope if it mduced peptide-specific CTLs in at least 2 donors (unless otherwise noted) and if those CTLs also recognized the endogenously expressed peptide The mduction of peptide-specific CTLs and the ability of the peptides to stimulate CTLs that recognize endogenously expressed p53 was observed (Table XXVII) Evaluation of A *03/A 11 immunogenicity HLA-A3 supermotif-beanng cross-reactive bmding peptides are also evaluated for immunogenicity using methodology analogous for that used to evaluate the immunogenicity of the HLA- A2 supermotif peptides Usmg this procedure, peptides that mduce an immune response are identified Examples of such peptides are shown in Table XXIII Evaluation of immunogenicity ofMotif/Supeimotif-Beanng Peptides Analogous methodology, as appreciated by one of ordinary skill m the art, is employed to determine immunogenicity of peptides bearing HLA class I motifs and/or supermotifs set out herem Usmg such a prodcedure peptides that induce an immune response are identified Example 4 Implementation of the Extended Supermotif to Improve the Binding Capacity of Native Epitopes by Creating Analogs HLA motifs and supermotifs (comprising primary and/or secondary residues) are useful in the identification and preparation of highly cross-reactive native peptides, as demonstrated herem Moreover, the definition of HLA motifs and supermotifs also allows one to engmeer highly cross-reactive epitopes by identifying residues within a native peptide sequence which can be analogued, or "fixed" to confer upon the peptide certain characteristics, e g greater cross-reactivity withm the group of HLA molecules that comprise a supertype, and/or greater bmding affinity for some or all of those HLA molecules Examples of analog peptides that exhibit modulated bmdmg affinity are set forth in this example and provided m Tables XXII through XXVII Analoguing at Primary Anchor Residues Peptide engineering strategies were implemented to further increase the cross-reactivity of the epitopes identified above On the basis of the data disclosed, e g , m related and co-pendmg U S S N 09/226,775, the mam anchors of A2-supermotιf-beaπng peptides are altered, for example, to introduce a prefened L, I, V, or M at position 2, and I or V at the C-termmus Peptides that exhibit at least weak A*0201 bmdmg (IC S0 of 5000 nM or less), and carrying suboptimal anchor residues at either position 2, the C-termmal position, or both, can be fixed by introducing canonical substitutions (L at position 2 and V at the C-termmus) Those analogued peptides that show at least a three- fold increase m A*0201 bmding and bmd with an IC 50 of 500 nM, or less were then tested for A2 cross-reactive bindmg along with their wild-type (WT) counterparts Analogued peptides that bind at least three of the five A2 supertype alleles were then selected for cellular screening analysis Additionally, the selection of analogs for cellular screenmg analysis was further restncted by the capacity of the WT parent peptide to bmd at least weakly, ; e , bmd at an IC 50 of 5000nM or less, to three of more A2 supertype alleles The rationale for this requirement is that the WT peptides must be present endogenously in sufficient quantity to be biologically relevant Analogued peptides have been shown to have mcreased immunogenicity and cross-reactivity by T cells specific for the WT epitope (see, e g , Parkhurst et al , J Immunol 157 2539, 1996, and Pogue et al , Proc Natl Acad Set USA 92 8166, 1995) In the cellular screening of these peptide analogs, it is important to demonstrate that analog- specific CTLs are also able to recognize the wild-type peptide and, when possible, tumor targets that endogenously express the epitope Nineteen p53 peptides met the criteria for analogumg at pnmary anchor residues by introducing a canonical substitution these peptides showed at least weak A*0201 bmdmg (IC 50 of 5000 nM or less) and earned suboptimal anchor residues These peptides were analogued and tested for bmdmg to A*0201 (Table XXII) Eighteen of the analog peptides representing 12 epitopes were tested then for cross-reactive binding Eleven of these analogs exhibited improved crossbmdmg capability (Table XXVII) The 11 analog peptides were additionally evaluated for in vitro immunogenicity using cellular screening In the case of p53, it is important to demonstrate mduction of peptide-specific CTL and to then use those cells to identify an endogenous tumor target Each assay also mcluded the epitope HBVc 18 as an internal control When peptide p53 139L2 was used to mduce CTLs m a normal donor, measurable CTL activity was observed in 3 of 48 wells Each well was expanded and two weeks later, reassayed agamst the mduction peptide and the appropnate wildtype peptide The p53 139L2-specιfic CTLs mamtamed their lytic activity Additionally, two of these cultures recognized the parental, wildtype peptide These cells were then used to assess endogenous target cell lmes Numerous HLA-A2 + , p53- expressmg tumor lines have been described (see, e g , Theobald et al , Proc Natl Acad Sci USA, 92 11993, 1995) and were readily available These included BT549, a breast infiltrating ductal carcinoma lme, and Saos-2/175, a transfected cell lme Saos-2, an osteogemc sarcoma that is HLA-A2 + and p53 , was used as the negative control cell line The results ofthe analysis showed that two mdividual CTL cultures to peptide p53 139L2 demonstrated significant lysis ofthe endogenous target BT549 Of the available analogs tested, ten mduced a peptide-specific response m 2 or more donors Of these 10, 8 generated CTLs that recognized the wild-type peptide and 4 of these recognized tumor targets (Table XXVII) Two of these analogs, p53 139L2 and p53 139L2B3, differed only at position three The assay results indicated that the CTLs to p53 139L2B3 recognized the target cells pulsed with wild-type peptide as well as the analog, and also recognized the tumor target cell lme BT549 Another analog peptide, p53 149M2, also demonstrated significant improvement over the wildtype peptide Six individual wells met the cntena for a positive response and the cells cultured in one of the wells mamtamed that activity upon expansion of the population All the CTLs generated recognized the wildtype peptide and were also able to lyse the Saos-2/175 transfected cell lme, which expresses p53 A fourth epitope, p53 69L2V8, also demonstrated recognition ofthe wildtype peptide Using methodology similar to that used to develop HLA-A2 analogs, analogs of HLA-A3 and HLA-B7 supermotif-beanng epitopes are also generated For example, peptides bmdmg at least weakly to 3/5 of the A3-supertype molecules can be engmeered at primary anchor residues to possess a prefened residue (V, S, M, or A) at position 2 The analog peptides are then tested for the ability to bmd A*03 and A*l 1 (prototype A3 supertype alleles) Those peptides that demonstrate < 500 nM binding capacity are then tested for A3-supertype cross-reactivity Examples of HLA- A3 supermotif analog peptides are provided in Table XXIII B7 supermotif-beanng peptides can, for example, be engmeered to possess a prefened residue (V, I, L, or F) at the C-termmal primary anchor position (see, e g Sidney et al (J Immunol 157 3480-3490, 1996) Analoged peptides are then tested for cross-reactive bmdmg to B7 supertype alleles Examples of B7-supermotιf-beaπng analog peptides are provided in Table XXIV Similarly, HLA-Al and HLA-A24 motif-beaπng peptides can be engineered at primary anchor residues to improvde binding to the allele-specific HLA molecule or to improve cross-reactive bindmg Examples of analoged HLA-Al and HLA-A24 motif-bearing peptides are provided in Tables XXV and XXVI Analoged peptides that exhibit improved bmding and/or or cross-reactivity are evaluated for immunogenicity using methodology similar to that described for the analysis of HLA-A2 supermotif- beanng peptides Usmg such a procedure, peptides that induce an immune response are identified, e g Table XXIII Analoguing at Secondary Anchor Residues Moreover, HLA supermotifs are of value m engineermg highly cross-reactive peptides and/or peptides that bmd HLA molecules with mcreased affinity by identifying particular residues at secondary anchor positions that are associated with such properties For example, the bindmg capacity of a B7 supermotif-beanng peptide representing a discreet single ammo acid substitution at position 1 can be analyzed A peptide can, for example, be analogued to substitute L with F at position 1 and subsequently be evaluated for mcreased binding affinity/ and or increased cross-reactivity This procedure identifies analogued peptides with modulated bmdmg affinity Engineered analogs with sufficiently unproved bmdmg capacity or cross-reactivity are tested for immunogenicity as above Other analoguing strategies Another form of peptide analoguing, unrelated to the anchor positions, mvolves the substitution of a cysteine with α-ammo butyric acid (e , Tables XXIII, XXVII) Due to its chemical nature, cysteme has the propensity to form disulfide bridges and sufficiently alter the peptide structurally so as to reduce bmdmg capacity Subtitution of α-amino butync acid for cysteme not only alleviates this problem, but has been shown to improve binding and crossbmdmg capabilities m some instances (see, e , the review by Sette et al , In Persistent Viral Infections. Eds R Ahmed and I Chen, John Wiley & Sons, England, 1999) Analoged peptides that exhibit improved bmdmg and/or or cross-reactivity are evaluated for immunogenicity using methodology similar to that descnbed for the analysis of HLA-A2 supermotif- beanng peptides Using such a procedure, peptides that mduce an immune response are identified This Example therefore demonstrates that by the use of even smgle ammo acid substitutions, the binding affinity and/or cross-reactivity of peptide ligands for HLA supertype molecules is modulated Example 5 Identification of peptide epitope sequences with HLA-DR binding motifs Peptide epitopes bearmg an HLA class II supermotif or motif may also be identified as outlined below using methodology similar to that descnbed m Examples 1-3 Selection of HLA-DR-supermotif-beanng epitopes To identify HLA class II HTL epitopes, the p53 protem sequence was analyzed for the presence of sequences bearing an HLA-DR-motif or supermotif Specifically, 15-mer sequences were selected comprising a DR-supermotif, further comprising a 9-mer core, and three-residue N- and C-terminal flanking regions (15 amino acids total) Protocols for predicting peptide binding to DR molecules have been developed (Southwood et al , J Immunol 160 3363-3373, 1998) These protocols, specific for mdividual DR molecules, allow the scoring, and ranking, of 9-mer core regions Each protocol not only scores peptide sequences for the presence of DR- supermotif pnmary anchors (I e , at position 1 and position 6) withm a 9-mer core, but additionally evaluates sequences for the presence of secondary anchors Usmg allele specific selection tables (see, e g , Southwood et al , ibid ), it has been found that these protocols efficiently select peptide sequences with a high probability of bmdmg a particular DR molecule Additionally, it has been found that performing these protocols in tandem, specifically those for DR1, DR4w4, and DR7, can efficiently select DR cross-reactive peptides The p53-denved peptides identified above were tested for then bindmg capacity for vanous common HLA-DR molecules All peptides were initially tested for bmdmg to the DR molecules m the pnmary panel DR1, DR4w4, and DR7 Peptides bmdmg at least 2 of these 3 DR molecules with an IC S0 value of 1000 nM or less, were then tested for bmdmg to DR5*0101, DRB1*1501, DRB1 *1101, DRB 1 *0802, and DRB 1* 1302 Peptides were considered to be cross-reactive DR supertype bmders if they _ bound at an IC 50 value of 1000 nM or less to at least 5 of the 8 alleles tested Following the strategy outlmed above, 50 DR supermotif-beanng sequences were identified withm the p53 protem sequence Of those, 6 scored positive in 2 of the 3 combined DR 147 algorithms These peptides were synthesized and tested for bmdmg to HLA-DRB 1*0101, DRB1*0401, DRB1*0701 with 3, 2, and 2 peptides bindmg <1000 nM, respectively Of the 6 peptides tested for bmdmg to these primary HLA molecules, 2 bound at least 2 of the 3 alleles (Table XXVII) These 2 peptides were then tested for bindmg to secondary DR supertype alleles DRB5*0101, DRB1*1501, DRB1* 1101, DRB1*0802, and DRBl*1302 Both peptides bound at least 5 of the 8 alleles tested, of which 8 occuned m distinct, non-overlappmg regions (Table XXIX) Selection ofDR3 motif peptides Because HLA-DR3 is an allele that is prevalent m Caucasian, Black, and Hispanic populations, DR3 binding capacity is an important cπtenon m the selection of HTL epitopes However, data generated previously mdicated that DR3 only rarely cross-reacts with other DR alleles (Sidney et al , J Immunol 149 2634-2640, 1992, Geluk et al , J Immunol 152 5742-5748, 1994, Southwood et al , J Immunol 160 3363-3373, 1998) This is not entirely surprising m that the DR3 peptide-bmdmg motif appears to be distinct from the specificity of most other DR alleles For maximum efficiency m developing vaccme candidates it would be desirable for DR3 motifs to be clustered m proximity with DR supermotif regions Thus, peptides shown to be candidates may also be assayed for their DR3 bmdmg capacity However, m view of the distmct bmdmg specificity of the DR3 motif, peptides bmdmg only to DR3 can also be considered as candidates for inclusion m a vaccme formulation To efficiently identify peptides that bind DR3, the p53 protein sequence was analyzed for conserved sequences carrying one of the two DR3 specific bmdmg motifs (Table III) reported by Geluk et al (J Immunol 152 5742-5748, 1994) Sixteen motif-positive peptides were identified. The conespondmg peptides were then synthesized and tested for the ability to bind DR3 with an affinity of <1000 nM No peptides were identified that met this bindmg cnteπon (Table XXX), and thereby qualify as HLA class II high affinity bmders In summary, 2 DR supertype cross-reactive binding peptides were identified from the p53 protein sequence (Table XXXI). Similarly to the case of HLA class I motif-bearing peptides, the class II motif-bearing peptides may be analogued to improve affinity or cross-reactivity For example, aspartic acid at position 4 of the 9- mer core sequence is an optimal residue for DR3 bmding, and substitution for that residue can improve DR 3 bmdmg Example 6 Immunogenicity of HTL epitopes This example determines lmmunogenic DR supermotif- and DR3 motif-bearmg epitopes among those identified usmg the methodology in Example 5 Immunogenicity of HTL epitopes are evaluated in a manner analogous to the determination of immunogenicity of CTL epitopes by assessing the ability to stimulate HTL responses and or by using appropriate transgenic mouse models Immunogenicity is determined by screenmg for. I ) in vitro pnmary mduction usmg normal PBMC or 2 ) recall responses from . cancer patient PBMCs Such a procedure identifies epitopes that mduce an HTL response. Example 7 Calculation of phenotvpic frequencies of HLA-supertvpes in vaπous ethnic backgrounds to determine breadth of population coverage This example illustrates the assessment of the breadth of population coverage of a vaccine composition comprised of multiple epitopes compnsmg multiple supermotifs and/or motifs In order to analyze population coverage, gene frequencies of HLA alleles were determined Gene frequencies for each HLA allele were calculated from antigen or allele frequencies utilizing the binomial distribution formulae gf=l-(SQRT(l-af)) (see, e g , Sidney et al , Human Immunol 45.79-93, 1996) To obtain overall phenotypic frequencies, cumulative gene frequencies were calculated, and the cumulative antigen frequencies derived by the use of the mverse formula [af=l-(l-Cgf) 2 J Where frequency data was not available at the level of DNA typing, conespondence to the serologically defined antigen frequencies was assumed To obtam total potential supertype population coverage no linkage disequihbnum was assumed, and only alleles confirmed to belong to each of the supertypes were mcluded (minimal estimates) Estimates of total potential coverage achieved by mter-loci combinations were made by adding to the A coverage the proportion of the non-A covered population that could be expected to be covered by the B alleles considered (e g , total=A+B*(l-A)). Confirmed members ofthe A3-lιke supertype are A3, Al 1, A31, A*3301, and A*6801 Although the A3-lιke supertype may also mclude A34, A66, and A*7401, these alleles were not mcluded m overall frequency calculations. Likewise, confirmed members ofthe A2-hke supertype family are A*0201, A*0202, A*0203, A*0204, A*0205, A*0206, A*0207, A*6802, and A*6901 Finally, the B7-lιke supertype-confirmed alleles are: B7, B*3501-03, B51, B*5301, B*5401, B*5501-2, B*5601, B*6701, and B*7801 (potentially also B*1401, B*3504-06, B*4201, and B*5602) Population coverage achieved by combinmg the A2-, A3- and B7-supertypes is approximately 86% in five major ethnic groups (see Table XXI) Coverage may be extended by including peptides beanng the Al and A24 motifs On average, Al is present in 12% and A24 m 29% ofthe population across five different major ethnic groups (Caucasian, North American Black, Chmese, Japanese, and Hispanic) Together, these alleles are represented with an average frequency of 39% in these same ethnic populations The total coverage across the major ethnicities when Al and A24 are combmed with the coverage of the A2-, A3- and B7-supertype alleles is >95% An analogous approach can be used to estimate population coverage achieved with combinations of class II motif-bearmg epitopes Example 8 Recognition Of Generation Of Endogenous Processed Antigens After Priming This example determines that CTL mduced by native or analogued peptide epitopes identified and selected as described m Examples 1-6 recognize endogenously synthesized, t e , native antigens, using a transgenic mouse model Effector cells isolated from transgenic mice that are immunized with peptide epitopes (as described, e g , in Wentworth et al , Mol Immunol 32 603, 1995), for example HLA-A2 supermotif- beanng epitopes, are re-stimulated in vitro usmg peptide-coated stimulator cells Six days later, effector cells are assayed for cytotoxicity and the cell lmes that contam peptide-specific cytotoxic activity are further. re-stimulated An additional six days later, these cell lmes are tested for cytotoxic activity on 51 Cr labeled Jurkat-A2 1/K b target cells m the absence or presence of peptide, and also tested on Cr labeled target cells bearmg the endogenously synthesized antigen, i e cells that are stably transfected with TAA expression vectors The result will demonstrate that CTL lmes obtamed from animals pruned with peptide epitope recognize endogenously synthesized antigen The choice of transgenic mouse model to be used for such an analysis depends upon the epιtope(s) that is bemg evaluated In addition to HLA-A*0201/K b transgenic mice, several other transgenic mouse models mcluding mice with human Al l, which may also be used to evaluate A3 epitopes, and B7 alleles have been charactenzed and others (e g , transgenic mice for HLA-Al and A24) are bemg developed HLA-DR1 and HLA-DR3 mouse models have also been developed, which may be used to evaluate HTL epitopes Example 9 Activity Of CTL-HTL Coniugated Epitopes In Transgenic Mice This example illustrates the mduction of CTLs and HTLs m transgenic mice by use of a tumor associated antigen CTL/HTL peptide conjugate whereby the vaccme composition compnses peptides to be administered to a cancer patient The peptide composition can compnse multiple CTL and/or HTL epitopes and further, can compnse epitopes selected from multiple-tumor associated antigens The epitopes are identified usmg methodology as described in Examples 1-6 This analysis demonstrates the enhanced immunogenicity that can be achieved by inclusion of one or more HTL epitopes m a vaccme composition Such a peptide composition can compnse an HTL epitope conjugated to a prefened CTL epitope contammg, for example, at least one CTL epitope selected from Tables XXVII and XXIII-XXVI, or other analogs of that epitope The HTL epitope is, for example, selected from Table XXXI The peptides may be pidated, if desired Immunization procedures Immunization of transgenic mice is performed as described (Alexander et al , J Immunol 159 4753-4761, 1997) For example, A2/K b mice, which are transgenic for the human HLA A2 1 allele and are useful for the assessment ofthe immunogemcity of HLA-A*0201 motif- or HLA- A2 supermotif-beanng epitopes, are primed subcutaneously (base of the tail) with 0 1 ml of peptide conjugate formulated m saline, or DMSO/salme Seven days after pruning, splenocytes obtained from these animals are restimulated with syngemc irradiated LPS-activated lymphoblasts coated with peptide The target cells for peptide-specific cytotoxicity assays are Jurkat cells transfected with the HLA- A2 1/K b chιmeπc gene (eg , Vitiello et al, J Exp Med 173 1007, 1991) In vitro CTL activation One week after priming, spleen cells (30xl0 6 cells/flask) are co-cultured at 37°C with syngeneic, inadiated (3000 rads), peptide coated lymphoblasts (lOxlO 6 cells/flask) m 10 ml of culture medιum/T25 flask After six days, effector cells are harvested and assayed for cytotoxic activity Assay for cytotoxic activity Target cells (1 0 to 1 5xl0 6 ) are mcubated at 37°C m the presence of 200 μl of 5l Cr After 60 minutes, cells are washed three times and resuspended m medium Peptide is added where required at a concentration of 1 μg/ml For the assay, 10 4 sl Cr-labeled target cells are added to different concentrations of effector cells (final volume of 200 μl) m U-bottom 96-well plates After a 6 hour mcubation period at 37°C, a 0 1 ml aliquot of supernatant is removed from each well and radioactivity is determmed in a Micromedic automatic gamma counter The percent specific lysis is determmed by the formula percent specific release = 100 x (experimental release - spontaneous release)/(maxιmum release - spontaneous release) To facilitate companson between separate CTL assays run under the same conditions, % 5 l Cr release data is expressed as lytic units/10 6 cells One lytic unit is arbitrarily defined as the number of effector cells required to achieve 30% lysis of 10,000 target cells m a 6 hour 5 l Cr release assay To obtain specific lytic units/10 6 , the lytic units/10 6 obtamed m the absence of peptide is subtracted from the lytic units/ 10 6 obtained m the presence of peptide For example, if 30% Cr release is obtained at the effector (E) target (T) ratio of 50 1 (l e , 5xl0 5 effector cells for 10,000 targets) in the absence of peptide and 5 1 (I e , 5xl0 4 effector cells for 10,000 targets) m the presence of peptide, the specific lytic umts would be [(l/50,000)-(l/500,000)] x 10 6 = 18 LU The results are analyzed to assess the magnitude of the CTL responses of animals mjected with the immunogemc CTL/HTL conjugate vaccme preparation The frequency and magnitude of response can also be compared to the CTL response achieved usmg the CTL epitopes by themselves Analyses similar to this may be performed to evaluate the immunogenicity of peptide conjugates contammg multiple CTL epitopes and/or multiple HTL epitopes In accordance with these procedures it is found that a CTL response is induced, and concomitantly that an HTL response is mduced upon admmistration of such compositions Example 10 Selection of CTL and HTL epitopes for inclusion m a cancer vaccme This example illustrates the procedure for the selection of peptide epitopes for vaccme compositions of the mvention The peptides in the composition can be m the form of a nucleic acid sequence, either smgle or one or more sequences (l e , mmigene) that encodes peptιde(s), or may be smgle and/or polyepitopic peptides The following principles are utilized when selecting an anay of epitopes for inclusion in a vaccme composition Each of the following principles is balanced in order to make the selection Epitopes are selected which, upon admmistration, mimic immune responses that have been observed to be conelated with tumor clearance For example, a vaccme can include 3-4 epitopes that come from at least one TAA Epitopes from one TAA can be used m combmation with epitopes from one or more additional TAAs to produce a vaccine that targets tumors with varying expression patterns of frequently-expressed TAAs as described, e g , in Example 15 Epitopes are preferably selected that have a binding affinity (IC50) of 500 nM or less, often 200 nM or less, for an HLA class I molecule, or for a class II molecule, 1000 nM or less Sufficient supermotif bearmg peptides, or a sufficient anay of allele-specific motif beanng peptides, are selected to give broad population coverage For example, epitopes are selected to provide at least 80% population coverage A Monte Carlo analysis, a statistical evaluation known m the art, can be employed to assess breadth, or redundancy, of population coverage When selectmg epitopes from cancer-related antigens it is often prefened to select analogs because the patient may have developed tolerance to the native epitope When creating a polyepitopic composition, e g a mmigene, it is typically desirable to generate the smallest peptide possible that encompasses the epitopes of mterest, although spacers or other flanking sequences can also be incorporated The principles employed are often similar as those employed when selecting a peptide compnsmg nested epitopes Additionally, however, upon determination ofthe nucleic . acid sequence to be provided as a mmigene, the peptide sequence encoded thereby is analyzed to determme whether any "junctional epitopes" have been created A junctional epitope is a potential HLA bmdmg epitope, as predicted, e , by motif analysis Junctional epitopes are generally to be avoided because the recipient may bmd to an HLA molecule and generate an immune response to that epitope, which is not present m a native protein sequence CTL epitopes for inclusion in vaccme compositions are, for example, selected from those listed m Tables XXVII and XXIII-XXVI Examples of HTL epitopes that can be mcluded in vaccme compositions are provided m Table XXXI A vaccine composition compπsed of selected peptides, when admmistered, is safe, efficacious, and elicits an immune response that results m tumor cell killing and reduction of tumor Example 11 Construction of Mmigene Multi-Epitope DNA Plasmids This example provides general guidance for the construction of a mmigene expression plasmid Minigene plasmids may, of course, contam various configurations of CTL and/or HTL epitopes or epitope analogs as descnbed herem Expression plasmids have been constructed and evaluated as described, for example, in co-pendmg U S S N 09/311,784 filed 5/13/99 A minigene expression plasmid may mclude multiple CTL and HTL peptide epitopes In the present example, HLA-A2, -A3, -B7 supermotif-beanng peptide epitopes and HLA-Al and -A24 motif- bearmg peptide epitopes are used m conjunction with DR supermotif-beanng epitopes and/or DR3 epitopes Prefened epitopes are identified, for example, m Tables XXVII, XXIII-XXVI, and XXXI HLA class I supermotif or motif-bearing peptide epitopes denved from multiple TAAs are selected such that multiple supermotifs/motifs are represented to ensure broad population coverage Similarly, HLA class II epitopes are selected from multiple tumor antigens to provide broad population coverage, i e both HLA DR-1-4-7 supermotif-beanng epitopes and HLA DR-3 motif-beaπng epitopes are selected for inclusion in the mmigene construct The selected CTL and HTL epitopes are then incorporated into a minigene for expression m an expression vector This example illustrates the methods to be used for construction of such a minigene-beaπng expression plasmid Other expression vectors that may be used for minigene compositions are available and known to those of skill m the art The mmigene DNA plasmid contains a consensus Kozak sequence and a consensus murme kappa Ig-light cham signal sequence followed by CTL and/or HTL epitopes selected in accordance with pπnciples disclosed herein The sequence encodes an open readmg frame fused to the Myc and His antibody epitope tag coded for by the pcDNA 3 1 Myc-His vector Overlapping oligonucleotides, for example eight oligonucleotides, averaging approximately 70 nucleotides in length with 15 nucleotide overlaps, are synthesized and HPLC-puπfied The oligonucleotides encode the selected peptide epitopes as well as appropriate linker nucleotides, Kozak sequence, and signal sequence The final multiepitope minigene is assembled by extendmg the overlapping oligonucleotides in three sets of reactions using PCR A Perkin/Elmer 9600 PCR machine is used and a total of 30 cycles are performed usmg the followmg conditions 95°C for 15 sec, annealing temperature (5° below the lowest calculated Tm of each primer pair) for 30 sec, and 72°C for 1 mm For the first PCR reaction, 5 μg of each of two oligonucleotides are annealed and extended Oligonucleotides 1+2, 3+4, 5+6, and 7+8 are combined m 100 μl reactions containing Pfu polymerase buffer (lx= 10 mM KCL, 10 mM (NH 4 ) 2 S0 4 , 20 mM Tns-chlonde, pH 8 75, 2 mM MgS0 4 , 0 1% Tnton X-100, 100 μg/ml BSA), 0 25 mM each dNTP, and 2 5 U of Pfu polymerase The full-length dimer products are gel-purified, and two reactions contammg the product of 1+2 and 3+4, and the product of 5+6 and 7+8 are mixed, annealed, and extended for 10 cycles Half of the two reactions are then mixed, and 5 cycles of annealing and extension earned out before flanking pnmers are added to amplify the full length product for 25 additional cycles The full-length product is gel-punfied and cloned mto pCR-blunt (Invitrogen) and mdividual clones are screened by sequencmg Example 12 The plasmid construct and the degree to which it induces immunogemcity The degree to which the plasmid construct prepared usmg the methodology outlined m Example 11 is able to induce unmunogemcity is evaluated through in vivo injections into mice and subsequent in vitro assessment of CTL and HTL activity, which are analysed usmg cytotoxicity and proliferation assays, respectively, as detailed e g , m U S S N 09/311 ,784 filed 5/ 13/99 and Alexander et al , Immunity 1 751- 761, 1994 Alternatively, plasmid constructs can be evaluated in vitro by testmg for epitope presentation by APC following transduction or transfection of the APC with an epitope-expressmg nucleic acid construct Such a study determines "antigenicity" and allows the use of human APC The assay determines the ability of the epitope to be presented by the APC m a context that is recognized by a T cell by quantifying the density of epitope-HLA class I complexes on the cell surface Quantitation can be performed by directly measuring the amount of peptide eluted from the APC (see, e g , Sijts et al , J Immunol 156 683-692, 1996, Demotz et al , Nature 342 682-684, 1989), or the number of peptide-HLA class I complexes can be estimated by measuring the amount of lysis or lymphokme release mduced by mfected or transfected target cells, and then determining the concentration of peptide necessary to obtamed equivalent levels of lysis or lymphokme release (see, eg , Kageyama et al , J Immunol 154 567-576, 1995) To assess the capacity of the minigene construct (e g , a pMin minigene construct generated as decπbed in U S S N 09/311,784) to induce CTLs in vivo, HLA-Al 1/K b transgenic mice, for example, are immunized intramuscularly with 100 μg of naked cDNA As a means of comparing the level of CTLs mduced by cDNA immunization, a control group of animals is also immunized with an actual peptide composition that comprises multiple epitopes synthesized as a single polypeptide as they would be encoded by the mmigene Splenocytes from immunized animals are stimulated twice with each of the respective compositions (peptide epitopes encoded m the minigene or the polyepitopic peptide), then assayed for peptide-specific cytotoxic activity in a 51 Cr release assay The results mdicate the magnitude of the CTL response directed against the A3-restπcted epitope, thus mdicatmg the in vivo immunogenicity ofthe minigene vaccme and polyepitopic vaccme It is, therefore, found that the minigene elicits immune responses directed toward the HLA-A3 supermotif peptide epitopes as does the polyepitopic peptide vaccine A similar analysis is also performed using other HLA-A2 and HLA-B7 transgenic mouse models to assess CTL induction by HLA-A2 and HLA-B7 motif or supermonf epitopes To assess the capacity of a class II epitope encodmg mmigene to induce HTLs in vivo, I-A b restricted mice, for example, are immunized intramuscularly with 100 μg of plasmid DNA As a means of comparing the level of HTLs mduced by DNA immunization, a group of control animals is also immunized with an actual peptide composition emulsified m complete Freund's adjuvant CD4+ T cells, ; e HTLs, are purified from splenocytes of immunized animals and stimulated with each of the respective compositions (peptides encoded m the mmigene) The HTL response is measured usmg a 3 H-thymιdιne mcorporation proliferation assay, (see, e g , Alexander et al Immunity 1 751-761, 1994) The results mdicate the magnitude of the HTL response, thus demonstrating the in vivo immunogenicity ofthe mmigene DNA mimgenes, constructed as described m Example 11 , may also be evaluated as a vaccme m combmation with a boostmg agent using a prune boost protocol The boostmg agent may consist of recombinant protein (e g , Barnett et al , Aids Res and Human Retroviruses 14, Supplement 3 S299-S309, 1998) or recombinant vaccmia, for example, expressmg a mmigene or DNA encodmg the complete protein of interest (see, e g , Hanke et al , Vaccine 16 439-445, 1998, Sedegah et al , Proc Natl Acad Sci USA 95 7648-53, 1998, Hanke and McMichael, Immunol Letters 66 177-181, 1999, and Robmson et al , Nature Med 5 526-34, 1999) For example, the efficacy of the DNA mmigene may be evaluated m transgenic mice In this example, A2 1/K b transgenic mice are immunized IM with 100 μg ofthe DNA mmigene encoding the lmmunogenic peptides After an incubation peπod (rangmg from 3-9 weeks), the mice are boosted IP with 10 7 pfu/mouse of a recombmant vaccmia virus expressmg the same sequence encoded by the DNA mmigene Control mice are immunized with 100 μg of DNA or recombmant vaccmia without the mmigene sequence, or with DNA encoding the mmigene, but without the vaccmia boost After an additional incubation period of two weeks, splenocytes from the mice are immediately assayed for peptide-specific activity in an ELISPOT assay Additionally, splenocytes are stimulated in vitro with the A2 -restricted peptide epitopes encoded in the minigene and recombmant vaccmia, then assayed for peptide-specific activity in an IFN-γ ELISA It is found that the minigene utilized in a prime-boost mode elicits greater immune responses toward the HLA-A2 supermotif peptides than with DNA alone Such an analysis is also performed using other HLA-A 11 and HLA-B7 transgenic mouse models to assess CTL induction by HLA- A3 and HLA-B7 motif or supermotif epitopes Example 13 Peptide Composition for Prophylactic Uses Vaccme compositions of the present invention are used to prevent cancer in persons who are at risk for developmg a tumor For example, a polyepitopic peptide epitope composition (or a nucleic acid compnsmg the same) contammg multiple CTL and HTL epitopes such as those selected in Examples 9 and/or 10, which are also selected to target greater than 80% of the population, is administered to an individual at nsk for a cancer, e g , breast cancer The composition is provided as a single polypeptide that encompasses multiple epitopes The vaccme is admmistered m an aqueous earner comprised of Freunds Incomplete Adjuvant The dose of peptide for the initial immunization is from about 1 to about 50,000 μg, generally 100-5,000 μg, for a 70 kg patient The initial admmistration of vaccme is followed by booster dosages at 4 weeks followed by evaluation of the magnitude of the immune response in the patient, by techniques that determme the presence of epitope-specific CTL populations m a PBMC sample Additional booster doses are admmistered as required The composition is found to be both safe and efficacious as a prophylaxis against cancer Alternatively, the polyepitopic peptide composition can be admmistered as a nucleic acid m accordance with methodologies known m the art and disclosed herem Example 14 Polyepitopic Vaccine Compositions Derived from Native TAA Sequences A native TAA polyprotein sequence is screened, preferably usmg computer algonthms defined for each class I and/or class II supermotif or motif, to identify "relatively short" regions of the polyprotein that compnse multiple epitopes and is preferably less in length than an entire native antigen This relatively short sequence that contains multiple distinct, even overlappmg, epitopes is selected and used to generate a mmigene construct The construct is engmeered to express the peptide, which conesponds to the native protem sequence The "relatively short" peptide is generally less than 1,000, 500, 250 ammo acids in length, often less than 100 ammo acids in length, preferably less than 75 amino acids in length, and more preferably less than 50 amino acids in length The protein sequence ofthe vaccme composition is selected because it has a maximal number of epitopes contained within the sequence, i e , it has a high concentration of epitopes As noted herein, epitope motifs may be nested or overlappmg (i e , frame shifted relative to one another) For example, with frame shifted overlappmg epitopes, two 9-mer epitopes and one 10-mer epitope can be present m a 10 ammo acid peptide Such a vaccme composition is administered for therapeutic or prophylactic purposes The vaccme composition will preferably mclude, for example, three CTL epitopes and at least one HTL epitope from TAAs This polyepitopic native sequence is admmistered either as a peptide or as a nucleic acid sequence which encodes the peptide Alternatively, an analog can be made of this native sequence, whereby one or more of the epitopes comprise substitutions that alter the cross-reactivity and/or binding affinity properties of the polyepitopic peptide The embodiment of this example provides for the possibility that an as yet undiscovered aspect of immune system processing will apply to the native nested sequence and thereby facilitate the production of therapeutic or prophylactic immune response-inducing vaccme compositions Additionally such an embodiment provides for the possibility of motif-bearing epitopes for an HLA makeup that is presently unknown Furthermore, this embodiment (absent analogs) directs the immune response to multiple peptide sequences that are actually present in native TAAs thus avoidmg the need to evaluate any j unctional epitopes Lastly, the embodiment provides an economy of scale when producmg nucleic acid vaccme compositions Related to this embodiment, computer programs can be denved m accordance with principles in the art, which identify in a target sequence, the greatest number of epitopes per sequence length Example 15 Polyepitopic Vaccme Compositions Directed To Multiple Tumors The p53 peptide epitopes of the present mvention are used m conjunction with peptide epitopes from other target tumor antigens to create a vaccme composition that is useful for the treatment of vanous types of tumors For example, a set of TAA epitopes can be selected that allows the targeting of most common epithelial tumors (see, e g , Kawashima et al , Hum Immunol 59 1-14, 1998) Such a composition can additionally mclude epitopes from CEA, HER-2/neu, and MAGE2/3, all of which are expressed to appreciable degrees (20-60%) in frequently found tumors such as lung, breast, and gastrointestinal tumors The composition can be provided as a smgle polypeptide that incorporates the multiple epitopes from the vanous TAAs, or can be admmistered as a composition compnsmg one or more discrete epitopes Alternatively, the vaccme can be administered as a mmigene construct or as dendritic cells which have been loaded with the peptide epitopes in vitro Targetmg multiple tumor antigens is also important to provide coverage of a large fraction of tumors of any particular type A single TAA is rarely expressed m the majority of tumors of a given type For example, approximately 50% of breast tumors express CEA, 20% express MAGE3, and 30% express HER-2/neu Thus, the use of a single antigen for immunotherapy would offer only limited patient coverage The combmation ofthe three TAAs, however, would address approximately 70% of breast tumors A vaccme composition compnsmg epitopes from multiple tumor antigens also reduces the potential for escape mutants due to loss of expression of an mdividual tumor antigen Example 16 Use of peptides to evaluate an immune response Peptides of the mvention may be used to analyze an immune response for the presence of specific CTL or HTL populations directed to a TAA Such an analysis may be performed usmg multimeπc complexes as described, e g , by Ogg et al Science 279 2103-2106, 1998 and Greten et al , Proc Natl Acad Sci USA 95 7568-7573, 1998 In the followmg example, peptides m accordance with the mvention are used as a reagent for diagnostic or prognostic purposes, not as an immunogen In this example, highly sensitive human leukocyte antigen tetramenc complexes ("tetramers") are used for a cross-sectional analysis of, for example, tumor-associated antigen HLA-A*0201-specιfic CTL frequencies from HLA A*0201-posιtιve individuals at different stages of disease or following immunization using a TAA peptide contammg an A*0201 motif Tetramenc complexes are synthesized as described (Musey et al , N Engl J Med 337 1267, 1997) Bnefly, punfied HLA heavy chain (A*0201 m this example) and β2-mιcroglobuhn are synthesized by means of a prokaryotic expression system The heavy chain is modified by deletion of the transmembrane-cytosohc tail and COOH-terminal addition of a sequence contammg a BirA enzymatic btotinylation site The heavy cham, β2-mιcroglobulm, and peptide are refolded by dilution The 45-kD refolded product is isolated by fast protem liquid chromatography and then biotinylated by BirA m the presence of biotm (Sigma, St Louis, Missouri), adenosme 5 'tnphosphate and magnesium Streptavidin-phycoerythnn conjugate is added m a 1 4 molar ratio, and the tetramenc product is concentrated to 1 mg/ml The resulting product is refened to as tetramer-phycoerythrm For the analysis of patient blood samples, approximately one million PBMCs are centrifuged at 300g for 5 minutes and resuspended m 50 μl of cold phosphate-buffered saline Tπ-color analysis is performed with the tetramer-phycoerythnn, along with antι-CD8-Tπcolor, and antι-CD38 The PBMCs are mcubated with tetramer and antibodies on ice for 30 to 60 mm and then washed twice before formaldehyde fixation Gates are applied to contam >99 98% of control samples Controls for the tetramers mclude both A*0201-negatιve individuals and A*0201-posιtιve umnfected donors The percentage of cells stamed with the tetramer is then determined by flow cytometry The results mdicate the number of cells m the PBMC - sample that contain epitope-restπcted CTLs, thereby readily indicating the extent of immune response to the TAA epitope, and thus the stage of tumor progression or exposure to a vaccme that elicits a protective or therapeutic response Example 17 Use of Peptide Epitopes to Evaluate Recall Responses The peptide epitopes ofthe mvention are used as reagents to evaluate T cell responses, such as acute or recall responses, in patients Such an analysis may be performed on patients who are m remission, have a tumor, or who have been vaccmated with a TAA vaccme For example, the class I restncted CTL response of persons who have been vaccmated may be analyzed The vaccme may be any TAA vaccme PBMC are collected from vaccmated individuals and HLA typed Appropriate peptide epitopes of the invention that, optimally, bear supermotifs to provide cross-reactivity with multiple HLA supertype family members, are then used for analysis of samples derived from individuals who bear that HLA type PBMC from vaccmated individuals are separated on Ficoll-Histopaque density gradients (Sigma Chemical Co , St Louis, MO), washed three times in HBSS (GIBCO Laboratories), resuspended m RPMI- 1640 (GIBCO Laboratones) supplemented with L-glutamme (2mM), pemcillm (50U/ml), streptomycin (50 μg/ml), and Hepes (lOmM) contammg 10% heat-inactivated human AB serum (complete RPMI) and plated usmg microculture formats A synthetic peptide compnsmg an epitope of the mvention is added at 10 μg/ml to each well and HBV core 128-140 epitope is added at 1 μg/ml to each well as a source of T cell help durmg the first week of stimulation In the microculture format, 4 x 10 5 PBMC are stimulated with peptide in 8 replicate cultures m 96- well round bottom plate m 100 μl/well of complete RPMI On days 3 and 10, 100 μl of complete RPMI and 20 U/ml final concentration of rIL-2 are added to each well On day 7 the cultures are transfened into a 96-well flat-bottom plate and restimulated with peptide, rIL-2 and 10 5 lπadiated (3,000 rad) autologous feeder cells The cultures are tested for cytotoxic activity on day 14 A positive CTL response requues two or more of the eight replicate cultures to display greater than 10% specific 51 Cr release, based on comparison with unmfected control subjects as previously described (Rehermann, et al Nature Med 2 1104,1 108, 1996, Rehermann et al , J Clin Invest 97 1655-1665, 1996, and Rehermann et al J Clin Invest 98 1432-1440, 1996) Target cell lines are autologous and allogeneic EBV-transformed B-LCL that are either purchased from the American Society for Histocompatibility and Immunogenetics (ASHI, Boston, MA) or established from the pool of patients as descnbed (Guilhot, et al J Virol 66 2670-2678, 1992) Cytotoxicity assays are performed m the followmg manner Target cells consist of either allogeneic HLA-matched or autologous EBV-transformed B lymphoblastoid cell lme that are mcubated overnight with the synthetic peptide epitope of the invention at 10 μM, and labeled with 100 μCi of 51 Cr (Amersham Corp , Arlington Heights, IL) for 1 hour after which they are washed four times with HBSS Cytolytic activity is determmed m a standard 4 hour, split-well 51 Cr release assay usmg U- bottomed 96 well plates contammg 3,000 targets/well Stimulated PBMC are tested at effector/target (E/T) ratios of 20-50 1 on day 14 Percent cytotoxicity is determined from the formula 100 x [(experimental release-spontaneous release)/maxιmum release-spontaneous release)] Maximum release is determmed by lysis of targets by detergent (2% Triton X-100, Sigma Chemical Co , St Louis, MO) Spontaneous release is <25% of maximum release for all experiments The results of such an analysis mdicate the extent to which HLA-restncted CTL populations have been stimulated by previous exposure to the TAA or TAA vaccme The class II restricted HTL responses may also be analyzed Purified PBMC are cultured m a 96- well flat bottom plate at a density of 1 5xl0 5 cells/well and are stimulated with 10 μg/ml synthetic peptide, whole antigen, or PHA Cells are routmely plated m replicates of 4-6 wells for each condition After seven days of culture, the medium is removed and replaced with fresh medium contammg lOU/ml IL-2 Two days later, 1 μCi 3 H-thymιdιne is added to each well and incubation is continued for an additional 18 hours Cellular DNA is then harvested on glass fiber mats and analyzed for 3 H-thymιdιne mcorporation Antigen- specific T cell proliferation is calculated as the ratio of 3 H-thymιdιne mcorporation m the presence of antigen divided by the 3 H-thymιdιne incorporation m the absence of antigen Example 18 Induction Of Specific CTL Response In Humans A human clinical trial for an immunogemc composition compnsmg CTL and HTL epitopes ofthe mvention is set up as an IND Phase I, dose escalation study Such a tnal is designed, for example, as follows A total of about 27 subjects are enrolled and divided mto 3 groups Group I 3 subjects are injected with placebo and 6 subjects are mjected with 5 μg of peptide composition, Group II 3 subjects are injected with placebo and 6 subjects are mjected with 50 μg peptide composition, Group III 3 subjects are injected with placebo and 6 subjects are mjected with 500 μg of peptide composition After 4 weeks following the first injection, all subjects receive a booster inoculation at the same dosage Additional booster inoculations can be administered on the same schedule The endpoints measured m this study relate to the safety and tolerabihty of the peptide composition as well as its immunogemcity Cellular immune responses to the peptide composition are an index of the intrinsic activity of the peptide composition, and can therefore be viewed as a measure of biological efficacy The following summarize the clmical and laboratory data that relate to safety and efficacy endpoints Safety The incidence of adverse events is monitored m the placebo and drug treatment group and assessed in terms of degree and reversibility Evaluation of Vaccine Efficacy For evaluation of vaccme efficacy, subjects are bled before and after injection Peripheral blood mononuclear cells are isolated from fresh hepaπmzed blood by Ficoll- Hypaque density gradient centrifugation, a quoted m freezing media and stored frozen Samples are assayed for CTL and HTL activity The vaccme is found to be both safe and efficacious Example 19 Therapeutic Use in Cancer Patients Evaluation of vaccme compositions are performed to validate the efficacy ofthe CTL-HTL peptide compositions in cancer patients The mam objectives of the tnals are to determme an effective dose and regimen for mducing CTLs m cancer patients, to establish the safety of mducmg a CTL and HTL response in these patients, and to see to what extent activation of CTLs improves the clmical picture of cancer patients, as manifested by a reduction m tumor cell numbers Such a study is designed, for example, as follows The studies are performed m multiple centers The tnal design is an open-label, uncontrolled, dose escalation protocol wherem the peptide composition is admmistered as a single dose followed six weeks later by a single booster shot of the same dose The dosages are 50, 500 and 5,000 micrograms per injection Drug-associated adverse effects (seventy and reversibility) are recorded There are three patient groupings The first group is mjected with 50 micrograms of the peptide composition and the second and third groups with 500 and 5,000 micrograms of peptide composition, respectively The patients withm each group range m age from 21-65, mclude both males and females (unless the tumor is sex-specific, e g , breast or prostate cancer), and represent diverse ethnic backgrounds Example 20 Induction of CTL Responses Using a Pπme Boost Protocol A prime boost protocol similar m its underlymg principle to that used to evaluate the efficacy of a DNA vaccme m transgenic mice, which was described m Example 12, may also be used for the administration of the vaccine to humans Such a vaccine regimen may mclude an initial admmistration of, for example, naked DNA followed by a boost usmg recombinant virus encoding the vaccme, or recombinant protein/polypeptide or a peptide mixture admmistered m an adjuvant For example, the initial immunization may be performed usmg an expression vector, such as that constructed in Example 11, in the form of naked nucleic acid admmistered IM (or SC or ID) m the amounts of 0 5-5 mg at multiple sites The nucleic acid (0 1 to 1000 μg) can also be admmistered usmg a gene gun Following an incubation period of 3-4 weeks, a booster dose is then administered The booster can be recombinant fowlpox virus admmistered at a dose of 5-10 7 to 5xl0 9 pfu An alternative recombmant virus, such as an MVA, canarypox, adenovirus, or adeno-associated virus, can also be used for the booster, or the polyepitopic protem or a mixture of the peptides can be admmistered For evaluation of vaccme efficacy, patient blood samples will be obtamed before immunization as well as at mtervals followmg admmistration of the initial vaccme and booster doses of the vaccine Peπpheral blood mononuclear cells are isolated from fresh hepaπmzed blood by Ficoll-Hypaque density gradient centnfugation, ahquoted m freezing media and stored frozen Samples are assayed for CTL and HTL activity Analysis of the results will indicate that a magnitude of response sufficient to achieve protective immunity agamst cancer is generated Example 21 Admmistration of Vaccme Compositions Using Dendntic Cells Vaccines compnsmg peptide epitopes of the mvention may be admmistered using antigen- presentmg cells (APCs), or "professional" APCs such as dendntic cells (DC) In this example, the peptide- - pulsed DC are administered to a patient to stimulate a CTL response in vivo In this method, dendntic cells are isolated, expanded, and pulsed with a vaccme compnsmg peptide CTL and HTL epitopes of the mvention The dendntic cells are infused back mto the patient to elicit CTL and HTL responses in vivo The induced CTL and HTL then destroy (CTL) or facilitate destruction (HTL) ofthe specific target tumor cells that bear the protems from which the epitopes m the vaccme are deπved For example, a cocktail of epitope-beanng peptides is administered ex vivo to PBMC, or isolated DC therefrom, from the patient's blood A pharmaceutical to facilitate harvesting of DC can be used, such as Progempoietm™ (Monsanto, St Louis, MO) or GM-CSF/IL-4 After pulsmg the DC with peptides and pnor to reinfusion into patients, the DC are washed to remove unbound peptides As appreciated clinically, and readily determmed by one of skill based on clmical outcomes, the number of dendntic cells reinfused mto the patient can vary (see, e g , Nature Med 4 328, 1998, Nature Med 2 52, 1996 and Prostate 32 272, 1997) Although 2-50 x 10 6 dendntic cells per patient are typically administered, larger number of dendntic cells, such as 10 7 or 10 8 can also be provided Such cell populations typically contam between 50-90% dendntic cells In some embodiments, peptide-loaded PBMC are mjected mto patients without purification of the DC For example, PBMC contammg DC generated after treatment with an agent such as Progempoietm™ are mjected mto patients without puπfication of the DC The total number of PBMC that are admmistered often ranges from 10 8 to 10 10 Generally, the cell doses mjected mto patients is based on the percentage of DC m the blood of each patient, as determined, for example, by lmmunofluorescence analysis with specific anti-DC antibodies Thus, for example, if Progempoietm™ mobilizes 2% DC m the peripheral blood of a given patient, and that patient is to receive 5 x 10 6 DC, then the patient will be injected with a total of 2 5 x 10 8 peptide-loaded PBMC The percent DC mobilized by an agent such as Progempoietm™ is typically estimated to be between 2-10%, but can vary as appreciated by one of skill in the art Ex vivo activation of CTL/HTL responses Alternatively, ex vivo CTL or HTL responses to a particular tumor-associated antigen can be induced by incubating in tissue culture the patient's, or genetically compatible, CTL or HTL precursor cells together with a source of antigen-presentmg cells (APC), such as dendntic cells, and the appropriate lmmunogenic peptides After an appropnate mcubation time (typically about 7-28 days), in which the precursor cells are activated and expanded mto effector cells, the cells are infused back mto the patient, where they will destroy (CTL) or facilitate destruction (HTL) of their specific target cells, i e , tumor cells Example 22 Alternative Method of Identifying Motif-Bearing Peptides Another way to identify motif-beaπng peptides is to elute them from cells bearing defined MHC molecules For example, EBV-transformed B cell lmes used for tissue typing have been extensively characterized to determine which HLA molecules they express In certain cases these cells express only a single type of HLA molecule These cells can then be infected with a pathogenic organism or transfected with nucleic acids that express the tumor antigen of interest Thereafter, peptides produced by endogenous antigen processing of peptides produced consequent to mfection (or as a result of transfection) will bmd to HLA molecules withm the cell and be transported and displayed on the cell surface The peptides are then eluted from the HLA molecules by exposure to mild acid conditions and their amino acid sequence determmed, e g , by mass spectral analysis (e g , Kubo et al , J Immunol 152 3913, 1994) Because, as disclosed herem, the majority of peptides that bmd a particular HLA molecule are motif-bearmg, this is an alternative modality for obtammg the motif-beanng peptides conelated with the particular HLA molecule expressed on the cell Alternatively, cell lmes that do not express any endogenous HLA molecules can be transfected with an expression construct encodmg a smgle HLA allele These cells are used as descnbed, i e , they are mfected with a pathogenic organism or transfected with nucleic acid encoding an antigen of mterest to isolate peptides conespondmg to the pathogen or antigen of mterest that have been presented on the cell surface Peptides obtamed from such an analysis will bear motιf(s) that conespond to bmdmg to the single HLA allele that is expressed m the cell As appreciated by one m the art, one can perform a similar analysis on a cell beanng more than one HLA allele and subsequently determine peptides specific for each HLA allele expressed. Moreover, one of skill would also recognize that means other than infection or transfection, such as loadmg with a protein antigen, can be used to provide a source of antigen to the cell The above examples are provided to illustrate the mvention but not to limit its scope For example, the human terminology for the Major Histocompatibility Complex, namely HLA, is used throughout this document It is to be appreciated that these pπnciples can be extended to other species as well Thus, other vanants of the mvention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims All publications, patents, and patent application cited herem are hereby incorporated by reference for all purposes TABLE I Bolded residues are preferred, italicized residues are less preferred: A peptide is considered motif-bearing if it has primary anchors at each primary anchor position for a motif or supermotif as specified in the above table. TABLE la k If 2 is V, or Q, the C-term is not L Bolded residues are preferred, italicized residues are less preferred: A peptide is considered motif-bearing if it has primary anchors at each primary anchor position for a motif or supermotif as specified in the above table. TABLE II POSITION ¥ F U " ¥ C-termmus SUPERMOTIFS Al 1° Anchor 1 ° Anchor Υ,l,L, V,M,S F,W,Y A2 1 ° Anchor 1 ° Anchor L,I,V,M, , L,I,V,M,A,T T.Q A3 prefened 1° Anchor Y,F,W, (4/5) Y.F.W, Y.F.W, (4/5) P, (4/5) 1 "Anchor V,S,M,A,Γ, (3/5) R,K L,I deleterious D,E (3/5); P, (5/5) D,E, (4/5) 1 ° Anchor 1° Anchor A24 Y,F, WJ. V, Y,\,Y, W,L.M L.M. T B7 prefened F,W,Y (5/5) 1 "Anchor F,W,Y (4/5) F.W.Y, 1 "Anchor L,I,V,M, (3/5) P (3/5) V,I,L,F,W; W, Y,A deleterious D,E (3/5); P(5/5); D,E, (3/5) G, (4/5) Q,N, (4/5) D,E, (4/5) G(4/5); A(3/5); Q,N, (3/5) 1° Anchor 1° Anchor B27 R,H,K V,Y,L,W,M, V,A 1° Anchor 1° Anchor B44 E.D F.W.Y.L.I.M.V.A 1° Anchor 1° Anchor B58 A,T,S F,W,Y,L,;, V.M.A 1° Anchor 1° Anchor B62 Q,L ,I, VM, F.W.Y.M./, V.L.A P POSITION 0 0 C-terminus MOTIFS A l prefened G.F.Y.W, 1 "Anchor D.E.A, Y.F.W, P, D,E,Q,N, Y,F,W, 1 "Anchor 9-mer S.T.M, Y deleterious D,E, R,H,K,L,I,V A, A, .P, \ A l preferred G.R.F A.S/T.CL.I 1 "Anchor G.S.T.C, A.S.T.C, L.I.V.M, D,E, 1 "Anchor 9-mer V, , D,E ),5 Y deleterious A R,H,K,D,E, D,E, P.Q.N, R.H.K, P.G. G,P, P,Y,F,W, POSITION 0 ® C-terminus @ or C-terminus A 1 peferred Y,F,W, 1 "Anchor D,E,A,Q,N. A, Y,F,W,Q,N, P,A_S,T,C, G.D.E, P, "Anchoi 10-mer S,T,M deleterious Q,P. R,H,K,G,L,I D.E, R.H.K. Q.N.A R,H,K.Y,F, R.H.K, V,M, W, A l preferred Y.F.W, S,T,C,L,I,V 1 "Anchor A, Y.F.W, P.G, Y.F.W. l d Anchθf 10-mer . O.E .S Y -j -^ deleterious R.H.K, R,H,K,D,E. G, P.R.H.K, Q,N, P,Y,F,W, Λ2 1 preferred Y.F. , Y . F.W, S.T.C, Y.F.W, Λ, 1 "Anchor 9-mer L.M.y. K.ρ, V.L.I.M.Λ A.T deleterious D.E.P. D,E,R,K,H R. .H D,E,R,K,H A2.1 preferred A.Y.F.W, 1 "Anchor L,V,I,M, G. F.Y.W.L, 1 "Anchor 10-mer LMJ.VQ. V.I. . V.L.IM.A. T Λ. T deleterious D.E.P. D.E. R.K.H.A, P, R,K,H, D.E.R.K, R.K.H, POSITION Θ I C- or teιτninus C-terminus A3 preferred R,H, , I "Anchor Y,F,W, P,R,H,K,Y, Y,F,W, 1 "Anchor L,M,V,I,S, F,W, ¥L,YJ ,H.F.A A,T,F,C.G D deleterious D.E.P. D.E A 1 1 preferred l°Anchor Y.F.W, Y.FW, Y.F.W, Y.FW,, P, l °Anchoι V.T.L. .I, K„RY,H S.A.G.N.C D,F deleterious D,E,P, A24 preferred Y,F,W,R,H,K, J "Anchor S,T,C Y.F.W, Y.F.W, 1 "Anchor 9-ιner Y,V, ,M F. .I.W deleterious D,E,G, D.E, Q.N.P, D.E.R.H.K. G, Λ.Q.N, A24 preferred 1 "Anchor Y.F.WJP, P. l°Anchor 10-mer Y,F,W, F.L.I.W deleterious G.D.E Q.N R.H.K D.E Q.N, D.E.A, A3101 preferred R.H.K, 1 "Anchor Y.F.W, Y,F,W, Y,F,W, A.P. 1 "Anchor .V.TΛL, R,K IS deleterious D,E,P, D,E, A.D.E, D.E, D,E, D,E, POSITION Θ @ I 0 C- o Ir terminus C-terminus A330) preferred 1 "Anchor Y.F.W A.Y.F.W I "Anchor M,V,A.L,F, R,K I.S.T deleterious G,P D,E A6801 preferred Y.F,W.S,T,C. I "Anchor Y,F,W.L,I, Y.F.W, TAnchor A,V,T,M,S, V,M R.K L.I deleterious G,P, D.E.G, R.H.K, 130702 preferred R.H. .F.W.Y, 1 "Anchor R,H,K, R,H,K, R,II,K, R.H.K, P,A, 1 "Anchor P L.M.F. W. r.Λ, l. V deleterious D,E,Q,N,P, D,E,P, D.E, D,E, G.D.E, Q.N, D,E, B3501 preferred F.W.Y L.I.V.M, l°Anchor F,W,Y, F.W.Y, l°Anchor P L,M,F,W,Y,/: V.Λ deleterious A.G.P, G. POSITION Θ • @ 0 C- or terminus C-terminus 1351 preferred L.I.V.M.F.W.Y, l°Anchor F.W.Y, s,τ,c, F.W.Y, F.W.Y, 1 "Anchor P L.I.V.F.W. YAM deleterious A,G,P,D,E,R,H,K, D,E, D,E,Q,N, G.D.E, S.T.C. 135301 preferred L.I.V. .F.W.Y, 1 "Anchor F,W,Y, S.T.C, F.W.Y, L.l.V.M.F, F.W.Y, 1 "Anchor P W,Y, , I, ,F,W,Y, Λ.L. V deleterious A,G,P,Q,N, R ' .H.K.Q.N, D,E, 135401 preferred F.W.Y, F,W,Y,L,I,V L.I.V. , A.L.I.V.M, F.W.Y.A.P, 1 "Anchor A,T,I,V,L, M.F. W. Y deleterious G.P.Q.N.D.E, G.D.E.S.T.C, R.H.K.D.E, D,E, Q.N.D.G.E, D,E, Iiiilicized residues indicate less preferred or "tolerated" residues. The information in Table II is specific for 9-mers unless otherwise specified. Secondary anchor specificities are designated for each position independently. Table III POSITION MOTIFS 1° anchor 1 1° anchor 6] 0 DR4 preferred F, M, Y I, M, T, I, V, S, T, C, P, A, M, H, M, H V, W, L, I, M, deleterious W, R. W, D. E DR1 preferred M, F, L, I, V, P, A, M, Q, V, M, A, T, S, P, M, A. V, M W. Y, L, I, C, deleterious C C, H F, D C, W, D G, D, E, D DR7 preferred M, F, L. 1, V. M, W, A, I, V, M,' S, A, C M, ι, v W, Y, Z P. L, deleterious c, G, G, R, D, N G DR Supermotif M, F, L, 1, V, V, M, S, T, A, C. W, Y, P, L, 1, DR3 MOTIFS 1 ° anchor 1 1° anchor 4 3 1 ° anchor S motif a L, I, V, M, F, preferred Y. D motif b L, I, V, M, F, D, N, Q, E, preferred A. Y, S, T K, R, H Italicized residues indicate less preferred or "tolerated" residues. Secondary anchor specificities are designated for each position independently. Table IV: HLA Class I Standard Peptide Binding Affinity. Table V. HLA Class II Standard Peptide Binding Affinity. Table VI Allelle-specific HLA-supertype members HLA-supertype Verified 3 Predicted b Al A*0101, A*2501, A*2601, A*2602, A*3201 A*0102, A*2604, A*3601, A*4301, A*8001 A2 A*0201, A*0202, A*0203, A*0204, A*0205, A*0206, A*0207, A*0208, A*0210, A*0211, A*0212, A*0213 A*0209, A*0214, A*6802, A*6901 A3 A*0301, A*l 101, A*3101, A*3301, A*6801 A*0302, A*l 102, A*2603, A*3302, A*3303, A*3401, A*3402, A*6601, A*6602, A*7401 A24 A*2301, A*2402, A*3001 A*2403, A*2404, A*3002, A*3003 B7 B*0702, B*0703, B*0704, B*0705, B*1508, B*3501, B*3502, B*3503, B*1511,B*4201,B*5901 B*3503, B*3504, B*3505, B*3506, B*3507, B*3508, B*5101, B*5102, B*5103, B*5104, B*5105, B*5301, B*5401, B*5501, B*5502, B*5601, B*5602,B*6701,B*7801 B27 B*1401, B*1402, B*1509, B*2702, B*2703, B*2704, B*2705, B*2706, B*2701, B*2707, B*2708, B*3802, B*3903, B*3904, B*3801, B*3901, B*3902, B*7301 B*3905, B*480.1, B*4802, B*1510, B*1518, B* 1503 B44 B*1801, B*1802, B*3701, B*4402, B*4403, B*4404, B*4001, B*4002, B*4101, B*4501, B*4701, B*4901, B*5001 B*4006 B58 B*5701, B*5702, B*5801, B*5802, B*1516, B*1517 1 B62 B*1501, B*1502, B*1513, B*5201 B*1301, B*1302, B*1504, B*1505, B*1506, B*1507, B*1515, B*1520, B*1521, B*1512, B*1514, B*151 ' 0 a. Verified alleles include alleles whose specificity has been determined by pool sequencing analysis, peptide binding assays, or by analysis ofthe sequences of CTL epitopes. b. Predicted alleles are alleles whose specificity is predicted on the basis of B and F pocket structure to overlap with the supertype specificity. §8 O © •5 π I o < c ■ - = - oc - = J. = - o ? z = < -si l©l©l©l©i©l©l©l©g©l §§§§§§ r _ ∞__ £ I Ϊ , T ? 0 κ!_ H 2Ξσvκoc„ © <N i u- ι/ι__c-J u 6Z9εε/oosn/x3d 88/.WΪ0 OΛV OO OO OO OO CTv __ ( ( OC >O iΛ- ooso r- un w-i- £ff _o oι w ff .-_- OG r r ____ c_ .__- .o f- — - r- — r- j _ _ r Table XIV p53 B62 Supermotif Peptides Position No. of Λminυ Λcids _^___a____H_a_____a_____a__a_____ 161 9 159 II 84 S 189 9 63 II UK 10 242 10 135 9 42 9 21 II 57 10 II 9 3 8 224 9 224 II 113 10 187 9 187 II 245 10 245 II £ 59 8 374 II 193 II 24 8 321 8 164 9 164 10 194 ID 264 9 264 11 43 8 43 II 35 10 330 9 330 II 44 10 44 II 66 8 263 8 263 10 30 II 322 11 3 13 "II 222 II 152 9 152 II 12 8 151 10 190 8 Table XIV p53 B62 Siiperiiiutif Peptides Posilion No. or Λmino Λcids _^ __^ 331 8 331 10 331 I I 136 8 136 I I 317 I I 65 9 196 8 196 10 202 I I 156 8 127 8 46 8 46 9 33 8 37 8 15 9 166 8 99 9 31 10 97 II 218 8 217 9 216 10 205 8 236 8 236 II 103 II Table XV p53 API Motif Peptides with Binding Data Posilion No. of Λ'OIOl Λπiino Λciils 119 8 8 229 8 8 226 9 9 226 II II 117 10 10 154 10 10 93 II II 210 II II 98 10 10 213 8 8 196 10 10 94 10 10 95 9 ° 225 10 10 97 II II _i t7ι »Ξ Table XVII p53 ΛQ3 Motif Peptides with Binding Data Position No of A*030l Λmino Λcids 45 10 32 8 14 II -00009 93 9 00014 93 II 160 9 340 8 44 II 169 10 169 II 263 8 263 II -00009 288 9 288 10 200 10 00002 268 9 239 10 00001 239 II 00012 210 II 311 9 00009 311 10 00035 311 II -00009 30 10 o 77 8 77 10 128 II 75 9 75 10 47 8 61) 10 60 II 359 1 58 8 153 9 153 II 92 10 00021 98 10 00003 80 9 72 8 354 10 00001 354 II 104 10 331 8 331 II 165 10 00014 165 II 00009 375 8 00004 375 II 363 8 05500 363 10 00001 4 1 > * X 3 ϋ __= - • a a __ α: M_Ϊ ;:_ ;:- Ξ2;i:κ»£ ( Oι ~ 3c Ξ S , Ξ κ - β0 00 βo * 0C - σ, 0 ° < • a © — ■ -» ■ — <* — — m © © — © — © © © © wn © © © © © o © © © © © O © © © © < © 2 S σ s Ξ o oe σs Ξ _ σ 2 Ξ σ * Ξ σ s oc _ oo 2 _- s _ _ o oc s * __ 5s ©_ii ©i ©__ — — - ©««,- — — < Tnbl . XVH pS3 All Motif Peptides with Binding Data Position No. or A'l lOI Λmino Λcids 312 9 00001 312 10 0.0002 274 9 0.0001 274 10 0.0002 147 10 0.0002 225 9 225 10 0.0003 122 II 0.1200 172 8 172 10 0.0017 146 II -0.0002 327 9 327 II 107 9 0.2600 205 9 0.0005 21)5 10 o nbleXVM p53 A24 Motif Peptides with Binding Data Posilion No. of A*240l Λmino Λcids 242 10 242 I I 339 10 204 9 0.0010 245 8 245 10 245 I I 43 8 43 1 1 0.0023 22 1 1 -0.0003 340 9 0.0001 340 I I 337 8 -0.0004 106 8 0.0280 106 9 0.0200 18 8 0.0016 18 9 0.0010 102 8 0.1 100 102 10 0.1200 125 10 5.1000 Table XIX p53 DR Super Motif Peptides with Binding Data Core Exemplary Posilion DRI DR2 DI DR3 DR4w4 DR4wl5 DR5 ll DR5 l2 SEQ ID NO. Sequence Sequence VTCTYSPΛL Λ SV TYSPΛLN 119 1057 LKDΛQΛGKE ΛLELKDΛQΛϋKEPGG 347 1058 VΛPΛPΛΛPT ΛPPVΛPΛPΛΛPTPΛΛ 70 1059 MPEΛΛPPVΛ ΛPRMPEΛΛPPVΛPΛP 63 1060 WPI.SSSVPS ΛPSWPLSSSVPSQKT 88 1061 IIIYNYMCNS CTTIHYNYMCNSSCM 229 1062 YFΪI.QIRGR IXiEYKTLQlRGRERF 324 0.0400 -0.0027 1063 SPDOIΠQW DLM SPΠDIEQWFTE 42 0.0150 1064 VEPPLSQF.T DPSVEPP SQETFSD 7 1065 LRVEYLDDR EGN RVEYLDDRNTF 198 0.0039 1066 VI.SPLPSQΛ ENNVLSPLPSQΛMDD 28 1067 ΛKI ' CPVO I .QLΛKTCPVQLWVD 134 1068 LWKLLPENN l-SDLWKI. PI-NNVLS 19 1069 LGFLI1SGTΛ GIRLGFU ISUTΛKSV 108 1.9000 0,0360 0.120(1 0.0027 8.3000 0.2000 1070 VRΛMΛIY Q GIRVRΛMΛIY QSQII 154 1071 LP GSTKRΛ IIIIEI.PPGST RΛLPN 296 1072 VVPYIiPPIiV IIS VVPYEPPEVGSD 214 1073 YMCNSSCMG IIYNYMCNSSCMGGMN 233 1074 WFTI-IJPCiPI) 11-υWFTEDPGPUEΛP 50 1075 LPNNTSSSP KRΛLPNNTSSS QPK 305 -0.0005 -0.0027 1076 MISGTΛ SV LGFLIISGTΛ SVTCT 111 1077 MK QI.ΛK.TC 1.NK.M I Q I.ΛKTCP VQ 130 0.2500 0.0016 0.0370 0.0006 0.0560 0.0080 1078 I.PSQΛ DDL l.SPLPSQΛ DDLMLS 32 1079 ITLEDSSGN LT1ITLEDSSGNLLG 252 0.0030 1080 NRRPILTI MOGMNRRPILTIITL 243 -0.0005 -0.0027 1081 VVRRCPIIIIE MTEVVRRCPIIIIERCS 169 1082 1.F.LK.UΛQΛG NF.ΛI.ELKDΛQΛGKEP 345 I0R3 I.SI' ΓS ΛM NNVL.SPLPS ΛMDDI, 29 I0K4 IHQWFI ΪΪDP PODIEOWFTEDPGPI) 47 1085 VOSI rim PPEVGSI THIIYNY 222 0.0380 1086 I.W VDSTPPP PVOI.WVI>STPI GTR 142 0.0301 ) 1087 VllST PPCiT Ql.WVDSTPl GTRVR 144 1088 FL1ISGTΛ S Rl.GFLIISGTΛKSVTC 110 108 FΠVRVCΛCP RNSFEVRVCΛCPGRD 267 1090 FRIISVVVPY RNTFR1ISVVVPYEPP 209 1091 LTI1T P.DS RPILTIITLROSSGN 249 1092 ILTIITLEI ) RRPILTIΓΓLEDSSG 248 0.0010 0.0100 1093 VRVCΛCPGR S1EVRVCΛCPORDRR 269 1094 LLGRNSFEV SGNLLGRNSFI.VRVC 261 1095 NK.MFCQLΛ SPΛI.NK.MFCQLΛKTC 127 1096 MDDLMLSPI_l SQΛMDDLMLSPDDIE 37 1097 VPSQKTYQG SSSVPSQKTYQGSYG 94 1098 VPYEPPEVG SVVVPYEPPEVGSOC 215 -0.0025 1 99 LSSSVPSQK S PLSSSVPSQKTYQ 90 1100 FRLGFLIISO SYGFRLGFLIISGTΛK. 106 1101 LDDRNTFRll VEYLDDRNTFRIISVV 203 1102 WVDSTPPPG VQLWVDSTPPPGTRV 143 1103 YEPP VGSD VVPYEPPEVGSDCTT 217 1104 LPENNVtSP WKLLPENNVLSP PS 23 1105 MCNSSCMGG YNYMCNSSCMGGMNR 234 1106 Table XlX p53 DR Super Motif Peptides with Binding Data Core Exemplary DR6wl9 DR7 DR8w2 DR9 DRw53 SEQ ID NO. Sequence Sequence VIΓTYSPΛL ΛKSVTCTYSPΛLNKM 1057 LKI QΛCKE ΛLELKDΛQΛGKEPGG 1058 VΛPΛPΛΛP1 ΛPPVΛPΛPΛΛPΓPΛΛ 1059 MPF.ΛΛPPVΛ ΛPRMPEΛΛPPVΛPΛP 1060 WPLSSSVPS ΛPSWPLSSSVPSQKT 106! IHYNYMCNS CrrillYNYMCNSsSCM 1062 YΠLQIRGR UGEYF1LQIRGRERF -00018 1063 1 SPDDIEQW DLMLSPDDIEQWFΓE 1064 VLI LSQΓ.I DPSVLPPLSQETFSD 1065 IRVEYLDUR EGNLRVEYLDDRNTF 1066 VI.SPLPSQΛ ENNVLSPLPSQΛMDD 1067 IΛKICPVQL 1-CQLΛKrCPVQLWVI) 1068 LWKLI.ITNN l-SDLWKLLPFNNVLS 1069 LGΓLIISGIΛ GIRLGFLIISGTΛKSV 00460 02800 I 7000 1070 VRΛMΛIY Q GIRVRΛMΛIYKQ≤QII 1071 1 PPCISIKRΛ IIIH PPGSrKRΛLPN 1072 VVPYhPPLV IIS VVPYEPPEVGSD 1073 YMΓNSSCMG IIYNYMCNSSCMGGMN 1074 WI π DP Pi) IIQWFrEDPGPDFΛP 1075 i ΓNNTSSSP KRΛL NNTSSSPQPK -00007 1076 11ISGIΛKSV IGILIISGΓAKSVICT 1077 MICQI Λ IC L NKMFCQI.ΛKTCPVQ 00096 01500 00320 1078 L SQΛMDDL LSPLPSQΛMDDLMLS 1079 IILCDSSGN LIIIΓLEDSSGNLLG 1080 MNRRPI Π MOGMNRRPILTIITL -00007 1081 VVRRCPΠIII MTIVVRRCPHHERCS 1082 111 K ΛQΛCi NhΛLELKDΛQΛCiKIP 1083 I.SI'LPSQΛM NNVLS LPSQΛMDDL 1084 IEQWI 11 DP PDniLQWIllDPGPD 1085 VGSIK'I mi PI VGSI ITIIIYNY 1086 I.WVDbllTP PVQI.WVDSIPPPGI 1087 VDSIPP GI QIWVDSI PPG1RVR 1088 I1.IISG1ΛKS RIGKLllSGTΛKSVrC 1089 FΓVRVCΛ P RNSf EVRVCΛCPGRD 1090 1 RIISVVVPY RNTFR1ISVVVPYEPP 1091 LIIIILEDS RPILTIIILEDSSGN 1092 ILΠΠLED RRPILTIITLEDSSG 00023 1093 VRVCΛCPGR SFEVRVCACPGRDRR 1094 LI RNSFEV SGNLLGRNSFFVRVC 1095 LNKMICQLΛ SPΛLNKMFCQLΛKTC 1096 MI3DLMLSPD SQAMDDLMLSPDDIE 1097 VPSQKTYQG SSSVPSQKTYQGSYG 1098 VPYEPPEVG SVVVPYEPPEVGSDC 1099 LSSSVPSQK SWPLSSSVPSQKTYQ 1100 FRLGFLIISG SYGFRLGFLIISGTΛK 1101 LDDRNΓFRII VEYLDDRNTFRIISVV 1102 VDSTPPPG VQLWVDSTPPPGTRV 1103 > FPPEVGSD VVPYEPPEVGSDCTT 1104 LPhNNVLSP WKLLPENNVLSPLPS 1105 MCNSSCMGG YNYMCNSSCMGGMNR 1106 Table XXa p53 DR 3a Motif Peptides with Binding Data Core Exemplary Posiuo DRI DR2w2DI DR2 202 DEU DR4 4 DR4wl5 DRSwl l DR5 l2 SEQ ID NO. Sequence Sequence LSPDD1EQW DLMLSPDDIEQWFTE 42 0.01 SO 1107 LRVEYLDDR EGNLRVF.YLDDR_NTF 198 0 0039 1108 LSQETFSDL EPPLSQETFSDLWK.L I I -00025 1109 FTEDPGPDE EQ FTEDΓGPDEAPR SI -0.0025 1110 LDGEYFTLQ KKPLDGEYFTLQIRG 320 -0.0025 m i ITLEDSSGN LTIITLEDSSGNLLG 252 0 0030 1112 LLPENNVLS LWKLLPENNVLSPLP 22 0.0029 1113 VGSDCΠIII PPEVGSDCTTIHYNY 222 0.0380 1114 LWVDSTPPP PVQLWVDSTPPPGTR 142 0.0300 1115 IRVF.GNLRV QHLIRVEGNLRVEYL 192 0.0960 1116 MFRELNEAL RFEMFRELNEALELK 337 0 0052 1117 YLDDRNTFR RVEYLDDRNTFRHSV 202 0.1800 1118 VPYEPPEVG SVVVPYEPPEVGSDC 215 -00025 1119 Table XXa p53 DR 3a Motif Peptides with Binding Data Core Exemplary DR6 l DR7 DR8 2 DR9 DRw53 SEQ ID NO. Sequence Sequence LSPDDIF.QW DLMLSPDD1EQWFTE 1107 LRVEYLDDR EGNLRVEYLDDRNTF 1108 LSQETFSDL EPPLSQETFSDLWKL 1109 FTEDPGPDE EQWFTEDPGPDEΛPR 1110 LDGEYFTLQ KKPLDGEYFTLQIRG llll ITLEDSSGN LTIITLEDSSGNLLG 1112 LLPENNVLS L KLLPENNVLSPLP 1113 VGSDCTTlll PPEVGSDCTTIHYNY 1114 LWVDSTPPP PVQLWVDSTPPPGTR 1115 IRVEGNLRV QHLIRVEGNLRVEYL 1116 MFRELNF.ΛL RFEMFRELNEΛLELK 1117 YLDDRNTFR RVEYLDDRNTFRHSV 1118 VPYEPPEVG SVVVPYEPPEVGSDC 1119 Table XXb p53 DR 3b Motif Peptides with Binding Dala Coic Exemplary Posilion DRI DR2w2βl DR_Z 2Q2 DRJ DR4w4 DR4wl5 DRSwll DRSwl2 SEQ ID NO Sequence Sequence FTLQIRGRE GEYFTLQIRGRERFE 325 00290 1120 VEGNLRVEY LIRVEGNLRVEYLDD 194 00930 1121 YKQSQIIMTE MΛIYKQSQHMTEVVR 160 -00025 1122 Tabl XXb P53 DR 3b Motif Peptides with Binding Dala Core Exemplary DR6 l9 DR7 DR8 2 DR9 DRw53 SEQ ID NO Sequence Seαucnce FΓLQIRGRE GEYFTLQIRGRERFE 1120 VEGNLRVF.Y L1RVEGNLRVEYLDD 1121 YKQSQI1M1 E MAIYKQSQIIMTEVVR 1122 TABLE XXI. Population coverage with combined HLA Supertypes PHENOTYPIC FREQUENCY Caucasian North Japanese Chinese Hispanic Average HLA-SUPERTYPES American Black a. Individual Supertypes A2 45.8 39.0 42.4 45.9 43.0 43.2 A3 37.5 42.1 45.8 52.7 43.1 44.2 B7 43.2 55.1 57.1 43.0 49.3 49.5 Al 47.1 16.1 21.8 14.7 26.3 25.2 A24 23.9 38.9 58.6 40.1 38.3 40.0 B44 43.0 21.2 42.9 39.1 39.0 37.0 B27 28.4 26.1 13.3 13.9 35.3 23.4 B62 12.6 4.8 36.5 25.4 11.1 18.1 B58 10.0 25.1 1.6 9.0 5.9 10.3 b. Combined Supertypes A2, A3, B7 84.3 86.8 89.5 89.8 86.8 87.4 A2, A3, B7, A24, B44, Al 99.5 98.1 100.0 99.5 99.4 99.3 A2, A3, B7, A24, B44, A1, 99.9 99.6 100.0 99.8 99.9 99.8 B27, B62, B58 Table XXII. A2 supermotif analogs A*0201 Source AA Sequence nM p53.24 9 KLLPENNVL 313 p53.24V9 9 KLLPENNVV 385 p53.25 11 LLPENNVLSPL 19 p53.25V9 11 LLPENNVLSPV 39 p53.65 9 RMPEAAPPV 119 p53.65L2 9 RLPEAAPPV 78 p53.65 10 RMPEAAPPVA 78 p53.65L2V10 10 RLPEAAPPVV 143 p53.229L2V9 9 CLTIHYNYV 263 P53.229B1L2V9 9 BLTIHYNYV 116 p53.236 8 YMCNSSCM 4546 p53.236L2M8 8 YLCNSSCV ~ Ip53 236 ϊϊ YMCNSSCMGGM ' 667 "" |p53.236L2Ml l 11 YLCNSSCMGGV 22 p53 ' 255 ϊϊ ΪTLEDSSGNLL Ϊ563 "" jp53.255L2Vl l 11 ILLEDSSGNLV 33 p53 " ;256 ϊδ T EDSSGNΪZ Ϊ667 " p53.256V10 10 TLEDSSGNLV 4167 Table XXII. Crossbinding of A2 supermotif peptides No. A2 A*0201 A*0202 A*0203 A*0206 A*6802 Source AA Sequence Alleles nM nM nM nM nM Crossbound p53.24 9 KLLPENNVL 313 1955 - 1194 ~ 1 p53.25 11 LLPENNVLSPL 19 6.2 4.5 12 1702 4 p53.65 10 RMPEAAPPVA 78 102 13 841 — 3 P 53.65 9 RMPEAAPPV 119 23 22 70 ~ 4 p53.1 13 10 FLHSGTAKSV 357 179 15 . 4625 — 3 p53.132 9 KMFCQLAKT 333 33 18 106 - 4 p53.135 9 CQLAKTCPV 208 43 143 90 - 4 p53.136 8 QLAKTCPV 455 -- 100 2643 1067 2 p53.164 9 KQSQHMTEV 500 130 170 285 -- 4 p53.187 1 1 GLAPPQHLIRV 79 39 11 55 -- 4 p53.193 11 HLIRVEGNLRV 385 1387 83 1194 1778 2 p53.229 9 CTTIHYNYM 278 287 2564 561 181 3 p53.263 10 NLLGRNSFEV 217 - 2500 881 - 1 p53.264 9 LLGRNSFEV 85 358 37 206 — 4 indicates binding affinity =10,000nM. Table XXII. Crossbinding of A2 supermotif analogs No. A2 A*0201 A*0202 A*0203 A*0206 A*6802 Source AA Sequence Alleles nM nM nM nM nM Crossbound p53.69 AAPPVAPA 5000 1536 1 177 1233 4706 p53.69L2V8 ALPPVAPV 217 7167 500 285 67 p53.101 11 KTYQGSYGFRL 1786 896 514 615 p53.101L2Vl l 1 1 KLYQGSYGFRV 81 48 24 116 p53.129 ALNKMFCQL 735 391 19 73 p53.129V9 ALNKMFCQV 75 165 7.7 15 p53.129B7V9 ALNKMFBQV 192 391 23 49 p53.129 10 ALNKMFCQLA 1316 1075 71 4625 p53.129V10 10 ALNKMFCQLV 217 287 71 7400 p53.132 KMFCQLAKT 333 33 18 106 p53.132V9 KMFCQLAKV 33 8.4 7.7 15 p53.132B4V9 KMFBQLAKV 125 13 9.1 37 8889 p53.132L2V9 KLFCQLAKV 98 3.6 3.4 10 1270 p53.135 CQLAKTCPV 208 43 143 90 p53.135L2 CLLAKTCPV 125 506 67 370 P 53.135B1B7 BQLAKTBPV 102 71 15 67 P53.135B1 L2B7 BLLAKTBPV 46 1 19 7.7 64 p53.139 9 KTCPVQLWV 725 606 217 15 2 p53.139L2 9 KLCPVQLWV 122 239 29 23 -- 4 P53.139L2B3 9 KLBPVQLWV 46 29 19 31 4 p53.149 9 STPPPGTRV 909 1 162 1031 129 1 p53.149M2 9 SMPPPGTRV 172 215 13 425 667 4 p53.149L2 9 SLPPPGTRV 122 226 13 9250 140 4 p53.164 9 KQSQHMTEV 500 130 170 285 4 p53.164L2 9 KLSQHMTEV 122 94 35 46 ;; 4 p53.216 10 VVVPYEPPEV 617 1870 455 1194 — 1 p53.216L2 10 VLVPYEPPEV 89 391 71 2056 3 p53.236 11 YMCNSSCMGGM 667 391 67 974 5333 2 P53.236L2M1 1 11 YLCNSSCMGGV 22 13 3.6 18 1569 4 P53.255 1 1 ITLEDSSGNLL 1563 1265 2857 507 6667 0 p53.255L2Vl l 1 1 ILLEDSSGNLV 33 123 71 206 4 ~ indicates binding affinity =10,000nM Table XXlll. HLA-A3 Supermotif-bearing Peptides No. of A3 Published Published A*0301 A* 1101 A*3101 A*3301 A*6801 CTL CTL Sequence Source Alleles CTL CTL nM nM nM nM nM Crossbound Wildtype Tumor KVYQGSYGFR p53.101.V2 38 62 72 40 4 KVYQGSYGFK p53.101 /V2K10 33 9.2 139 38 4 KTYQGSYGFK p53.101 22 14 129 67 4 CTYSPALNK p53.124 24 6 1500 518 36 3 BVYSPALNK p53.124.B lV2 16 13 439 500 4 BVYSPALNR p53.124.B lV2R9 25 8.3 33 85 15 5 KMFCQLAK p53.132 29 17 353 727 3 GVRVRAMAIYK p53.154.V2 58 136 419 3 GTRVRAMA1YK p53.154 10 18 16 533 3 RVRAMAIYK p53.156 7.3 8.2 4.9 4603 2667 3 RVRAMAIYR p53.156.R9 41 1667 8.6 138 667 3 VVRRCPHHER p53.172 111 3529 NT NT NT 1 VVRRBPHHEK p53.172.B5K10 61 29 196 3810 3 1/2 1/2 SVBMGGMNK p53.240.V2B3K9 . 13 17 9000 30 3 SVBMGGMNRK p53.240.V2B3K10 100 75 - 17 3 SVBMGGMNR p53.240.V2B3 162 95 120 853 1 1 4 SSCMGGMNR p53.240 550 4.3 NT NT NT 1 SSCMGGMNRR p53.240 - 70 NT NT NT 1 SSBMGGMNK p53.240 20 5.5 - 140 3 SSBMGGMNRK p53.240 262 38 720 103 3 RVCACPGR p53.273 31 122 106 193 571 4 RVCACPGRDRR p53.273 379 207 346 667 3 SVSRHKKLMFK p53.376.V2 33 55 295 1509 3 SVSRHKKLMFR p53.376.V2Rl l 196 2857 184 1381 500 3 STSRHKKLMFK p53.376 36 46 295 533 3 Table XXIV. B7 Supermotif Peptides No. of B7 B*0702 B*3501 B*5101 B*5301 B*5401 AA Sequence Source Alleles nM nM nM nM nM Crossbound 10 FPSWPLSSSV p53.88.Fl 3.2 72 55 93 0.30 5 8 FPALNKMI p53.127.FH8 324 - 220 - 357 3 9 FPILTIITI p53.249.FH9 74 36 9.0 4.0 1.8 5 9 FPILTIITL p53.249.Fl 6.5 8.0 17 7.2 5.0 5 u, Table XXV. HLA-A1 Motif-Bearing Peptides Λ Λ o n A*0101 AA Sequence Source nM 10 PTQKTYQGSY p53.98.T2 36 10 GTAKSVTCTY p53.117 76 10 GTDKSVTCTY p53.U7.D3 42 10 RVDGNLRVEY p53.196.D3 46 10 VGSDCTTIHY p53.225 96 9 GSDCTTIHY p53.226 0.80 11 GSDCTTIHYNY p53.226 68 9 GTDCTTIHY p53.226.T2 0.90 Table XXVIa. HLA-A24 Motif-Bearing Peptides A*2402 Sequence Source nM TYQGSYGF p53.102 109 TYQGSYGFRL p53.102 100 TYQGSYGFRF p53.102.F10 30 SYGFRLGF p53.106 429 SYGFRLGFF p53.106.F9 121 TYSPALNKMF p53.125 2.4 Table XXVI b A24 Analog Peptides Peptide AA Seαuence Source A*2401 nM 52.008 8 •TYQGSYGF P53.102 109.1 52.0081 8 SYGFRLGF p53.106 428.6 52.0103 10 TYQGSYGFRL P53.102 100 52.0104 10 TYSPALNKMF P53.125 2.4 52.0144 11 TYLWWVNNQSL CEA.353 46.2 52.0147 11 TYLWWVNGQSL CEA.531 92.3 57.0042 9 LYWVNGQSF CEA.533.Y2F9 15.8 57.0051 9 EYVNARHCF Her2/neu.553.F9 150 57.007 9 TYSDLWKLF p53.18.Y2F9 5.5 57.0071 9 SYGFRLGFF p53.106.F9 121.2 57.0096 10 TYQGSYGFRF p53.102.F10 30 Table XXVII b. Immunogenicity of A2 Supermotif Peptides A*0201 A*0202 A*0203 A*0206 A*6802 No. A2 Alleles CTL CTL CTL Source AA Sequence nM nM nM nM nM Crossbound Peptide 1 Wild-type Tumor p53.135 9 CQLAKTCPV 208 2 43.0 143.0 90.0 4 1/4 0/4 p53.69 8 AAPPVAPA 5000 1536 1177 1233 4706 0 p53.69L2V8 8 ALPPVAPV 217 7167 500 285 67 4 2/4 1/3 0/3 2 p53.129 9 ALNKMFCQL 735 391 19 73 3 p53.129V9 9 ALNKMFCQV 75 165 7.7 15 4 0/1 p53.129B7V9 9 ALNKMFBQV 192 391 23 49 4 2/4 0/3 0/2 P 53.132 9 KMFCQLAKT 333 33 18 106 4 p53.132V9 9 KMFCQLAKV 33 8.4 7.7 15 4 1/3 0/2 0/2 p53.132B4V9 9 KMFBQLAKV 125 13 9.1 37 8889 4 5/5 0/4 0/4 p53.132L2V9 9 KLFCQLAKV 98 3.6 3.4 9.5 1270 4 2/3 1/3 0/3 p53.139 9 KTCPVQLWV 725 606 217 15 2 p53.139L2 9 KLCPVQLWV 122 239 29 23 ~ 4 2/5 2/3 1/3 J p53.139L2B3 9 KLBPVQLWV 45 29 19 31 4 3/4 2/3 1/2 oe p53.149 9 STPPPGTRV 909 1162 1031 129 1 p53.149L2 9 SLPPPGTRV 122 226 13 9250 140 4 2/3 1/3 0/3 p53.149M2 9 SMPPPGTRV 172 215 13 425 667 4 2/4 2/4 2/4 p53.216 10 VVVPYEPPEV 617 1870 455 1 194 — 1 p53.216L2 10 VLVPYEPPEV 89 391 71 2056 3 1/1 1/1 P 53.255 1 1 ITLEDSSGNLL 1563 1265 2857 507 6667 0 p53.255L2Vl l 1 1 ILLEDSSGNLV 33 123 71 206 4 1/3 0/3 0/2 1) Number of donors yielding a positive response/total tested. 2) — indicates binding affinity =10,000nM. Table XXVIII. PR supertype primary binding DR147 DR147 DR1 DR4w4 DR7 Algo Sequence Source Cross- nM nM nM Sum binding 2 GFRLGFLHSGTAKSV p53.108 2.6 5.4 89 3 2 LNKMFCQLAKTCPVQ P53.130 20 804 167 3 2 MGGMNRRPILTΠTL P53.243 — — 0 2 RRPILTIITLEDSSG P 53.248 5000 450C 0 2 KRALPNNTSSSPQPK P53.305 — — 0 3 DGEYFTLQIRGRERF P53.324 125 ~ 1 — indicates binding affinity =10.000nM I © Table XXX. DR3 binding DR3 Sequence Source nM EPPLSQETFSDLWKL p53.11 - LWKLLPENNVLSPLP p53.22 ~ DLMLSPDDIEQWFTE p53.42 — EQWFTEDPGPDEAPR P53.51 - PVQLWVDSTPPPGTR p53.142 - MAIYKQSQHMTEVVR p53.160 ~ QHLIRVEGNLRVEYL p53.192 3125 LIRVEGNLRVEYLDD p53.194 3226 EGNLRVEYLDDRNTF p53.198 — RVEYLDDRNTFRHSV p53.202 1667 SVWPYEPPEVGSDC p53.215 ~ PPEVGSDCTTIHYNY p53.222 7895 LTIITLEDSSGNLLG p53.252 - KKPLDGEYFTLQIRG p53.320 ~ GEYFTLQIRGRERFE p53.325 - RPEMFRELNEALELK p53.337 — ~ indicates binding affinity =10,000nM Table XXXI. HLA Class II Supermotif and Motif-Bearing Epitopes DRB 1 DRB 1 DRB 1 DRB1 DRB1 DRB 1 DRB 1 DRB 1 DRB5 No. of DR Sequence Source *0101 ♦ 0301 ♦ 0401 ♦ 0701 *0802 ♦ 1101 ♦ 1302 ♦ 1501 ♦ 0101 Alleles nM nM nM nM nM nM nM nM nM Crossbound GFRLGFLHSGTAKSV p53.108 2.6 5.4 89 29 100 76 253 167 8 LNKMFCQLAKTCPVQ p53.130 20 804 167 1531 2500 365 5688 541 5 UI NJ

Claims: WHAT IS CLAIMED IS 1. An isolated prepared P53 epitope consisting of a sequence selected from the group consisting ofthe sequences" set out in Tables XXIII, XXIV, XXV, XXVI, XXVII, and XXXI. 2. A composition of claim 1, wherein the epitope is admixed or joined to a CTL epitope. 3. A composition of claim 2, wherein the CTL epitope is selected from the group set out in claim 1. 4. A composition of claim 1, wherein the epitope is admixed or joined to an HTL epitope. 5. A composition of claim 4, wherein the HTL epitope is selected from the group set out in claim 1. 6. A composition of claim 4, wherein the HTL epitope is a pan-DR binding molecule. 7. A composition of claim 1, comprising at least three epitopes selected from the group set out in claim 1. 8. A composition of claim 1, further comprising a liposome, wherein the epitope is on or within the liposome. 9. A composition of claim 1, wherein the epitope is joined to a lipid. 10. A composition of claim 1 , wherein the epitope is joined to a linker. 11. A composition of claim 1 , wherein the epitope is bound to an HLA heavy chain, β2-microglobulin, and strepavidin complex, whereby a tetramer is formed. 12. A composition of claim 1, further comprising an antigen presenting cell, wherein the epitope is on or within the antigen presenting cell. 13. A composition of claim 12, wherein the epitope is bound to an HLA molecule on the antigen presenting cell, whereby when a cytotoxic lymphocyte (CTL) is present that is restricted to the HLA molecule, a receptor ofthe CTL binds to a complex ofthe HLA molecule and the epitope. 14. A clonal cytotoxic T lymphocyte (CTL), wherein the CTL is cultured in vitro and binds to a complex of an epitope selected from the group set out in Tables XXIII, XXIV, XXV, XXVI, and XXVII, bound to an HLA molecule. 15. A peptide comprising at least a first and a second epitope, wherein the first epitope is selected from the group consisting of the sequences set out in Tables XXIII, XXIV, XXV, XXVI, XXVII, and XXXI; wherein the peptide comprise less than 50 contiguous amino acids that have 100% identity with a native peptide sequence. 16. A composition of claim 15, wherein the first and the second epitope are selected from the group of claim 14. 17. A composition of claim 16, further comprising a third epitope selected from the group of claim 15. 18. A composition of claim 15, wherein the peptide is a heteropolymer. 19. A composition of claim 15, wherein the peptide is a homopolymer. 20. A composition of claim 15, wherein the second epitope is a CTL epitope. 21. A composition of claim 20, wherein the CTL epitope is from a tumor associated antigen that is not P53. 22. A composition of claim 15, wherein the second epitope is a PanDR binding molecule. 23. A composition of claim 1, wherein the first epitope is linked to an a linker sequence. 24. A vaccine composition comprising: a unit dose of a peptide that comprises less than 50 contiguous amino acids that have 100% identity with a native peptide sequence of P53, the peptide comprising at least a first epitope selected from the group consisting ofthe sequences set out in Tables XXIII, XXIV, XXV, XXVI, XXVII, and XXXI; and; a pharmaceutical excipient. 25. A vaccine composition in accordance with claim 24, further comprising a second epitope. 26. A vaccine composition of claim 24, wherein the second epitope is a PanDR binding molecule. 27. A vaccine composition of claim 24, wherein the pharmaceutical excipient comprises an adjuvant. 28. An isolated nucleic acid encoding a peptide comprising an epitope consisting of a sequence selected from the group consisting of the sequences set out in Tables XXIII, XXIV, XXV, XXVI, XXVII, and XXXI. 29. An isolated nucleic acid encoding a peptide comprising at least a first and a second epitope, wherein the first epitope is selected from the group consisting of the sequences set out in Tables XXIII, XXIV, XXV, XXVI, XXVII, and XXXI; and wherein the peptide comprises less than 50 contiguous amino acids that have 100% identity with a native peptide sequence. 30. An isolated nucleic acid of claim 29, wherein the peptide comprises at least two epitopes selected from the sequences set out in Tables XXIII, XXIV, XXV, XXVI, XXVII, and XXXI. 31. An isolated nucleic acid of claim 30, wherein the peptide comprises at least three epitopes selected from the sequences set out in Tables XXIII, XXTV, XXV, XXVI, XXVH, and XXXI. 32. An isolated nucleic acid of claim 29, wherein the second peptide is a CTL epitope. 33. An isolated nucleic acid of claim 32, wherein the CTL is from a tumor- associated antigen that is not P53. 34. An isolated nucleic acid of claim 20, wherein the second peptide is an HTL epitope.

Inventors: CELIS ESTEBAN, CHESNUT ROBERT, FIKES JOHN, KEOGH ELISSA, SETTE ALESSANDRO, SIDNEY JOHN, SOUTHWOOD SCOTT, CELIS, ESTEBAN, CHESNUT, ROBERT, FIKES, JOHN, KEOGH, ELISSA, SETTE, ALESSANDRO, SIDNEY, JOHN, SOUTHWOOD, SCOTT
Applicants: CELIS ESTEBAN, CHESNUT ROBERT, EPIMMUNE INC, FIKES JOHN, KEOGH ELISSA, SETTE ALESSANDRO, SIDNEY JOHN, SOUTHWOOD SCOTT, CELIS, ESTEBAN, CHESNUT, ROBERT, EPIMMUNE, INC., FIKES, JOHN, KEOGH, ELISSA, SETTE, ALESSANDRO, SIDNEY, JOHN, SOUTHWOOD, SCOTT
Application year: 2000
Main classification: A61K38
IPC codes: A61K9, A61K35, A61K39, A61P35, C07K7, C07K14, C12N15